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Skeletal dysplasias are a complex group of over 350 disorders of cartilage and bone with a 
combined incidence of 1/5000. Diagnosis is difficult and based on clinical and radiographic findings, 
with many cases having no known genetic cause. An allelic series of mutations has been identified in
aggrecan that results in a broad phenotypic spectrum, including spondyloepimetaphyseal dysplasia
(SEMD) and familial osteochondritis dissecans (OCD). Aggrecan, a large chondroitin sulfated
proteoglycan, attracts ions and water molecules, allowing the cartilage to withstand the high 
mechanical load found in the skeletal joint. The SEMD (p.D2276N) and OCD (p.V2303M) causative 
mutations are found at highly conserved residues in the C-type lectin domain (CLD) which interacts 
with other extracellular matrix (ECM) molecules to provide stability. 
PolyGene Transgenetics introduced mutations into the C57Bl/6 mouse line using 
homologous gene targeting. The resultant mice were assessed with radiography, morphometry and
growth measurements. Histological techniques, electron microscopy, RNA-sequencing and SDS-
PAGE Western blotting were used to analyse the underlying patho-molecular mechanisms. 
The homozygous V2019M Acan (OCD) mouse exhibits mild disproportionate short stature, 
whereas the homozygous D1983N Acan (SEMD) mouse has severe disproportionate short stature with 
associated skeletal abnormalities, including mid-face hypoplasia. OCD and SEMD mice also exhibit 
intervertebral disc degeneration, which has not previously been reported in human patients. OCD and 
SEMD growth plate cartilage is disorganised, with reduced aggrecan in the extracellular matrix, 
increased apoptosis and mis-expression of other extracellular matrix proteins. The unfolded protein 
response is not upregulated in either OCD or SEMD cartilage, although SEMD chondrocytes exhibit 
mild cellular stress. Comparative transcriptomic analysis indicates that autophagic flux, vesicular 
transport and regulation of chondrocyte differentiation are altered between these two models.  
The data presented in this thesis demonstrates that OCD and SEMD mice recapitulate the 
human short stature phenotypes and that altered matrix organisation may impair cellular 
differentiation, causing reduced bone growth. These mouse models could be used to further 
investigate the disease mechanisms of these two skeletal disorders.  
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Chapter 1. Introduction 
1.1. Limb pattern development 
The tetrapod limb (Figure 1A) is comprised of three compartments: the proximal 
stylopod which contains a single large bone such as the femur, the middle zeugopod with 
two bones and the distal autopod which forms the digits (Mariani and Martin 2003). Limb 
patterning begins when the limb bud is formed from mesenchymal cells covered with a layer 
of ectoderm (Figure 1B). Limb bud initiation and positioning is controlled by rostral and 
caudal HOX signalling. This signalling then affects the expression T-box transcription factors 
which determine the limb bud’s ultimate fate, TBX4 promoting hindlimb identity and TBX5 
the forelimb (Gibson-Brown, Agulnik et al. 1996). At the distal end of the limb bud is a thick 
ectodermal layer known as the apical ectodermal ridge (AER) which is primarily responsible 
for patterning the proximal-distal axis and maintaining the proliferative state which is 
required for limb growth (Mariani, Fernandez-Teran et al. 2017, Petit, Sears et al. 2017).
Mesenchymal FGF10 expression is elicited by either TBX4 or TBX5, creating a positive 
regulatory feedback loop with ectodermal (AER) FGF8 expression. The zone of polarising 
activity (ZPA), a posterior area of mesodermal cells, controls the anterior-posterior axis by 
the secretion of the gradient morphogen sonic hedgehog (SHH). The dorso-ventral axis is 
patterned by the non-AER ectoderm under the regulation of WNT family member 7A. The 
presence and interaction of all three centres is required for the correct patterning of the limb 
and involves the specific coordination of many genes and their regulatory elements (Liu, 
Nakamura et al. 2003, Mariani, Fernandez-Teran et al. 2017,  Parr and McMahon 1995, Petit,
Sears et al. 2017). As an example, bone morphogenetic protein (BMP4) in the mesenchyme 
upregulates Gremlin1 (GREM1) forming a negative feedback loop which controls the area of 
the AER (Figure 1C). SHH becomes the main upregulator of GREM1 expression and a 
feedback loop forms between GREM1, BMP4, FGFs (AER) and SHH (ZPA) (Zuniga, Laurent et 
al. 2012). As the limb bud grows, the concentration of SHH near the GREM1 expression
decreases and FGF inhibition of GREM1 occurs. This decreases downstream GREM1 signalling 
and halts the feedback loop. 
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1.2. Bone development 
The human musculoskeletal system is comprised of many different tissue types that work 
in synchrony to protect the internal organs and allow movement. The adult human skeleton 
is comprised of 206 bones which are connected to each other and the various muscles with 
ligaments and tendons respectively. The bones of the joint are covered by a layer of cartilage, 
which helps to prevent any damage to the bones that might be caused during movement. The 
development of the human skeleton occurs by two main processes: the formation of the long 
bones occurs through the process of endochondral ossification; the flat bones, such as those 
in the skull’s cranial vault, develop by intramembranous ossification (Mackie, Ahmed et al. 
2008, Karaplis 2008).
1.2.1. Endochondral ossification
Endochondral ossification relies upon formation of an initial cartilaginous template 
(Figure 2A). Mesenchymal stem cells condense and differentiate into cartilage cells or 
chondrocytes which begin to proliferate and secrete collagen, proteoglycan and glycoproteins 
to form an extracellular matrix. This matrix is arranged around the cells which sit in cavities 
called lacunae (Karaplis 2008). The chondrocytes in the centre of the condensation cease
proliferation, enter hypertrophy (vastly increasing their cytoplasmic to nuclear ratio) and 
begin to secrete indian hedgehog (Figure 2B). As the cells mature in this hypertrophic zone 
they express collagen type X, matrix metalloproteinase 13 (MMP13) and vascular endothelial 
growth factor (VEGF) (Mackie, Ahmed et al. 2008). The perichondrial cells next to this region
are induced to differentiate to osteoblasts and begin to secrete matrix to form a bone collar
(Long, Chung et al. 2004). It was thought that the vast majority of the hypertrophic cells
enter terminal differentiation and become apoptotic; however, more recent work has shown 
that these cells may also transdifferentiate into osteoblasts, with the exact proportion 
estimated as much as 60% (Ono, Ono et al. 2014, Yang, Tsang et al. 2014, Zhou, von der 
Mark et al. 2014). The expression of VEGF and several other factors causes blood vessels to 
invade and vascularise the tissue. Osteoprogenitor cells (chondroclasts) are attracted into 
the tissue and use the remaining matrix as a scaffold to begin bone formation (primary 
spongiosa). Osteoclasts degrade the cartilage ECM, which is then replaced by a characteristic 
bone matrix secreted by the osteoblasts. (Karaplis 2008) This forms the primary ossification
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centre. As interstitial growth continues some of the proliferating chondrocytes assume a
flattened discoid morphology, dividing perpendicular to the axis of growth and move over 
each other to form columns parallel to the axis of bone growth (Kronenberg 2003). As the 
skeleton develops, a secondary ossification site forms at the epiphysis of the long bone as the 
chondrocytes again cease proliferation and enter a hypertrophic state, initialising bone 
formation (Figure 2A). The secondary ossification centre is provided with nutrition by vessels 
known as the cartilage canals which originate from the perichondrium. These canals then 
recede during aging as they are gradually replaced by cartilage at their terminal ends in a 
process known as chondrification (Ytrehus, Ekman et al. 2004). The cells below the secondary 
ossification centre slow their rate of proliferation, forming a resting zone (Figure 2B).  
Chondrocytes in the resting zone are small, rounded and continue to secrete some 
extracellular matrix proteins (Mackie, Ahmed et al. 2008). The cells act as a reserve, storing
lipids, glycogen and proteoglycan aggregates in preparation for future growth and increased 
matrix production. Above the secondary ossification centre (adjacent to the synovial cavity or 
joint space) a residual layer of cartilage forms the articular surface to protect the underlying 
bone from damage. This articular cartilage is also divided into zones with differences in cell 
morphology and ECM organisation (Figure 2C). The superficial zone is adjacent to the joint 
space with tightly packed flattened cells arranged parallel to the synovial cavity. This zone 
provides the remaining articular zones with a source of cartilage progenitors (Kozhemyakina, 
Zhang et al. 2015) and expresses a high level of the lubricating glycoprotein lubricin to 
facilitate joint movement (Jay and Waller, 2014). The intermediate zone forms approximately
half of the total articular cartilage volume and consists of sparsely arranged rounded 
chondrocytes. Cells in the deep zone below this are organised in columns perpendicular to 
the joint. This region comprises about 30% of the cartilage and provides the greatest 
resistance to compression. The last zone, which resides between the deep zone and the 
underlying subchondral bone, is the calcified cartilage. A ‘tidemark’ separates the uncalcified 
and calcified tissue. Cells in this region are sparse and have entered a hypertrophic state 
(Sophia Fox, Bedi et al. 2009). The area of cartilage between the two ossification sites forms 
the epiphyseal growth plate (Mackie, Tatarczuch et al. 2011) and longitudinal bone growth 
continues at this site until maturity is reached and the primary and secondary ossification 
centres fuse (Kronenberg 2003). After this time periosteal appositional growth stills occurs, 
increasing  bone diameter as  mineralised  tissue is  added to  the periosteal  bone  surface by 
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osteoblasts (Figure 2B). This acts in tandem with the action of osteoclasts which break down 
the older bone tissue around the medullary cavity to increase its size (Rauch 2004).
1.2.2. Regulatory signalling 
Endochondral ossification is a highly complex process which involves many interacting 
regulatory cell signalling pathways (Figure 2B). The transcription factor SRY-related high-
mobility group-box gene 9 (SOX9) has been implicated in the initial formation of cartilage 
condensations and has been shown to drive both condensation cell survival and their 
differentiation to chondrocytes. At later stages proliferating chondrocytes have the highest 
expression of SOX9, where it seems to increase proliferation, production of matrix and 
expression of other key signalling molecules such as SOX5, SOX6 and IHH (Akiyama, 
Chaboissier et al. 2002). Further to this, SOX9 also acts to suppress hypertrophy by inhibition 
of the transcription factor RUNX2 and the WNT signalling pathway (Zhou, Zheng et al. 2007,
Topol, Chen et al. 2009). The cell signalling protein indian hedgehog (IHH) is expressed by pre-
hypertrophic chondrocytes and is a key modulator of chondrocyte proliferation and 
differentiation and osteoblast differentiation. IHH binds to its receptor patched-1 (PTCH1) 
which is expressed in the proliferative zone and adjacent perichondrium. The binding of IHH 
and PTCH1 activates smoothened (SMO) which triggers a gene activation cascade. The 
classical IHH pathway involves the delay of hypertrophy through the upregulation of 
parathyroid hormone-related protein (PTHRP) in the early proliferative region. PTHRP binds 
to parathyroid hormone receptor 1 (PTH1R) which is expressed in the proliferative zone and 
highly expressed by chondrocytes undergoing hypertrophy, delaying terminal differentiation. 
However, IHH has also shown an ability to accelerate chondrocyte proliferation and 
maturation by signalling independently of PTHRP (Karp, Schipani et al. 2000) through the BMP 
and canonical WNT pathways (Mak, Kronenberg et al. 2008). The bone morphogenetic 
proteins (BMPs) or growth and differentiation factors (GDFs) have been implicated in 
condensation, chondrocyte proliferation, maturation and maintenance of articular cartilage 
(Bandyopadhyay, Tsuji et al. 2007, Nilsson, Parker et al. 2007, Salazar, Gamer et al. 2016).
The BMPs are part of the TGFβ superfamily, signalling through cell surface serine-threonine 
kinase receptors (BMPR1/2) to phosphorylate the SMAD transcription factor proteins. These 
interacting proteins form a signalling gradient across the growth plate and articular cartilage, 
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with the highest BMP expression in the hypertrophic zone (decreasing towards the resting 
zone) and the superficial zone (decreasing towards the deep zone). However, the highest 
SMAD phosphorylation is found in the proliferative, pre-hypertrophic and superficial zones. 
This is thought to be due to increased expression of the BMP antagonists SMAD7 in the 
hypertrophic zone and GREM1 and SMAD7 in the intermediate and deep zones of the articular 
cartilage. BMP signalling is currently thought to act to promote chondrocyte maturation in 
the proliferative and pre-hypertrophic zones (by increasing IHH expression) and helps to 
maintain the articular cartilage surface (although the exact mechanism is so far unknown) 
(Seki and Hata 2004, Estrada, Wang et al. 2013, Garrison, Yue et al. 2017). In addition to this, 
double knockout mice for the BMPR1A and BMPR1B receptors exhibit markedly reduced 
cartilage condensations, matrix production and SOX5/6/9 expression indicating an important 
role for BMP signalling in early chondrogenesis (Grimsrud, Romano et al. 2001, Yoon, 
Ovchinnikov et al. 2005). The fibroblast growth factor (FGF) signalling pathway is 
antagonistic to the BMP pathway and is very complex, with 22 FGF and 4 FGF receptor genes 
implicated in endochondral ossification. The function and expression of many FGFs is 
unknown but the FGF receptors are expressed in distinct regions: FGFR1 by pre-
hypertrophic, hypertrophic and perichondrial cells; FGFR2 in the perichondrium, periosteum 
and primary spongiosa; FGFR3 by proliferating chondrocytes. In postnatal development FGF 
signalling through FGFR3 appears to inhibit chondrocyte proliferation and differentiation, 
both through the Janus kinase–signal transducer and activator of transcription-1 (JAK-STAT1) 
pathway and inhibition of IHH expression (Sahni, Ambrosetti et al. 1999, Liu, Xu et al. 2002). 
However, in early development FGF/FGFR3 signalling has the opposite effect and is required 
for proper proliferation and initiation of hypertrophy. Thus far only the roles of FGF9 and 18 
have been investigated, indicating substantial redundancy between the two ligands and 
complex interactions with signalling molecules such as SOX9, VEGF and RUNX2. This 
indicates that FGF signalling is biphasic according to the stage of development and has a role 
at every point of growth, from limb patterning to vascularisation (Liu, Lavine et al. 2007, 
Karuppaiah, Yu et al. 2016, Hung, Schoenwolf et al. 2016). In addition to those already
discussed, chondrocyte hypertrophy appears to be regulated by a number of transcription 
factors, including Runt-related transcription factor 2 (RUNX2/CBFAI) myocyte enhancer factor 
2c (MEF2C) and forkhead box (FOX) proteins. All three have been shown to increase 
expression of COL10A1 and RUNX2 is also able to directly transcribe other markers of 
hypertrophy,  such  as  IHH  and  MMP13  (Yoshida,  Yamamoto  et  al. 2004, Arnold, Kim et al.
19
2007, Hirata, Kugimiya et al. 2012, Yoshida, Hata et al. 2015). The study of regulatory 
signalling in long bone growth is very complex due to redundancy between ligands (as in the 
FGF pathway) cross interaction between pathways (the antagonistic interaction of BMP and 
FGF signalling) and multiphasic roles (FGFR3 initially increases proliferation but then acts to 
supress it during postnatal development). In addition to this, many other factors also 
appear to be involved. These factors include vitamin D, cytokines, glucocorticoids, WNTs, 
thyroid hormone and androgen. Recent research has even revealed cross talk between the 
FGF and IHH/PTHRP pathways with autophagy and its master regulator mTORC (Cinque, 
Forrester et al. 2015, Zhang, Bai et al. 2017) further illustrating how little is known about 
these complex signalling interactions.  
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1.2.3. Intramembranous ossification and the development of the skull 
The development of the skull is complex as although the facial bones and those in the 
cranial base are formed by endochondral ossification, those in the cranial vault develop by 
intramembranous ossification. In addition to this, the facial bones originate from the neural 
crest (Noden 1983) but the cranial vault or neurocranium has its origins in both the cranial 
neural crest and mesoderm (Jiang, Iseki et al. 2002). The neurocranium consists of five major 
bones or calvaria: two frontal, two parietal and a single occipital bone (Figure 3A). 
Intramembranous ossification does not involve the formation of a cartilaginous precursor as 
the mesenchymal stem cells differentiate straight into osteoprogenitor cells and then 
osteoblasts after the formation of condensations (Hall and Miyake 2000) (Figure 3C). These 
osteoblasts deposit collagens, proteoglycans and other extracellular matrix proteins to 
produce osteoid, a bone matrix formed predominantly of collagen type I (McKee and Cole 
2012). Some of the osteoblasts then differentiate into osteocytes and the bone matrix 
mineralises. This forms a structure of bone spicules around primary ossification centres which 
expand with maturity. This immature woven bone is then slowly replaced by stronger mature 
lamellar bone. Where these cranial bone ‘plates’ meet (sagittal, metopic) or overlap 
(lambdoid, coronal) they are connected by a flexible fibrous tissue known as a suture (or 
fontanelle where there are more than two bone fronts) (Figure 3A-B). This flexible model 
allows both passage through the birth canal and expansion of the neurocranium during 
development, as the sutures function as sites of bone growth (Opperman 2000, Jin, Sim et al. 
2016). Each bone growth site is comprised of osteogenic bone fronts, the fibromesenchymal 
suture, the underlying dura mater that surrounds the brain and the external periosteum 
(pericranium) above. The cells in the centres of the fibromesenchymal suture maintain an 
undifferentiated state throughout development as those adjacent to the two bone fronts 
gradually differentiate into bone cells as the skull expands. This continues until growth ceases 
and the sutures fuse (Beederman, Farina et al. 2014, Katsianou, Adamopoulos et al. 2016). 
The regulation of cranial growth and maintenance of suture patency involves the interplay 
between signals from the dura mater, osteogenic front and fibromesechymal suture. 
Investigation  of  the  premature  suture  fusion  disorder  craniosynostosis  has  implicated
a   variety  of  transcription factors  (such  as  MSX2)  and  signalling  pathways,  including  the
22
canonical WNT, FGF and TGFβ/BMP pathways (Kim, Rice et al. 1998, Warren, Brunet et al. 
2003). 
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1.3. The vertebral column 
The human vertebral column is comprises of 24 bony vertebral bodies and the sacrum, 
interspersed with intervertebral discs (IVD) (Figure 4D). The IVD provide the spine with both 
flexibility and shock absorption and are formed of the outer annulus fibrosus and inner 
nucleus pulposus (Ferguson 2008).  The formation of the spinal skeleton is initiated during 
early embryonic development (week 4) as somitocoel and pre-sclerotome cells migrate to 
surround the notochord and neural tube, forming the perichordal tube or sclerotome (Figure 
4A). The large vacuolated notochordal cells within this structure generate osmotic pressure 
against basement sheath of the notochord, providing structure and aiding in sclerotome 
elongation (Aszódi, Chan et al. 1998, Stemple 2005). The regulation of vertebral body and IVD 
formation involves the complex interaction of many signalling molecules secreted by both 
the notochord (NOG, SHH, FOXA1) and sclerotome (BMP, TGF-β, SOX9, PAX1) to ensure 
correct patterning and differentiation (Peters, Wilm et al. 1999, Pearson, Lemons et al. 2005, 
Baffi, Moran et al. 2006, Maier, Lo et al. 2013). Segmental patterning of the sclerotome 
occurs under the regulation of the HOX transcription factors as the mesenchymal sclerotome 
cells condense to form areas of variable cellular density (Pearson, Lemons et al. 2005, 
Rodrigues-Pinto, Richardson et al. 2014) (Figure 4B). High density segments form the putative 
annulus fibrosus (IVD) and expand to accommodate the notochord, which retracts from the 
low density segments that will form the vertebral bodies (McCann, Tamplin et al. 2012) 
(Figure 4C). The exact mechanism by which the notochord is removed from the putative 
vertebrae is not currently known but both Eph/ephrin and ROBO/SLIT signalling pathways 
have been implicated in its regulation (Lawson and Harfe 2015). Those cells which will form 
the vertebrae differentiate into chondrocytes to form a cartilaginous structure (Aszódi, Chan 
et al. 1998). The development of the vertebral bodies and adjacent cartilage endplates 
continues by endochondral ossification, driven by SHH and FGF signalling molecules secreted 
by the notochord (Chan, Au et al. 2014, Ashley, Enomoto-Iwamoto et al. 2016) and other 
regulatory molecules, including the transcription factor osterix (Chen, Feng et al. 2014). The 
remnants of the notochord then form the nucleus pulposus (NP). The NP contains a 
heterogeneous cell population which varies with age, disease and species. In newborn 
humans the nucleus pulposus consists of clustered large vacuolated notochordal-like cells 
which decrease in number during childhood as the proportion of smaller chondrocyte-like 
cells increases (Purmessur, Guterl et al. 2013, Chan, Au et al. 2014). This  transition  is thought
25
to occur through both differentiation of notochordal-like cells to a chondrogenic 
phenotype (regulated by a canonical Wnt-Shh feedback loop)  and cellular migration from 
other tissues (McCann, Tamplin et al. 2012, Tanaka, Sakai et al. 2012, Chen, Feng et al. 
2014). The exact function of each cell type is not currently known but notochordal-like cells 
have been shown to have a protective role against degeneration in vitro, suggesting that 
they play an important role in the maintenance and repair of the NP (Erwin, Islam et al. 
2011, Chan, Au et al. 2014).  
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1.4. Cartilage and the extracellular matrix 
Cartilage is a dynamic tissue which is usually comprised of a single cell type (the 
chondrocyte) and a highly organised and complex extracellular matrix (ECM) (Figure 5A). This 
ECM is continuously remodelled throughout life and in response to injury and degenerative 
disease. ECM composition and organisation also differs between its tissue type (hyaline, 
elastic or fibrocartilage), location and indeed its location within that particular sub-type of 
cartilage (Onnerfjord, Khabut et al. 2012). 
1.4.1. The articular surface and growth plate 
Hyaline cartilage is a highly specialised translucent tissue found on the articular joint 
surface and in the epiphyseal growth plate. The chondrocytes within this tissue exist in a 
mostly avascular, hypoxic, aneural and alymphatic environment, using glycolysis for ATP 
production (Karaplis 2008). The cartilage ECM consists of networks of interacting molecules 
that provide structural support for the chondrocyte cells and 90% of the tissue’s dry weight 
(Hardingham and Fosang 1992) (Figure 5). In addition to its important structural role it has 
also been shown to be involved in cell adhesion, migration, proliferation, differentiation, and 
survival, mostly through integrin-mediated cell-matrix signalling (Buckwalter and Mankin 
1998, Toole 2001, Pulai, Del Carlo Jr et al. 2002, Schmidt and Friedl 2010, Gao, Liu et al. 
2014). The two major structural components are collagen type II and the proteoglycan 
aggrecan; however, the ECM is comprised of many families of molecules, including 
collagens, proteoglycans and non-collagenous glycoproteins (Frantz, Stewart et al. 2010). 
The matrix composition of articular and growth plate hyaline cartilage varies depending on a 
number of factors, including zone and distance from the cell. The pericellular matrix 
encircles the chondrocyte forming a capsule. This matrix is mainly comprised of a collagen 
type VI microfibrillar network (Zelenski, Leddy et al. 2015) and is enriched in proteoglycan 
(perlecan, biglycan) (Kavanagh and Ashhurst 1999, Melrose, Roughley et al. 2007) collagen type 
IX (Parsons, Gilbert et al. 2011) hyaluronan (Knudson 1993) and glycoproteins such as 
matrilin 3 (Vincourt,  Etienne  et  al. 2012). It  is  thought that  the structure  of this matrix 
capsule
28
influences cell response to stimuli, facilitates mechanotransduction and allows the 
modification of ECM molecules as they are secreted and move towards the interterritorial 
matrix. As an example, the pericellular matrix can affect cartilage metabolism by the 
incorporation of the catabolic matrilin 3 into the matrix where it then exerts an anabolic 
effect (Vincourt, Etienne et al. 2012, Wilusz, Sanchez-Adams et al. 2014). The thicker 
territorial matrix surrounds each chondron and is postulated to provide resistance to 
mechanical stress (Sophia Fox, Bedi et al. 2009). It contains a network of larger banded 
collagen fibrils comprised of collagen types II, IX and XI. As these collagen fibrils move into 
the interterritorial matrix, which lies between the chondrons, they enlarge and move parallel 
to the adjacent fibrils (Prein, Warmbold et al. 2016). Cartilage’s main tensile strength and 
resistance to compression are provided by the combined action of these heterotopic collagen 
fibrils (which provide tensile strength) and proteoglycan aggregates (which provide resistance 
to compression) (Roughley and Mort 2014). These aggregates lie within the collagen network
and are formed from the large proteoglycan aggrecan, cartilage link protein and the 
glycosaminoglycan hyaluronan. Aggrecan has a great number of attached sulfated chains 
which have a high fixed charge and become hydrated in proximity to the aqueous joint space 
environment, creating an osmotic pressure in the spaces between the collagen fibrils. When a 
mechanical force is applied through movement of the joint the water is displaced and the 
ECM compresses without any structural damage occurring. As the force abates, water is 
pulled back into the cartilage from the joint space and the cartilage re-swells. This mechanism 
is not only useful for resistance to mechanical load but is thought to aid with nutrition and 
waste removal (Roughley and Mort 2014). In the articular cartilage collagen fibril diameter 
and orientation differ depending on the distance from the joint space. In the superficial zone, 
directly adjacent to the joint surface, the thin collagen fibrils are parallel to the joint space 
and there is a low abundance of proteoglycan. In the intermediate zone below, fibril diameter 
and orientation are more varied and proteoglycan abundance is increased. The deep zone 
contains the greatest amount of proteoglycan and collagen fibrils are organised perpendicular 
to the joint surface (Sophia Fox, Bedi et al. 2009). Matrix composition also changes according 
to the zone of chondrocyte differentiation; for example, the collagens expressed by
hypertrophic cells in the deep articular zone and the hypertrophic growth plate zone consist 
of 45% collagen type X (Shen 2005).  
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1.4.2. The intervertebral disc 
The intervertebral disc (IVD) is a mostly avascular tissue comprised of three parts,
each with a distinct cartilaginous matrix composition according to function, which will be 
discussed in brief. Each IVD is comprised of a central nucleus pulposus (NP) surrounded by a
lamellar annulus fibrosus (AF) and bordered by two cartilage endplates which connect the 
IVD to the vertebral bodies (Chan, Au et al. 2014). The cartilage endplates are composed of
hyaline cartilage rich in collagens type II and X and provide the IVD with both nutrition and 
waste removal through its nutrient supply channels (Rodrigues-Pinto, Richardson et al. 2014). 
The annulus fibrosus (AF) is formed from both fibrous and cartilaginous tissue (known as 
fibrocartilage) and contains collagen fibers interspersed with elastic fibers. This matrix 
composition allows fibrocartilage to resist tension and so it is also found in the tendon, 
ligament and meniscis. Interestingly, it also forms during the wound healing response to 
hyaline cartilage damage (Freemont and Hoyland 2006). This alteration in matrix composition 
can cause additional problems; for example, the replacement of the flexible cartilaginous
nucleus pulposus with the more rigid fibrocartilage during disc degeneration can cause 
fissure formation. The outer annulus fibrosus (AF) is predominantly formed of parallel 
collagen type I fibers which are inserted through the endplates into the upper and lower 
vertebrae (Risbud and Shapiro 2011). These collagen fibers lie between the AF lamellae in the 
inter-lamellar matrix. This matrix is comprised of a proteoglycan-rich gel, elastic fibers, 
elongated fibroblast-like cells and a cross-bridge network which interconnects the lamellae 
(Tavakoli, Elliott Dawn et al. 2016). The inner AF encircles the NP and, although similar to the 
outer AF, is more cartilaginous in structure with rounded cells and an increased proportion of 
both proteoglycan and collagen type II fibers (Rodrigues-Pinto, Richardson et al. 2014). The 
nucleus pulposus (NP) has a hyaline cartilage-like structure and, much like hyaline cartilage, 
provides the IVD with resistance to compression and tensile strength through its collagen 
fibril network and proteoglycan aggregates. Unlike hyaline cartilage however the nucleus 
pulposus contains a heterogeneous cell population formed of large vacuolated notochordal-
like cells and smaller chondrocyte-like cells (Chan, Au et al. 2014). The NP matrix is comprised 
of randomly organised collagen fibers, radial elastin fibers and an aggrecan-rich gel, which 
becomes  less  gelatinous with  age  due to  proteoglycan  loss  (Massey,  van  Donkelaar et al. 
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2012).  These changes in matrix composition and those due to age and disease state will
be discussed in greater detail in the following section. 
1.4.3. Collagens
The collagens are a group of ubiquitously expressed structural proteins of which 28 
types have thus far been described. They are the most abundant proteins in the cartilage 
extracellular matrix, comprising ~60% of its dry weight (Eyre 2004). Each collagen molecule is
formed of three polypeptide α chains organised into a triple helix. These proteins can either
be homotrimeric (in which each  α chain is identical) or, more commonly, heterotrimeric 
(where each chain may be encoded by an individual gene) (Bella and Hulmes 2017). The triple 
helix is created through hydrogen bond formation between Xaa-Yaa-Gly triple helix motifs in 
which Xaa and Yaa can be a number of different amino acids (most often proline and 
hydroxyproline). These motifs are known as the collagenous (COL) domains and they are 
interspersed with a number of non-collagenous (NC) domains, such as a thrombospondin 
domain (Shoulders and Raines 2009). The collagen protein family is large and can be divided 
into a number of categories. More recent research has illustrated the important roles of even 
minor low abundant collagens in the cartilage ECM; however, for the purposes of this thesis
only a small number of the fibrillar, network, beaded filament and FACIT collagens will be 
discussed (Bella and Hulmes 2017, Luo, Sinkeviciute et al. 2017) (Table 1). 
1.4.3.1. Fibril-forming/fibrillar collagens 
The collagen fibrillary network provides cartilage with structure and allows it to resist 
both tensile and shear stress. Fibrillar collagens are secreted as procollagens and are 
characterised by a large COL1 domain, a short COL2 domain and a trimeric C-terminal NC1 
domain. They can then be divided into three clades according to their N-terminal structure. 
Clade A collagens (types I, II and III) have an additional von Willebrand factor type C (VWC) 
domain. The COL2 and VWC domains are cleaved off during processing, leaving the COL1
domain surrounded by two telopeptides which allow for crosslinking during fibril formation 
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Collagen Structure Relevant tissue location Function 
Fibril-forming (clade A) 
I Heterotrimer Bone Structure, resistance to mechanical force 
II Homotrimer Artic lar and hyaline cartil ge Structure, resistance to mechanical force 
III Homotrimer Artic lar cartil ge 
Structure, response to ti sue injury, collagen I   brillo-
genesis 
Fibril-forming (clade B) 
V Heterotrimer Artic lar cartil ge, bone Fibril nucleati n 
XI Heterotrimer Cartil ge Fibril nucleati n, ECM organisati n 
Fibril-forming (clade C) 
XXIV Homotrimer Bone 
Collagen I   brillogenesis in early development,   bril 
diameter regulatio  
XXVII Homotrimer Proliferati e cartil ge 
Structure, pericellular ECM organisati n, bone miner-
alisati n 
Network forming 
IV Heterotrimer Artic lar cartil ge Chondrocyte phenotype and survival 
VI Heterotrimer  Cartil ge, invertebral disc Mechanotransduc  on, chondrocyte a  achment 
VIII 
Homo/
heterotrimer 
Perichondrium, periosteum, 
cartil ge, calvarium 
Response to ti sue injury 
X Homotrimer 
Hypertrophic and calcifying 
cartil ge 
Hypertrophy and bone mineralisati n 
FACIT 
IX Heterotrimer Cartil ge Collagen   brillogenesis, ECM organisati n 
XII Homotrimer Perichondrium, bone 
Mechanical proper  es and organisati n of collagen I 
fi rils 
XIV Homotrimer 
Artic lar cartil ge, invertebral 
disc 
Collagen I   brillogenesis in early development, di  er-
entiati , mechanical stress 
XVI Homotrimer Cartil ge 
Di  erenti tio , cell adhesion, proliferatio , focal ad-
hesion 
XX Homotrimer Sternal cartil ge Possible cytokine receptor 
XXII Homotrimer Artic lar cartil ge 
Fibrillogenesis, cell adhesion, osteogenesis, mechani-
cal stress 
Transmembrane 
XIII Homotrimer Chondrocytes Cell adhesion 
Table 1  Collagens of the musculoskeletal ECM 
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(Bella and Hulmes 2017). Clade B is comprised of the minor fibril-forming collagens (types V
and XI) which have an N-terminal thrombospondin domain. Their processing differs from 
clade A collagens as the N-terminal domains are only partially cleaved and the C-terminal 
propetide is removed. The resultant structure is thought to help in fibril diameter regulation 
(Bella and Hulmes 2017). Clade C collagens are structurally quite different from other fibrillar 
collagens and form thin, non-striated fibrils (Koch, Laub et al. 2003, Plumb, Dhir et al. 2007). 
They consist of a short interrupted COL1 domain and non-helical NC1 domain. The C-terminal
region is removed during processing to mature collagen but the N-terminal region is retained 
(Bella and Hulmes 2017). Collagen type XXVII is expressed in the pericellular matrix of both 
proliferating chondrocytes, where it is thought to regulate ECM organisation and 
hypertrophic chondrocytes, where it is associated with bone mineralisation (Hjorten, Hansen 
et al. 2007, Plumb, Dhir et al. 2007, Plumb, Ferrara et al. 2011, Ricard-Blum 2011). 
1.4.3.2. Fibril-associated collagens with interrupted triple helices (FACIT) 
The FACIT collagens, as their name suggests, associate with the collagen fibril surface 
and have a number of interruptions in their triple helix domain. In addition to this, FACIT 
collagens also have great variation in the number of COL domains (2-10) an N-terminal 
thrombospondin domain and a diverse number of other NC domains (Ricard-Blum 2011). The 
main FACIT collagen in cartilage is the heterotrimeric collagen type IX which is predominantly 
expressed by proliferative chondrocytes and covalently links to collagen type II/XI fibrils via its 
NC-1 domain (Eyre, Pietka et al. 2004). Mutations in the genes encoding the three α(IX) chains 
(COL9A1, COL9A2 and COL9A3) have been shown to cause multiple epiphyseal dysplasia 
(Paassilta, Lohiniva et al. 1999, Czarny-Ratajczak, Lohiniva et al. 2001, Jackson, Marcus-
Soekarman et al. 2010).  
1.4.3.3. Network-forming collagens 
The network-forming collagens retain their C-terminal NC domains during processing 
(Khoshnoodi, Cartailler et al. 2006). The homotrimeric collagen type X is the predominant 
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collagen expressed in the hypertrophic zone, where it forms pericellular hexagonal networks 
and has an important role in endochondral ossification (Kwan, Cummings et al. 1991, Shen 
2005).  Collagen type X is also implicated in bone mineralisation through annexin V-mediated 
binding to mineral and alkaline phosphatase-containing matrix vesicles, which calcify the 
matrix (Kirsch and Pfaffle 1992). Mutations in the COL10A1 gene cause Schmid metaphyseal 
chondrodysplasia (MCDS) (Chan, Weng et al. 1998) and Spondylometaphyseal dysplasia 
(SMD) (Ikegawa, Nishimura et al. 1998). Collagen type VI is a heterotrimeric beaded filament 
collagen which, unlike other collagens, is assembled into aggregates before secretion 
(Cescon, Gattazzo et al. 2015). It is able to interact with a number of ECM molecules including 
matrilins and small leucine-rich proteoglycans (SLRPs) (Wiberg, Klatt et al. 2003) and forms a
microfibrillar network in the pericellular matrix. This network has roles in chondrocyte 
attachment to the matrix and mechanotransduction in response to osmotic stress (Marcelino 
and McDevitt 1995, Zelenski, Leddy et al. 2015). The importance of this is illustrated by the 
collagen VI null mouse which has joint degeneration, delayed bone age, altered osteoblast 
morphology, ostepenia and reduced mineralisation (Alexopoulos, Youn et al. 2009, 
Christensen, Coles et al. 2012, Izu, Ezura et al. 2012).  
1.4.3.4. Collagen fibril structure 
Collagen fibrils are heterotopic, composed of many different collagenous and non-
collagenous molecules (Bruckner 2010). Collagen type II is the predominant fibrillar collagen 
in the cartilage extracellular matrix, making up 95% of the total collagen present and most of 
the collagen fibril superstructure (Figure 6). The remainder of the structure consists of 
collagen type XI microfibrils which nucleate assembly and regulate lateral fibril growth 
(Bruckner 2010). The ratio of collagen II and XI is therefore essential in order to assemble 
fibrils of the correct length and width. In immature cartilage this process is enhanced by the 
presence of collagen type IX which also provides the fibrils with a negatively charged surface 
(due to its attached dermatan sulfate chains) and stabilises the fibrillar network by binding to 
a number of non-collagenous ECM proteins, such as COMP via its NC4 (thrombospondin) 
domain (Blaschke, Eikenberry et al. 2000, Bruckner 2010, Acharya, Yik et al. 2014). The 
important  role of  collagen IX is  further  demonstrated  by the null  mouse  which  has altered 
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chondrocyte morphology (Brachvogel, Zaucke et al. 2013). In addition to those collagens 
mentioned, fibril assembly can also be affected by non-collagenous proteins, including
matrilins, perlecan and SRLPs (Svensson, Aszodi et al. 2002, Wiberg, Klatt et al. 2003, 
Douglas, Heinemann et al. 2006, Kvist, Johnson et al. 2006). This illustrates the complexity of 
collagen fibrillogenesis and the number of molecules required for correct organisation. As an 
example, tenascin X has been shown to not only regulate the rate of fibril assembly but fibril 
packing density (Mao, Taylor et al. 2002, Egging, van den Berkmortel et al. 2007). As skeletal 
development continues and the fibrils move further towards the territorial matrix the 
composition of fibrils alters with a decrease in collagen type IX abundance and an increase in 
the proportion of decorin (which is also dermatan sulfated). It is hypothesised that this assists 
in the fusion of immature fibrils to form the larger fibrils found in the interterritorial matrix 
(Bruckner 2010). Interestingly, during articular cartilage maturation the proportion of collagen 
type XI also decreases as it is slowly replaced by collagen type V. In addition to this, the 
abundance of collagen type III also increases in damaged areas of cartilage where it is cross-
linked to the collagen II fibrils, providing additional structural support to a weakened collagen 
network (Wu, Weis et al. 2009, Wu, Weis et al. 2010). 
1.4.4. Glycoproteins 
The non-collagenous glycoproteins fulfil the role of adaptor proteins in the 
extracellular matrix (along with the small proteoglycans) and connect the fibrillar collagen 
network with the proteoglycan aggregates to stabilise the extracellular matrix (Zaucke 2016) 
(Table 2). Furthermore, they have also been implicated in collagen fibrillogenesis, cell-cell and 
cell-matrix interactions and growth factor binding (Svensson, Aszodi et al. 2002, Haudenschild, 
Hong et al. 2011). There are a great number of glycoproteins in the ECM (Zaucke 2016) 
including chondroadherin (Hessle, Stordalen et al. 2014) and von Willebrand factor A-domain-
related protein (WARP) (Hansen, Allen et al. 2012). 
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Glycoprotein Function 
Thrombospondins 
TSP-1 
TSP-2 
TSP-3 
TSP-5/COMP 
Cell-cell and cell-matrix interac tions, angiogenesis 
Collagen  fibrillogenesis, chondrocyte di fferentiation 
Unknown 
Cell-matrix interaction, articular chondrocyte phenotype
Collagen  fibrillogenesis, growth factor binding 
Matrilins 
Matrilin 1/CMP 
Matrilin 3 
Cell a ttachment, ECM organisation 
ECM organisation, growth factor binding 
Fibulins  
Fibulin 1 
Fibulin 2 
Fibulin 3 
Cell adhesion 
Integrin-mediated cell adhesion and migration 
Chondrocyte differentiation
Proteoglycans 
Asporin (See table 3)
PRELP (See table 3)
Perlecan (See table 3)
WARP ECM organisation 
Chondroadherin Cell-cell and cell-matrix interac tions 
CILP 
Fibronec tin 
Laminin 
Nidogen 
Tenascin C 
TGFβ-binding 
Cell-matrix interaction
Chondrocyte phenotype and survival 
Chondrocyte phenotype and survival 
Development, cartilage repair 
Table 2  Glycoproteins of the musculoskeletal ECM 
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TSP-4 
Other glycoproteins
1.4.4.1. The Thrombospondins: Cartilage oligomeric matrix protein 
The thrombospondin (TSP) family is a group of five matricellular proteins, of which 
TSP5 or cartilage oligomeric matrix protein (COMP) is the best characterised of those found 
in cartilage (Tan and Lawler 2009). It is a 552kDa glycoprotein (Oldberg, Antonsson et al. 
1992) which exists as a homopentamer (Morgelin, Heinegard et al. 1992) and is expressed in 
several tissues including skeletal muscle, tendon, synovium, skin and ligament (DiCesare, 
Hauser et al. 1994, DiCesare, Morgelin et al. 1994, Di Cesare, Carlson et al. 1997). The exact 
function of COMP is not fully known; however, it is thought to act as a bridging molecule in 
the cartilage ECM, interacting with many ECM proteins including aggrecan, matrilin3, 
fibronectin and collagen type II and IX (Di Cesare, Chen et al. 2002, Mann, Ozbek et al. 2004, 
Chen, Herndon et al. 2007, Acharya, Yik et al. 2014). Further to this, it has also been 
implicated in collagen fibrillogenesis (Halasz, Kassner et al. 2007) cell attachment, growth 
factor binding and the complement system (Chen, Thomas et al. 2005, Tan, Duquette et al. 
2009). The COMP gene is comprised of 19 exons encoding an N-terminal oligomerisation 
domain, 4 Type II (epidermal growth factor-like) repeats, 8 TSP Type III repeats and a C-
terminal globular domain (Oldberg, Antonsson et al. 1992). Mutations in the C-terminal 
domain and Type III repeats have been shown to cause the skeletal dysplasias 
pseudoachondroplasia and multiple epiphyseal dysplasia (Briggs, Hoffman et al. 1995, Deere, 
Sanford et al. 1998, Jackson, Mittaz-Crettol et al. 2012, Briggs, Brock et al. 2014). The COMP 
null mouse has no skeletal phenotype, indicating that other members of the TSP family may 
compensate for its absence (Svensson, Aszodi et al. 2002). This finding strongly suggests that 
the disease pathology caused by COMP mutations is due to the effects of the mutant protein 
itself rather than a loss of protein (antimorphic or dominant-negative effect).  
1.4.4.2. The Matrilins 
The matrilins are a family of four oligomeric matrix proteins comprised of varying 
arrangements of von Willebrand factor-like (VWA) and EGF-like domains which form either 
trimers (MATN1/4) or tetramers (MATN2/3) through an oligomerisation domain. Matrilin 1 
and 3 are also able to form both homo- and hetero-oligomers (Kleemann-Fischer, Kleemann 
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et al. 2001). The two predominant matrilins in cartilage are matrilin 1 and 3 (Klatt, Becker et 
al. 2011) although only matrilin 4 is present in the superficial layer of articular cartilage (Klatt, 
Paulsson et al. 2002). There is also some redundancy in function as the characterisation of 
single and double matrilin 1 and 3 null mice indicates that other matrilin family members may 
try to compensate for their loss in the cartilage ECM (Nicolae, Ko et al. 2007). Matrilins are 
thought to act as adaptor proteins within the matrix, connecting the aggrecan-hyaluronan 
aggregates with the collagen fibrillar network. Matrilins 1, 3 and 4 are able to form 
complexes with the small leucine-rich proteoglycans (SLRPs) biglycan and decorin, which 
then interact with collagen type VI microfibrils. The matrilins then bind to aggrecan or collagen 
type II fibrils, forming a matrilin-SLRP bridge between these large structures and the collagen 
type VI microfibrils (Wiberg, Klatt et al. 2003). Matrilin 3 is also able to bind a number of 
other proteins, including type IX collagen (Budde, Blumbach et al. 2005). In addition to this, 
the matrilins have a high binding affinity for another adaptor protein, COMP, which is also 
able to interact with aggrecan and collagens type II and IX (Thur, Rosenberg et al. 2001, Chen, 
Herndon et al. 2007, Otten, Hansen et al. 2010). Thus far, no causative mutations for skeletal 
disorders have been found in matrilin 1; however, a number of polymorphisms are 
associated with susceptibility to mandibular prognathism, osteoarthritis and idiopathic 
scoliosis in certain ethnic populations (Meulenbelt, Bijkerk et al. 1997, Strusberg, Sembaj et 
al. 2002, Jang, Park et al. 2010, Zhang, Zhao et al. 2014). This may be explained by recent 
research which highlighted a possible mechanotransduction role. Matrilin 1-null mice 
exhibited a reduced anabolic gene expression response to mechanical loading and had 
increased articular surface damage when subjected to the surgical destabilization of the 
medial meniscus (DMM) osteoarthritis model, indicating its protective role against 
mechanical stress (Chen, Cossman et al. 2016). Matrilin 3 polymorphisms are also associated 
with a predisposition to osteoarthritis (Min, Meulenbelt et al. 2006) and antimorphic 
missense mutations are implicated in a range of skeletal disorders, including 
spondyloepimetaphyseal dysplasia and multiple epiphyseal dysplasia (Chapman, Mortier et 
al. 2001, Borochowitz, Scheffer et al. 2004). In addition to the previously discussed functions, 
matrilin 3 is also thought to play an important role in cartilage homeostasis, chondrocyte 
proliferation and hypertrophy, due to its role in Sox9, TGF-β and BMP2 signalling and 
upregulation of osteoarthritis-associated genes for MMPs and pro-inflammatory cytokines 
such as  MMP13 (Klatt,  Klinger et  al. 2009,  Yang,  Trehan et al.  2014,  Zhang,  Ji  et al.  2015, 
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Muttigi, Han et al. 2016). Furthermore, the removal of either matrilin 1 or 3 from the
pericellular matrix reduced the chondrocyte’s response to mechanical loading, decreasing
mechanically induced IHH signalling, proliferation and differentiation (Kanbe, Yang et al.
2007).  
1.4.5. Proteoglycans and glycosaminoglycans
The proteoglycans form around 10% of the cartilage extracellular matrix and form 
aggregates which allow the tissue to resist compression and distribute mechanical load. 
Further to this, they also have roles in matrix assembly and innate immunity through their 
interaction with Toll-like receptors (TLRs) and the complement pathway (Orlowsky and Kraus 
2015). Proteoglycans are comprised of a protein core and a mixture of attached 
glycosaminoglycan (GAG) chains, such as dermatan sulfate (DS) heparan sulfate (HS) keratin 
sulfate (KS) and the predominant chondroitin sulfate (CS) (Knudson and Knudson 2001). DS, 
HS and CS are all attached to the protein core by the serine residue in a serine-glycine motif 
via a tetrasaccharide linker whereas KS is either N or O-linked (to serine or threonine residues). 
The composition of these sulfate chains can have a great effect on proteoglycan function; for 
example, heparan sulfate is well-known to sequester growth factors (Vlodavsky, Bar-Shavit 
et al. 1991). The important GAG hyaluronan is unusual as, unlike the others mentioned, it is 
not attached to a protein core and is released by transmembrane hyaluronan synthases into 
the extracellular matrix (Aspberg 2016). Once in the ECM it interacts with a number of cell 
surface receptors such as CD44 and forms aggregates with large proteoglycans like aggrecan 
(Misra, Hascall et al. 2015). Proteoglycans are implicated in both chondrogenesis and post-
natal skeletal development and this section will highlight a few of the most important (Table 
3). 
1.4.5.1. Small leucine-rich proteoglycans (SLRPs) 
The small leucine-rich proteoglycans are regulators of extracellular matrix assembly 
due to their ability to binds collagens (Aspberg 2016) and include fibromodulin, epiphycan and 
chondroadherin (Iozzo and Schaefer 2015). They consist of a leucine-rich repeat (LLR) region, 
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Proteoglycan Main GAG Location Function 
Class I SLRPS 
Biglycan CS 
Extracellular    
Bone mineralisatio , osteoblast di  erentiati , infl mmati n, 
angiogenesis, collagen   brillogenesis, cell growth 
Decorin DS 
Cell growth, collagen   brillogenesis, angiogenesis, autophagy, 
immunity, infl mmatio  
Asporin Bone mineralisatio , chondrogenesis, growth factor binding 
Class II SLRPS 
Fibromodulin KS 
Extracellular 
Possible growth factor sequestratio , collagen   brillogenesis, 
PRELP Osteclast formati n, complement ac  vati n, ECM organisati n 
Keratocan Osteogenesis, infl mmati n 
KS  Lumican Collagen fi rillogenesis, infl mmatio  
Osteoadherin Bone mineralisatio , osteoblast a  achment 
Class III SLRPS 
Epiphycan DS/CS 
Extracellular  
Chondrogenesis, growth plate organisati n 
Opti in Angiogenesis 
Osteoglycin Collagen   brillogenesis 
Class IV SLRPS 
Chondroadherin Extracellular Collagen   brillogenesis 
Pericellular and basement membrane 
Perlecan HS 
Pericellular/
extracellular 
Cell adhesion, cell death, endochondral bone formatio , growth 
factor regulatio , car  lage biomechanics, angiogenesis, collagen 
Modular (hyalectans/lecticans) 
Aggrecan CS 
Extracellular  
Carti age development and homeostasis, growth factor seques-
tratio , proliferatio , cell adhesion, cell-matrix interactio  
Versican CS Growth factor sequestratio , cell adhesion, infl mmati n 
Transmembrane 
Syndecan 1-4 HS 
Cell surface  
Morphogen regulatio , growth factor regulatio , angiogenesis 
CSPG4 CS Cell migratio , proliferatio , proteolyti  ac  vity, apoptosis 
Betaglycan CS/HS Carti age development and homeostasis 
GPI-anchored  
Glypican 1-6 HS Cell surface Morphogen regulatio , angiogenesis, car  lage development 
Intracellular 
Serglycin Heparin 
Intracellu-
lar/cell sur-
face 
Cell adhesion, MMP expression, infl mmati n, growth factor 
regulatio  
Table 3 Proteoglycans of the cartilage ECM 
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stabilised by N- and C-terminal cysteine bridges (Aspberg 2016). They are divided into five 
classes according to their structure and are either canonical (classes I-III, leucine-rich repeat 
cysteine capping (LRRCE) motif, long leucine-rich repeats) or non-canonical (classes IV-V, 
leucine-rich repeat C-terminal (LRRCT) motif). They can be further subdivided according to 
their attached sulfate chains: chondroitin (class III) dermatan (class I, III) keratan (class II, III) 
or none at all (class III-V) (Knudson and Knudson 2001). SLRPs are able to regulate collagen 
fibril diameter and polymerisation rate, binding to the fibrils by leucine-rich repeats as they 
form (Douglas, Heinemann et al. 2006). After this some SLRPs remain bound to the collagen 
fibrils, acting as a bridge with other molecules and protecting against fibril degradation. In 
addition to this, they are implicated in growth factor regulation, cell growth, inflammation, 
bone formation and innate immunity (Yamaguchi and Ruoslahti 1988, Merline, Moreth et al. 
2011, Grafe, Yang et al. 2014, Iozzo and Schaefer 2015). The best characterised SLRP is the 
class I decorin which is mainly associated with collagen type I and II fibrillogenesis (Robinson, 
Sun et al. 2017). Indeed,  decorin deficient mice are reported to have irregular collagen fibrils 
resulting in skin fragility (Danielson, Baribault et al. 1997). It is strongly expressed in growth 
plate cartilage and has been found to increase with age in the interterritorial matrix of 
articular cartilage (Del Santo, Marches et al. 2000). Decorin is able to bind to its ligands via 
both the protein core and its attached chondroitin and dermatan sulfate chains, which 
allows it to interaction with a vast number of ligands. Decorin is therefore able to affect 
several signalling pathways, ECM molecule processing and growth factor sequestration. As 
an example, it is able to affect cell proliferation via its ability to bind TGF-β (Gubbiotti, Vallet 
et al. 2016).  
1.4.5.2. Hyalectans 
The hyalectans or lecticans are a group of chondroitin sulfate proteoglycans which 
include versican and neurocan. The major lectican proteoglycan in the cartilage ECM is 
aggrecan which forms large aggregates with cartilage link protein and hyaluronan 
(Hardingham and Fosang 1992). Aggrecan (in conjunction with the other proteoglycans) 
provides the tissue with its resistance to compression as its large fixed negative charge attracts 
ions and water molecules, allowing the cartilage to withstand the high mechanical load in the 
skeletal joint (Aspberg 2012). This important proteoglycan will be discussed in greater detail 
in section 1.4.8. Versican is structurally very similar to aggrecan and is expressed as a number 
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of isoforms, depending on tissue and disease state (Iozzo and Schaefer 2015). It has a tightly
regulated dynamic expression pattern suggestive of important roles in early limb patterning, 
joint morphogenesis and nerve patterning (Snow, Riccio et al. 2005). After early 
development, expression levels of versican decrease and it is mainly confined to the 
interterritorial matrix of growth plate and articular cartilage where it forms aggregates with 
link protein and hyaluronan (Matsumoto, Kamiya et al. 2006). Versican is also able to bind 
other ECM proteins, including tenascins, fibulins and a number of cell surface molecules. 
Such a variety of binding partners allows this diverse proteoglycan to be involved in processes 
such as proliferation, migration, adhesion, inflammation and cell phenotype (Wu, Pierre et al. 
2005, Wight, Kang et al. 2014, Wight, Kinsella et al. 2014). 
1.4.5.3. Pericellular and basement membrane proteoglycans 
Proteoglycans in this category are either present in a basement membrane or 
anchored to the cell surface and most are heparan sulfated (Iozzo and Schaefer 2015). 
Perlecan is a non-hyaluronan binding heparan sulfate proteoglycan which is expressed in a 
wide variety of tissues. In cartilage it is mainly localised to the pericellular and inter-territorial 
matrix in the pre-hypertrophic and hypertrophic zones (SundarRaj, Fite et al. 1995) and is 
implicated in growth factor sequestration and cell-matrix interaction (Chang, Tseng et al. 
2015). Perlecan null mice are embryonic lethal with a wide variety of phenotypic features in
the heart, brain and cartilage, including growth plate disorganisation, reduced bone 
mineralisation and an altered collagen fibril network. This research suggests that perlecan is 
essential for growth plate organisation (Costell, Gustafsson et al. 1999). In humans,
mutations that lead to a reduction in the amount of functional perlecan have been shown to 
cause lethal dyssegmental dysplasia, Silver-Handmaker type (DSSH) (Arikawa-Hirasawa, 
Wilcox et al. 2001) and Schwartz-Jampel syndrome (SJS) (Arikawa-Hirasawa, Le et al. 2002). 
1.4.5.4. Transmembrane and GPI-anchored proteoglycans 
The transmembrane and GPI-anchored proteoglycans are cell surface proteins and, 
apart from phosphacan and CSPG4, all are predominantly heparan sulfated (Iozzo and 
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Schaefer 2015). The glypicans are GPI-anchored proteoglycans with a range of functions, 
including hedgehog signalling regulation (Filmus and Capurro 2014). In the case of glypican 3
a loss of function mutation has been shown to alter hedgehog signalling and lead to 
Simpson–Golabi–Behmel syndrome, a condition with a broad phenotypic spectrum including 
craniofacial abnormalities (Filmus and Capurro 2014). Many of the transmembrane 
proteoglycans belong to the syndecan family, cell surface receptors with a vast array of 
ligands including growth factors, ECM proteins, cytokines and cell-cell adhesion receptors. 
This ability to bind such a wide variety of proteins and their capability for extracellular 
domain shedding means that syndecans are involved in angiogenesis, inflammation, ECM 
organisation and many other biological processes (Choi, Chung et al. 2011). 
1.4.6. Aggrecan 
The chondroitin sulphate proteoglycan aggrecan is also known as chondroitin sulfate 
proteoglycan core protein 1 (CSPG1) and is expressed in several tissues, including the brain 
(Kwok, Dick et al. 2011, Morawski, Bruckner et al. 2012). It is the founding member of the 
lectican protein family which includes versican, brevican and neurocan and is 2.5MDa in size 
(Ruoslahti 1996). It consists of a 250kDa protein core and approximately 100 chondroitin 
sulfate glycosaminoglycan and 30 keratan sulfate chains attached to a large domain between 
the 3 globular domains of the core (Wiedemann, Paulsson et al. 1984) (Figure 7). Aggrecan is
the predominant proteoglycan of the extracellular matrix, has a short half-life of 3.4 years (in 
its uncleaved form) and is found in the pericellular, interterritorial and territorial matrix 
(Poole, Pidoux et al. 1982, Maroudas, Bayliss et al. 1998). It is involved in many biological 
processes essential for normal cartilage growth such as chondrocyte differentiation, 
proliferation and survival, growth factor binding and regulatory signalling (Lauing, Cortes et 
al. 2014). Its key role, however, is in its ability to form large sulfated aggregates with 
cartilage link protein and hyaluronan, allowing the cartilage to resist compression forces 
(Roughley and Mort 2014).   
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1.4.6.1. Gene structure and expression pattern
The human aggrecan (ACAN) gene is found on chromosome 15 and is comprised of 19 
exons. Exon 1 is non-coding and exons 2 to 19 encode an N-terminal globular domain (G1) a 
second globular domain (G2) two interglobular domains and a C-terminal selectin-like globular 
domain (G3) (Figure 5C) which is subject to alternative splicing (Doege, Sasaki et al. 1991). 
Aggrecan is expressed in development after mesenchymal condensation and throughout the 
growth plate during post-natal growth. Chondrocytes in the resting zone express low levels 
of aggrecan which increases significantly as the cells proliferate and then decreases as they 
enter a mature hypertrophic state (Domowicz, Cortes et al. 2009). 
1.4.6.2. Protein structure and function 
The N-terminal G1 domain is encoded by exons 3-6 and consists of a 100 amino acid
immunoglobulin-like repeat (A subdomain) and two cysteine-rich proteoglycan tandem 
repeats (B and B’ subdomains) (Kiani, Chen et al. 2002). The interaction of these three 
disulphide-bonded subdomains allows the formation of proteoglycan aggregates through 
the binding of the G1 domain to hyaluronan and link protein. The protein sequences of the 
G1 domain and cartilage link protein are very homologous (Doege, Sasaki et al. 1987) and 
these large aggregates are arranged as a single hyaluronan filament bound to several 
aggrecan proteins. Both the B and B’ subdomains are required to bind to hyaluronan and this 
non-covalent binding appears to be enhanced by the A subdomain (Watanabe, Cheung et al. 
1997). The A subdomain also binds to link protein (Matsumoto, Shionyu et al. 2003) which
then binds to hyaluronan, stabilising the aggregate (Roughley and Mort 2014). This 
aggregation does not occur immediately upon aggrecan’s secretion but is delayed depending 
on G1 maturation (immature cartilage forms aggregates more readily) and abundance of link 
protein (Vincent 2000) possibly to allow aggrecan to move past the chondrocyte’s HA coat 
and into the ECM before aggregation occurs (Roughley and Mort 2014).  Furthermore, an 
inbalance in the ratio of aggrecan to link protein (by overexpression of either the G1 domain 
or link protein) has been shown to reduce cell adhesion (Cao, Zhang et al. 1998). The 
presence  of  an  immunoglobulin-like  repeat (A subdomain) in the G1 also suggests that this
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domain may have a role in cell attachment and survival, as the majority of proteins with 
similar immunoglobulin hypervariable regions are important for cell recognition and 
adhesion (Kiani, Chen et al. 2002). 
The interglobular domain (IGD) is coded by exon 7 and resides between the G1 and 
G2 domains (Valhmu, Palmer et al. 1995). It has an important role in aggrecan turnover as it 
contains a large number of proteinase cleavage sites (Figure 5C). The G2 domain is coded by 
exons 8-10 and is unique in the lectican protein family as it is only found in aggrecan. It 
consists of two proteoglycan tandem repeats, similar to those in the G1 domain, but is not 
able to bind to hyaluronan or link protein (Fosang and Hardingham 1989, Valhmu, Palmer et 
al. 1995). Little is known about this domain’s function but it is highly conserved and has been 
shown to inhibit protein secretion, suggesting it is likely to play an important role, possibly in 
protein quality control (Kiani, Lee et al. 2001, Aspberg 2012).
The G2 domain is then followed by GAG-attachment regions, a keratan sulfate (KS)-
rich domain and two chondroitin sulfate domains (CS1 and CS2) (Wiedemann, Paulsson et al. 
1984, Doege, Sasaki et al. 1991) which are coded by exons 11-12. The KS-rich domain is 
comprised of proline-serine sequences within repeats of six amino acids. These serine 
residues can attach to O-linked oligosaccharides which act as the keratan sulfate linkage
regions. KS chains have been shown to interact with collagen fibrils and appear to have a 
protective role in OA pathogenesis. However, the number of KS repeats varies quite 
considerably between species (rat aggrecan has no keratan sulfate chains) and so keratan 
sulfation, although useful, is perhaps not essential for basic aggrecan function (Lohmander, 
Yoshihara et al. 1996, Guerassimov, Zhang et al. 1999, Hedlund, Hedbom et al. 1999). Both 
the CS1 and CS2 domains consist of amino acid repeats containing serine-glycine sequences 
which can attach to chondroitin-6- and chondroitin-4-sulfate (Roughley and Mort 2014). 
These three regions are functionally very important as it is the addition of GAG chains that 
provides aggrecan with its large anionic charge (Valhmu, Palmer et al. 1995). The importance 
of these sulfate chains in the growth plate is also illustrated by a number of skeletal dysplasia 
disorders and animal models with defects in chondroitin sulfate synthesis or sulfation (Faiyaz 
ul Haque, King et al. 1998). Consistency in the number of chondroitin sulfate chains is not, 
however, required for relatively normal aggrecan function as the number of these amino acid 
repeats (and  so chondroitin  sulfate chains) varies  within a  population (between 13 and 33).
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Interestingly, this variable number tandem repeat (VNTR) is only found in humans (Doege, 
Coulter et al. 1997).  
The large C-terminal G3 domain is encoded by the remaining 13-19 exons of the 
aggrecan gene. It consists of two Type II (epidermal growth factor-like) repeats (Baldwin, 
Reginato et al. 1989) a C-type lectin domain (CLD) and a complement regulatory protein
domain (CRP) (Doege, Sasaki et al. 1987) (Figure 7B). The CLD domain is constitutively
expressed but the remaining domains are modulated with alternative splicing (Baldwin, 
Reginato et al. 1989, Doege, Sasaki et al. 1991, Fulop, Walcz et al. 1993, Grover and Roughley 
1993, Bonaventure, Kadhom et al. 1994, Fulop, Cs-Szabo et al. 1996) which is thought to 
modify binding interactions with other ECM molecules (Day, Olin et al. 2004). This also varies 
between species as most animals (except humans) do not express the EGF1 subdomain 
(Fülöp, Cs-Szabó et al. 1996). The CLD domain of the lectican protein family interacts in a 
calcium-dependent manner with extracellular matrix molecules that contain EGF repeats,
such as fibrillins (Isogai, Aspberg et al. 2002) fibulins (Aspberg, Adam et al. 1999, Olin, 
Morgelin et al. 2001) and tenascins (Aspberg, Miura et al. 1997, Rauch, Clement et al. 1997). 
The role of the other domains is currently unclear but the entire G3 domain has been
implicated in aggrecan secretion (Kiani, Lee et al. 2001) cell adhesion (Miura, Aspberg et al.
1999) proliferation (Zhang, Cao et al. 1998) and organisation of the proteoglycan aggregates 
within the matrix (Olin, Morgelin et al. 2001, Lundell, Olin et al. 2004). The G3 domain has 
also shown binding affinity with a number of proteins, including connective tissue growth 
factor (CCN2) (Aoyama, Hattori et al. 2009).  
1.4.6.3. Folding, post-translation modification and trafficking 
The aggrecan core protein undergoes post-translational modification. After synthesis 
of the initial polypeptide, N-linked mannose-rich oligosaccharides are added co-
translationally in the rough endoplasmic reticulum. The importance of this modification is 
illustrated by a number of animals models with defects in aggrecan N-linked glycosylation 
(Aspberg 2012). Quality assured protein folding within the endoplasmic reticulum (ER) is
regulated by a range of molecular chaperones. Although the exact mechanism is not  known, 
a number of chaperones have been suggested including binding immunoglobulin protein 
(BIP) proline  disulfide isomerase  (due to aggrecan’s  numerous  disulfide  bonds) heat shock 
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protein 25 (HSP25) (as it can bind the G3 domain) HSP70, calnexin and calreticulin (due to the 
N-linked oligosaccharides) (Zheng, Luo et al. 1998, Luo, Guo et al. 2000, Chen, Wang et al. 
2001). After  folding, in order to begin the addition of chondroitin sulfate chains, xylosylation 
occurs in the late endoplasmic reticulum compartment and cis Golgi (Vertel 1995). As the 
modified aggrecan core protein transitions through the cis and medial Golgi, 
glycosyltransferases add sugars in a sequential manner. These linkage chains are then 
extended and sulfated to form chondroitin sulfate chains. O-linked oligosaccharides are also
added during O-linked glycosylation in the late Golgi with some extended and sulfated to 
form keratan sulfate chains (Luo, Gao et al. 2000, Kiani, Chen et al. 2002). As the cartilage
matures several changes in sulfation occur. The length of chondroitin sulfate chains 
decreases from ~66 at birth to ~14 repeats in adulthood. Furthermore, the composition of 
the attached monosaccharides alters, increasing the proportion of 6-O-sulfation compared to 
4-O-sulfation over time (Plaas, Wong-Palms et al. 1997). As this occurs, the keratan sulfate 
chains increase in length with increased sulfation of the galactose residues (Santer, White et 
al. 1982). The composition of the attached sulfated chains is variable and may be altered in a 
disease state (Heinegard 2009). 
1.4.6.4. Degradation and turnover 
Aggrecan turnover occurs as part of general cartilage homeostasis at different rates 
depending on its position in the matrix, as the turnover rate is much higher in the pericullar 
and territorial matrix compared to the interterritorial (Mok, Masuda et al. 1994). This 
aggrecan degradation leads to an accumulation of aggrecan fragments over time (Dudhia,
Davidson et al. 1996). Interestingly, despite the apparent importance of the G3 domain and 
its conservation between species, its abundance decreases with age, relative to the other 
aggrecan domains. This was shown to be independent of normal aggrecan turnover and 
possibly due to proteolytic degradation (Dudhia, Davidson et al. 1996). This raises interesting 
questions about the function of the G3 domain in the ECM and disease, especially as the G3 
cleavage product has a 6-fold longer half-life than the uncleaved aggrecan molecule 
(Maroudas, Bayliss et al. 1998) and the CLD subdomain is able to activate both the classical 
and alternate complement pathways, implicating aggrecan in joint inflammation (Melin Fürst, 
Mörgelin et al. 2013). The aggrecan aggregate can undergo degradation by a number of 
methods, including proteolytic cleavage  and  non-enzymic  glycation  and  the  aggrecan core
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protein  contains  several proteolytic cleavage sites (Figure 7A). These sites are subject to 
various enzymes including serine proteases (HtrA1, plasmin) aspartic proteinases (Cathepsin 
K, D and B) and cysteine proteases (calpain) (Fosang, Neame et al. 1992, Sandy and 
Verscharen 2001, Troeberg and Nagase 2012). It is thought that the proteolytic cleavage of 
aggrecan can exert both a protective and a pathogenic effect. Cleavage mediated by the 
matrix metalloproteinases (MMPs) appears to be involved (but not essential) in cartilage 
homeostasis and protects against   arthritic   changes.   In   contrast,   the   a   disintegrin   
and   metalloproteinase   with thrombospondin motifs (ADAMTS) aggrecanases (ADAMTS 4
and 5) are associated with increased GAG loss, decreased aggrecan functionality (and so
cartilage destruction) in degenerative diseases such as osteoarthritis (Clements, Price et al. 
2003, Little, Meeker et al. 2005, Sandy 2006, Boeuf, Graf et al. 2012). GAG loss may also 
occur due to non-enzymic glycation which increases with age, modifying lysine residues in 
the G1 domain, altering hyaluronan binding and either preventing or reducing aggregation 
(Verzijl, DeGroot et al. 2001, Roughley and Mort 2014).   
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1.5. Aggrecan-related skeletal dysplasias 
The skeletal dysplasias are a complex group of 481 (Chen, Jiang et al. 2016) disorders of 
cartilage and bone with a combined incidence of 1 in 5000 (Geister and Camper 2015). The 
diagnosis of these disorders is based on clinical and radiographic findings and precise 
classification is often difficult. As discussed previously in this chapter, mutations in several 
extracellular matrix proteins have been implicated as the genetic cause of these conditions; 
however, in many cases no causative mutation is found. Genome wide associations studies 
(GWAS) have shown that aggrecan gene sinle ̀ ncleotide ̀ polyŵorphisŵs affect adult height 
(Weedon, Lango et al. 2008) and there are a number of skeletal animal models with 
mutations in aggrecan (Watanabe, Nakata et al. 1997, Primorac, Johnson et al. 1999). In 
recent years aggrecan has therefore become a novel and promising target with causative 
mutations identified in cases of spondyloepiphyseal dysplasia Kimberley type (SEDK) 
(Gleghorn, Ramesar et al. 2005, Sentchordi‐Montané, Aza‐Carmona et al. 2018) various 
idiopathic short stature conditions, Ĩaŵilial osteochondritis dissecans (Stattin, Wiklund et al. 
2010) and spondyloepimetaphyseal dysplasia (SEMD) aggrecan type (Tompson, Merriman et 
al. 2009). In recognition of this, aggrecan skeletal disorders are now beginning to be classified 
together as a separate group forming a spectrum from mild idiopathic short stature to the 
severe SEMD (Warman, Cormier-Daire et al. 2011). Although little is known about the possible 
disease mechanisms involved, several of the reported patients with idiopathic short stature 
responded to growth hormone treatment (Gkourogianni, Andrew et al. 2017, van der Steen, 
Pfundt et al. 2017, Crippa, Giangiobbe et al. 2018). This treatment increased the height of the 
probands compared to their affected family members; however, there was no reported effect 
on any skeletal abnormality or the accelerated degenerative disease associated with these 
disorders and so there is clear scope for further phenotype drug amelioration. Thus far, 47 
pathogenic mutations have been reported in 48 families (Dateki 2017, Hu, Gui et al. 2017, van 
der Steen, Pfundt et al. 2017, Crippa, Giangiobbe et al. 2018) (Figure 8, Appendix A). All of the 
mutations are inherited in an autosomal dominant manner, except the recessive causative 
SEMD mutation (Tompson, Merriman et al. 2009) and only five were de novo mutations (Tatsi, 
Gkourogianni et al. 2017). The mutations have been found throughout the ACAN gene in every 
domain and the vast majority cause premature truncation of the protein due to novel stop 
codons, nonsense mutations, deletions, insertions or duplications. 13 are nonsense mutations, 
18  missense mutations, 10 cause  frameshifts, 1 a reciprocal chromosomal translocation and 2
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affect  splicing  and are  predicted  to cause the skipping of either exon 2 or 10 (Nilsson, Guo
et al. 2014, Sentchordi‐Montané, Aza‐Carmona et al. 2018). All patients within the disease 
spectrum exhibited short stature but most appeared to be within the normal range for weight
and length at birth (Gkourogianni, Andrew et al. 2017). During childhood and puberty, the 
majority of the probands displayed a normal or accelerated bone maturation (Dateki, 
Nakatomi et al. 2017, Gkourogianni, Andrew et al. 2017, Tatsi, Gkourogianni et al. 2017, van 
der Steen, Pfundt et al. 2017) coupled with premature growth cessation (Gkourogianni, 
Andrew et al. 2017) although delayed bone maturation has been reported (Tatsi, 
Gkourogianni et al. 2017, Sentchordi‐Montané, Aza‐Carmona et al. 2018). There does not 
appear to be any difference between the average height of patients with missense mutations 
and those with mutations that led to premature truncation of the aggrecan protein 
(Gkourogianni, Andrew et al. 2017). Interestingly, however, all of the cases associated with 
osteochondritis dissecans (OCD) had causative missense mutations in the C-type lectin domain
of the G3 globular domain (Figure 8) (Nilsson, Guo et al. 2014, Aspberg personal 
communication 2017, Gkourogianni, Andrew et al. 2017, van der Steen, Pfundt et al. 2017). 
Many conditions were associated with a range of other skeletal abnormalities such as
brachydactyly (Gkourogianni, Andrew et al. 2017) short thumbs (Gkourogianni, Andrew et al. 
2017, van der Steen, Pfundt et al. 2017) and broad toes (van der Steen, Pfundt et al. 2017) 
although two families were reported with short stature and no bone abnormalities (Hu, Gui et 
al. 2017). Further to this, patients also exhibited dysmorphic facial features such as mid-face
hypoplasia (Gkourogianni, Andrew et al. 2017, Tatsi, Gkourogianni et al. 2017, van der Steen, 
Pfundt et al. 2017) frontal bossing (Gkourogianni, Andrew et al. 2017) or posterially rotated 
ears (Gkourogianni, Andrew et al. 2017, van der Steen, Pfundt et al. 2017). There was often 
vertebral involvement including lumbar lordosis (van der Steen, Pfundt et al. 2017) scoliosis, 
flattened vertebral bodies (Gleghorn, Ramesar et al. 2005) and invertebral disc degeneration 
(Dateki, Nakatomi et al. 2017, Gkourogianni, Andrew et al. 2017). Furthermore, as is often the 
case with skeletal dysplasias, 22 of the mutations also presented with early-onset 
osteoarthritis or joint pain (Gleghorn, Ramesar et al. 2005, Stattin, Tegner et al. 2008, 
Gkourogianni, Andrew et al. 2017, Tatsi, Gkourogianni et al. 2017, van der Steen, Pfundt et al. 
2017, Sentchordi-Montané, Aza-Carmona et al. 2018) although joint degeneration was not 
associated with mutations in a particular aggrecan domain. This shows a clear phenotypic 
spectrum for aggrecan disorders from mild disproportionate short stature to the severe short 
stature  and skeletal  abnormalities  of SEMD. Furthemore, single nucleotide polymorphisms in 
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the aggrecan gene are associated with lumbar intervertebral disc degeneration without short 
stature and osteoarthritis (Perera, Dissanayake et al. 2017) illustrating the importance of 
aggrecan in both common and rare conditions.  
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1.5.1. Dominant familial osteochondritis dissecans (fOCD) 
Osteochondrosis can refer to a number of cartilage and bone disorders found in both 
humans and animals. It can occur in the vertebral column (Scheuermann's disease) several of 
the articular joints (Legg-Calve-Perthes, Panner’s disease, Frieberg’s disease, Kohler’s disease) 
and in non-articular cartilage (Osgood-Schlatter disease, Sever’s disease) (McCoy, Toth et al. 
2013). It is defined by the formation of lesions in the cartilage which, in the final clinical stage 
(osteochondritis dissecans) leads to the separation of cartilage and subchondral bone from 
the cartilage surface. Osteochondritis latens and manifesta lesions (which form before the 
closure of the epiphyseal growth plate) can eventually undergo ossification and resolve 
(Figure 9C). Those lesions which remain or develop after growth cessation are structurally 
weak and lead to the formation of clefts through the articular cartilage (osteochondritis 
dissecans). The cartilage and bone tissue above this fissure can then dissociate from the 
surface and form a loose body which requires surgical removal in order to reduce the 
accompanying joint pain and stiffness. The formation of clefts then usually leads to the 
development of osteoarthritis (McCoy, Toth et al. 2013). Osteochondrosis is a particularly 
common problem in horses and pigs and extensive research has been conducted on the 
disorder’s progression in these commercially valuable animals. This research is additionally 
important as the condition only presents in humans during the last stage (osteochondritis 
dissecans) when the symptoms are most obvious and the lesions are already formed, 
providing little information on the initial cause. The resultant data from both animal and 
human studies has indicated that the condition is multifactorial and is associated with 
genetic predisposition, the male gender, repetitive micro-trauma (such as sports injuries) 
major trauma and local ischemic necrosis in the growth plate (Takahara, Ogino et al. 1999, 
Tóth, Nissi et al. 2015). GWAS studies of both animals and humans have implicated ECM 
proteins, vesicular transport, posttranslational modification and cellular differentiation, 
including the PTH/PTHRP and WNT signalling pathways which are vital for proper growth 
plate differentiation (Bates, Jacobs et al. 2014). Further to this, analysis of cartilage biopsies 
from patients with normal stature showed abnormal mineralisation, mislocalisation of 
matrix proteins and abnormally wide type II collagen heterofibrils. Type I, II, VI and X 
collagens and aggrecan appeared to be partially co-accumulated within the ER and there 
were a number of budding vesicles containing ECM material present. In addition to this, the 
chondrocytes  contained  vacuoles,  inclusion  bodies,  irregular  hyperchromatic  nuclei  and
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several filopodia (Skagen, Horn et al. 2011). This indicates that chondrocyte differentiation, 
matrix organisation and protein secretion are perturbed in late-stage osteochondrosis, 
whether as a secondary effect or as a potential cause of the disorder. Osteochondritis 
dissecans has been reported in a number of short stature patients with dominant causative 
missense mutations in the C-type lectin domain of the G3 globular domain of aggrecan 
(Nilsson, Guo et al. 2014, Aspberg personal communication 2017, Gkourogianni, Andrew et 
al. 2017, van der Steen, Pfundt et al. 2017). This phenotype was initially reported in 
several generations of a large Swedish family with mild disproportionate short stature 
and early-onset osteoarthritis (Stattin, Tegner et al. 2008, Stattin, Wiklund et al. 2010) 
(Figure 9A). All the patients displayed short stature which appeared to be responsive to 
growth hormone treatment. Characteristic osteochondritis dissecans lesions were observed 
in the hip, knee and/or elbow (depending on the patient) although lesions were most often 
found on the medial femoral condyle (Figure 9B). The age of symptom onset resulting from 
these lesions was variable but tended to occur in late childhood or adolescence. 
Inheritance was fully penetrant but some family members exhibited additional skeletal 
abnormalities such as brachydactyly, tibia vara or scoliosis. The dominant causative missense 
mutation (c.6907G>A) causes an amino acid change (p.V2303M) in the C-type lectin domain 
of the G3 domain. The V2303 residue is highly conserved between species and is found in a 
beta strand of the ligand-interaction site of the aggrecan CLD, buried in the hydrophobic 
core of the protein (Lundell, Olin et al. 2004). Computational modelling indicates that 
the p.V2303M mutation causes a conformational change in the aggrecan CLD (Stattin, 
Wiklund et al. 2010). Mass spectrometry analysis of patient articular cartilage obtained 
from knee arthroplasty indicated that the wild type and mutant aggrecan protein were 
equally secreted into the matrix and glycosaminoglycan sulfation appeared to be 
unaffected. An in vitro study of different splice variants of the recombinant mutant G3 
domain of aggrecan in mammalian cells indicated that the p.V2303M ACAN mutation 
disrupted interaction with other extracellular matrix proteins. The mutant G3 domain 
showed a loss or reduced affinity for the aggrecan ligands fibulin 1, fibulin 2 and tenascin R, 
suggesting that the mutation may exert an antimorphic effect (Stattin, Wiklund et al. 
2010). A further in vitro study investigated chondrocyte differentiation in mesenchymal 
stromal cells (MSCs) and induced pluripotent stem cells (iPSCs) generated from patients 
with the p.V2303M ACAN mutation. Data from both  methods  indicated   that  the mutant  
aggrecan was retained within the endoplasmic reticulum (ER) with little staining in the
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interterritorial matrix. Analysis of MSC pellets indicated aggrecan was downregulated by 50%
but link protein was upregulated. Furthermore, there was an increase in the expression of 
the SLRPs asporin, osteoadherin, fibromodulin, decorin, PRELP, lumican, bigylcan and 
mimecan and the lectican proteoglycans versican and perlecan. In addition to this, collagen VI 
and XI and the glycoproteins matrilin 3, COMP, fibronectin and tenascin-C were also 
upregulated. Interestingly, CILP2 was found in the heterozygous mutant ECM but not in that 
of the control. Immunostaining and transmission electron microscopy (but not mass spectral
analysis) indicated a decrease in type II collagen and fibrillar material, suggesting that type II 
collagen may have been removed during processing and so was not properly bound within 
the ECM. GAG content decreased in patient cultures overtime, potentially due to either 
degradation, synthesis inhibition or delayed differentiation. iPSC pellets were comprised of 
densely packed cells, suggesting a delay in differentiation or a decreased amount of matrix. 
Overall this in vitro data suggests that the p.V2303M ACAN mutation disrupts ECM 
interactions and impedes aggrecan secretion, contrary to mass spectral analysis of late-stage 
lesions obtained from patient knee arthroplasty (Xu, Stattin et al. 2016).  
58
Fi
gu
re
 7
 F
am
ili
al
 o
st
e
o
ch
o
n
d
ri
ti
s 
d
is
se
ca
n
s 
(O
C
D
) 
(A
)
Fa
m
ili
al
 O
CD
 i
s 
a 
do
m
in
an
tl
y-
in
he
ri
te
d 
di
so
rd
er
 (
St
at
ti
n,
 T
eg
ne
r 
et
 a
l 
20
08
).
 (
B
) 
M
RI
 (
le
ft
) 
an
d 
ra
di
og
ra
ph
ic
 (
ri
gh
t)
 i
m
ag
es
 s
ho
w
in
g 
a 
le
si
on
(a
rr
ow
s)
 in
 t
he
 a
r  
cu
la
r 
ca
rt
ila
ge
 a
nd
 u
nd
er
ly
in
g 
su
bc
ho
nd
ra
l 
bo
ne
 (
St
at
ti
n,
 W
ik
lu
nd
 e
t 
al
 2
01
0)
. 
(C
) 
 A
 s
ch
em
at
ic
 s
ho
w
in
g 
th
e 
fo
rm
at
io
n 
of
ea
rl
y 
le
si
on
s 
an
d 
ei
th
er
 s
ub
se
qu
en
t 
he
al
in
g 
or
 p
ro
gr
es
si
on
 t
o 
O
CD
 (M
cC
oy
, T
ot
h 
et
 a
l 2
01
3)
.
A
 
 C
 
B
 
59
1.5.2. Spondyloepimetaphyseal dysplasia (SEMD) aggrecan type 
The spondyloepimetaphyseal dysplasias (SEMD) are a group of heterogenous bone and 
cartilage disorders characterised by involvement of the vertebral bodies, epiphyses and 
metaphyses. There are X-linked, autosomal recessive and autosomal dominant (Grosch, 
Gruner et al. 2013) forms with causative mutations in genes such as COL2A1 (Tysoe, Saunders 
et  al. 2003)  MATN3  (Borochowitz,  Scheffer et  al. 2004)  and  MMP13  (Kennedy,  Inada et al. 
2005). A clinical study reported SEMD in three patients from a single potentially 
consanguineous family (Figure 10) (Tompson, Merriman et al. 2009). Sequencing data revealed 
homozygosity for a c.6799G<A missense mutation in ACAN which causes an amino acid 
change (D2267N) in the C-type lectin domain of the G3 globular domain. This is unlike all the 
other aggrecan mutations reported thus far which are all inherited in an autosomal dominant 
manner. The homozygous phenotype was characterised by extreme short stature (66-71cm) 
and a range of bone abnormalities such as accessory carpal ossification centres, irregular 
epiphyses and widened metaphyses. As reported with many other aggrecanopathies, there 
were a number of craniofacial irregularities observed, including severe mid-face hypoplasia 
and relative mandibular prognathism. This indicates the possible involvement of both 
intramembranous and endochondral ossification. Thus far, the three patients have not 
complained of any joint pain or shown any signs of osteoarthritis. The D2276 residue is highly 
conserved between species and is one of five residues required for the coordination of a 
calcium ion. This calcium ion (in conjunction with two others in the CLD) is an important part 
of the CLD calcium coordinating loops which mediates calcium-dependent ligand binding with 
ECM molecules such as tenascin R. In vitro analysis of two different variants of the 
recombinant mutant G3 domain of aggrecan (with and without the EGF repeats) in 
mammalian cells indicated that the p.D2267N ACAN mutation alters cation-dependent binding 
with tenascin C but does not affect secretion of the G3 domain (Tompson, Merriman et al. 
2009). In addition to the potential disruption caused to ligand binding by the D2267N ACAN
mutation, the mutation also introduces a novel N-linked glycosylation recognition site, causing 
the mutant G3 domain to  migrate  more  slowly.  This was confirmed by N-glycanase 
treatment which then allowed the mutant G3 domain to migrate at a similar rate to the 
wildtype G3 domain (Tompson, Merriman et al. 2009).  It has been  suggested  that  this  
glycan substitution may  also hinder ligand interaction (Aspberg 2012); however, little is known
60
about the effect of the p.D2267N ACAN mutation on the interactions between aggrecan and 
other ECM molecules.
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1.6. Disease mechanisms of the skeletal dysplasias 
Although little is known about the possible mechanisms involved in the disease 
progression of the aggrecanopathies, many studies have been conducted in animal models of 
other skeletal dysplasias. This research has identified several pathways which have not been 
fully investigated in the aggrecanopathies and could be implicated in the disorders caused by 
antimorphic aggrecan mutations. 
1.6.1. The classical pathway: ER stress and the unfolded protein response (UPR) 
Previous studies of skeletal dysplasia have demonstrated that cells expressing these 
mutations in ECM molecules, such as COMP and collagen type X, produce misfolded protein.
This disrupts protein folding and trafficking and impairs secretion of mutant protein from the 
rough endoplasmic reticulum (ER) (Pirog-Garcia, Meadows et al. 2007, Mullan, Mularczyk et 
al. 2017). The resultant misfolded protein accumulation causes the ER cisternae to enlarge
and may activate the unfolded protein response (UPR). The UPR is thought to be the main
pathway used by the cell to reduce stress caused by protein retention (Figure 11Aii). It
attempts to reduce the protein accumulation by downregulating translation and re-folding or 
degrading the misfolded protein. Eventually prolonged UPR activation causes upregulation of
apoptosis pathways leading to increased cell death. BIP is often used as a marker for
endoplasmic reticulum stress as it is bound to the ER stress sensors Inositol-requiring kinase 1 
(IRE1) (PKR)-like endoplasmic reticulum kinase (PERK) and activating transcription factor 6 
(ATF6) during their inactive state. During upregulation of the UPR pathway, BIP dissociates 
from these sensors and acts as a protein chaperone and potentially anti-apoptotic factor (Lee
2005). BIP dissociation causes cleavage of ATF6 in the Golgi (Figure 11Aii). The cleaved ATF6 
then moves to the nucleus where it upregulates the transcription of ER chaperones (Lee 
2005). Chaperones assist in the folding and processing of secreted proteins and so are often
upregulated in response to the presence of misfolded proteins. Protein re-folding is also 
assisted by protein disulfide isomerases (PDIs) which catalyse the formation and breakage of 
disulfide bonds between cysteine residues as proteins fold. The dissociation of BIP causes 
IRE1 to autophosphorylate and  catalyse  the  alternative splicing  of  Xbp1 (Figure 11Aii).  The 
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spliced  XBP1 then  acts  as  a  transcription  factor, upregulating other UPR genes including
those associated with endoplasmic reticulum-associated protein degradation (ERAD) thus 
reducing the total protein accumulation (Calfon, Zeng et al. 2002, Hiramatsu, Messah et al. 
2014). The last aim of the UPR occurs via the phosphorylation of EIF2A by PERK (Figure 
11Aii). This causes attenuation of translation, reducing the amount of accumulated protein
burden on the ER (Harding, Zhang et al. 1999). 
1.6.2. Other possible disease mechanisms 
Although the UPR is thought to be the main response to protein accumulation in the 
ER several other associated pathways have been reported (Figure 11) including possible roles 
for oxidative stress and integrin and nuclear factor-κB (NFκB) signalling (Pahl and Baeuerle 
1995, Pirog-Garcia, Meadows et al. 2007, Suleman, Gualeni et al. 2012, Posey, Coustry et al. 
2015). The ER overload response (EOR) also occurs in response to mutant protein 
accumulation in the ER but acts independently of the UPR (Figure 11Ai). This protein 
accumulation appears to cause a release of calcium from the ER and the production of 
reactive oxygen intermediates (ROS) which then induce apotosis and NFκB (Pahl and 
Baeuerle 1997, Ekeowa, Freeke et al. 2010). This calcium release has also been shown to 
indirectly upregulate both apoptosis and macroautophagy. The upregulation of 
macroautophagy is also associated with the UPR and acts as a protective mechanism by 
degrading misfolded protein aggregates (Ishida, Yamamoto et al. 2009) (Figure 11A). During 
macroautophagy, cytoplasm is sequestered by an isolation membrane through the 
recruitment of ATG proteins (Figure 11B). The isolation membrane precursor can originate 
from a variety of sources, including mitochondrial, plasma and nuclear membranes, although 
most evidence points to the endoplasmic reticulum as the main source (Nascimbeni, 
Giordano et al. 2017, Sakoh-Nakatogawa, Kirisako et al. 2015). The membrane then elongates 
to form a double-membraned autophagosome. This autophagosome subsequently fuses with 
an endosome and then a lysosome, degrading the inner membrane and cytoplasmic contents 
through the action of lysosomal enzymes (Sakoh-Nakatogawa, Kirisako et al. 2015). Research 
has also shown that modulation of this pathway can elicit a pathogenic response; for 
example, the Sumf1 knock-out mouse exhibits a short stature phenotype partially caused by 
increased cell death due to impaired autophagy (Settembre, Fraldi et al. 2008).  
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1.7. Aggrecan model systems 
There are a number of naturally occurring aggrecan mutations in animals which have 
allowed for the in vivo study of aggrecan’s role in cartilage development and homeostasis. 
Unfortunately this research has had its limitations for a variety of reasons, for example,
variable penetrance of the mutation (Dexter Bulldog dwarfism) (Cavanagh, Tammen et al. 
2007). Furthermore, due to the important role of aggrecan, several of these mutations lead 
to embryonic or perinatal homozygous lethality (nanomelia chick and cmd/cmd-bc mouse). In
addition to this, all of the existing animal models are caused by functionally null mutant 
aggrecan alleles due to haploinsufficiency (through nonsense-mediated mRNA decay) or the 
production of truncated proteins (Cavanagh, Tammen et al. 2007). This occurs through 
deletions (cmd, cmd-bc) premature termination codons (nanomelia, Dexter BD1) or novel 
initiation codons (Dexter BD2). Therefore, although this work has been extremely useful it 
may be of limited relevance to the study of human aggrecan disorders which are caused by 
possibly antimorphic missense mutations (Gleghorn, Ramesar et al. 2005, Tompson, 
Merriman et al. 2009).  
1.7.1. Nanomelia chicken 
The autosomal recessive nanomelia mutation (G4553T) introduces a premature stop 
codon in exon 10 which codes for the CS2 domain (Li, Schwartz et al. 1993, Primorac, Stover 
et al. 1994). This causes a truncated aggrecan precursor to be produced which is not secreted 
from the ER and is thought to be degraded in the cytoplasm (Li, Schwartz et al. 1993, Vertel, 
Walters et al. 1993, Primorac, Johnson et al. 1999). The mutation causes a chondrodysplasia 
phenotype and embryonic lethality (Landauer 1965) with defects in both endochondral and
intramembranous ossification (Wong, Lawton et al. 1992) (Figure 12A). The affected chicken
embryos have a range of skeletal abnormalities including an abnormal mandible and maxilla 
(forming a parrot-like beak) micromelia and a large, brachycephalic head (Landauer 1965). The 
growth plate is very disorganised with a small hypertrophic zone and both increased proliferation 
and apoptosis in the proliferative and hypertrophic zones. The IHH, FGF and BMP chondrocyte 
differentiation signalling pathways are altered, with overlap of pre-hypertrophic and 
hypertrophic markers and premature expression of osteopontin, a marker of mineralisation. 
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This suggests that hypertrophy and ossification are accelerated in this aggrecan null model
and indicates that aggrecan is vital for correct chondrocyte differentiation (Domowicz, 
Cortes et al. 2009). 
1.7.2. Cartilage matrix deficiency (cmd) and cmd-bc mouse 
The spontaneous C57BL/6 Cmd mutation is a 7bp deletion in exon 5 (which codes for 
the G1 domain) and causes both heterozygous and homozygous phenotypes. As with the 
nanomelic chick, a truncated aggrecan precursor is produced and aggrecan mRNA levels are 
reduced to 81% (Watanabe, Kimata et al. 1994). Homozygosity for the mutation causes
perinatal lethality due to respiratory failure caused by abnormal tracheal cartilage.
Homozygous neonates have disproportionate short stature with a short snout and tail,
protruding tongue and cleft palate (Figure 12B). The disorganised growth plate lacks zonation
and has a reduced number of hypertrophic chondrocytes (Kobayakawa 1985, Wai, Ng et al. 
1998). In addition to this the expression pattern of other ECM proteins, such as link protein, 
syndecan 3, and collagen types IX, X and XI, was shown to be abnormal (Wai, Ng et al. 1998).
Mice heterozygous for the cmd mutation have proportionate short stature and age-
associated spinal disc degeneration (Rittenhouse, Dunn et al. 1978, Watanabe, Kimata et al. 
1994, Watanabe, Nakata et al. 1997). The affected mice develop cervical lordosis and thoraco-
lumbar kyphosis, causing spine misalignment, disc herniation and spastic paralysis of the hind 
limbs. This causes a decrease in movement and the mice die within 19 months through 
starvation. As with the homozygous mouse, heterozygous mice have a disorganised growth 
plate and transcript levels of aggrecan are reduced to 41% (Watanabe, Nakata et al. 1997). 
The cmd-bc mutation spontaneously arose on the BALB/c GaBc background and is thought to 
be caused by a non-homologous recombination event. It is autosomal recessive and is a large 
deletion which results in the loss of exons 2-18. Homozygous mice are phenotypically very 
similar to the cmd model with disproportionately short limbs and snout, enlarged abdomen, 
protruding tongue and cleft palate (Krueger, Kurima et al. 1999). A phenotype rescue study 
performed in C57BL/6 cmd-bc embryos showed that mutant mice had disorganised growth 
plates with areas of hypocellularity, reduced ECM and lack of zonation. Further to this, 
apoptosis was increased, proliferation decreased and IHH, SOX9 and FGF chondrocyte 
differentiation signalling pathways altered. The transgenic expression of chick aggrecan was 
able to restore the growth plate zonation, cell  morphology and  expression patterns of these 
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vital signalling factors. It also increased proliferation and reduced apoptosis. This again 
suggests that the presence of aggrecan in the epiphyseal growth plate is essential for 
the regulation of chondrocyte survival and differentiation (Lauing, Cortes et al. 2014).  
1.7.3. Dexter Bulldog dwarfism 
Dexter Bulldog dwarfism is one of the oldest described naturally-occurring animal 
models and was first reported in the 18th century (Cavanagh, Tammen et al. 2007). Initially 
thought to only be found in Dexter cattle, it has more recently been reported in miniature 
Highland cattle (Catalina Cabrera, McNabb et al. 2016). Thus far, two causative mutations 
have been reported with variable penetrance and both heterozygous and homozygous 
phenotypes (Cavanagh, Tammen et al. 2007) (Figure 12D). Heterozygous cows have 
disproportionate short stature with rhizomelia, mild irregular vertebral bodies and posterior 
vertebral wedging. Transcript levels of the mutant aggrecan are decreased to 8% due to 
nonsense-mediated decay (Harper, Latter et al. 1998, Cavanagh, Tammen et al. 2007). 
Homozygosity of the mutant alleles causes embryonic lethality, resulting in mid to late term 
spontaneous abortion. Stillborn calves exhibit extreme short-limbed dwarfism, a large 
abdominal hernia, and a range of skeletal abnormalities such as marked vertebral 
platyspondyly, shortened vertebral column, extreme rib shortening and micromelia. The 
disproportionally large head has many craniofacial abnormalities including relative 
prognathism, midfacial retraction and cleft palate. The bulldog dwarfism 1 mutation (BD1, 
2266_2267insGGCA) is a 4bp insertion in exon 11 which codes for the GAG-attachment 
region. This results in a frameshift, introduction of a premature stop codon and the loss of 
part of the GAG attachment region and the G3 domain. The BD2 mutation (-198C>T) is much 
rarer and is a transition in exon 1 which introduces a novel ATG start codon and 
consequently a large frameshift. The putative mutant protein arising from this mutation 
therefore does not resemble normal aggrecan (Harper, Latter et al. 1998, Cavanagh, 
Tammen et al. 2007).   
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A large scale N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen was conductedto 
identify novel disease genes in laboratory mice (C57BL/6J and C3H.Pde6b+ cross). Mice 
homozygous for the A1946V Acan missense mutation in the C-type lectin domain had bone 
deposits in multiple joints by 18 months of age (Figure 12E). Further to this, by 12 months of
age the mice exhibited metabolic obesity. Adipocytes in white adipose tissue were enlarged 
and showed inflammatory infiltration. Adipocytes in brown adipose tissue, on the other 
hand, exhibited reduced fat accumulation (Potter, Bowl et al. 2016). 
1.7.5. Cartilage Calcification Insufficient (CCI) rat 
The CCI rat exhibits disproportionate short-stature with a short vertebral column, tail 
and skull length (Figure 12F). The unknown causative mutation spontaneously arose in a Jcl-
derived Sprague-Dawley colony and is thought from progeny phenotype analysis to be 
inherited in an autosomal recessive manner. The resting and proliferative zones are wide and 
disorganised with a poorly formed secondary ossification centre, indicating that endochondral 
ossification is delayed. The randomly organised bone spicules are enlarged and the cranial 
base synchondrosis abnormal. Additional research revealed an abnormal expression pattern 
for aggrecan in both the growth plate and articular cartilage, with a suggestion that aggrecan 
synthesis was affected (Takeuchi, Nagayama et al. 2015, Tanaka, Watanabe et al. 2015). 
Analysis of this model has not so far elucidated the causative mutation or a potential disease 
mechanism but a mutation in the Acan gene has not yet been ruled out. 
1.7.6. Models associated with abnormal post-translational sulfation 
In addition to models caused by mutations in the aggrecan gene itself, there are a 
number of models resulting from defects in proteins involved with aggrecan's post-
1.7.4. A1946V Acan mouse 
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translational modification. As an example, the brachymorphic mouse has a short stature 
phenotype resulting from decreased levels of 3ʹ-phosphoadenosine 5ʹ-phosphosulfate 
(PAPS) synthase and  so  undersulfation of  proteoglycan (Pennypacker, Kimata et al. 1981)  
(Figure 12C).  Furthermore, the chondroitin 4-sulfotransferase 1 (C4st1) gene trap mouse 
displays disproportionate short stature due to abnormal chondroitin 4-O-sulfation (Kluppel, 
Wight et al. 2005) (Figure 12G) illustrating the importance of correct post-translational 
modification  of aggrecan.
70
(A
)
Th
e 
na
no
m
el
ic
 c
hi
ck
 e
xp
re
ss
es
 a
 t
ru
nc
at
ed
 a
gg
re
ca
n 
pr
ec
ur
so
r 
an
d 
di
sp
la
ys
 a
 s
ho
rt
 s
ta
tu
re
 e
m
br
yo
ni
c 
le
th
al
 p
he
no
ty
pe
. 
(B
) 
Th
e 
m
ur
in
e 
cm
d 
m
ut
at
io
n 
is
ho
m
oz
yg
ou
s 
le
th
al
. N
eo
na
te
s 
ex
pr
es
s 
a 
tr
un
ca
te
d 
ag
gr
ec
an
 p
re
cu
rs
or
 a
nd
 e
xh
ib
it
 s
ho
rt
 s
ta
tu
re
. (
C
) 
Th
e 
br
ac
hy
m
or
ph
ic
 m
ou
se
 e
xh
ib
it
s 
a 
sh
or
t 
st
at
ur
e 
ph
en
ot
yp
e
du
e 
to
 r
ed
uc
ed
 a
gg
re
ca
n 
su
lfa
ti
on
 (
Sc
hw
ar
tz
 a
nd
 D
om
ow
ic
z 
20
02
, 
sc
al
e 
ba
rs
 =
 1
0m
m
).
 (
D
) 
D
ex
te
r 
ca
tt
le
 d
is
pl
ay
 a
 h
et
er
oz
yg
ou
s 
sh
or
t 
st
at
ur
e 
ph
en
ot
yp
e 
an
d
ho
m
oz
yg
ou
s 
le
th
al
it
y 
(C
av
an
ag
h,
 T
am
m
en
 e
t 
al
 2
00
7)
. 
(E
) 
Th
e 
A
19
46
V
 A
ca
n
 m
ou
se
 e
xh
ib
it
s 
la
te
-o
ns
et
 jo
in
t 
de
te
ri
or
at
io
n 
an
d 
bo
ny
 d
ep
os
it
s 
(w
hi
te
 a
rr
ow
) 
(P
ot
te
r,
Bo
w
l e
t 
al
 2
01
6)
. 
(F
) 
Th
e 
CC
I r
at
 e
xh
ib
it
s 
di
sp
ro
po
rt
io
na
te
 s
ho
rt
 s
ta
tu
re
 d
ue
 t
o 
an
 u
nk
no
w
n 
ag
gr
ec
an
 s
ul
fa
ti
on
 d
ef
ec
t 
(T
an
ak
a,
 W
at
an
ab
e 
et
 a
l 2
01
5)
. (
G
) 
Th
e 
C
4
st
1
ge
ne
 t
ra
p 
m
ou
se
 h
as
 a
 s
ho
rt
 s
ta
tu
re
 p
he
no
ty
pe
 d
ue
 t
o 
ab
no
rm
al
 c
ho
nd
ro
it
in
 s
ul
fa
ti
on
 (K
lu
pp
el
, W
ig
ht
 e
t 
al
 2
00
5)
.
Ke
y:
 m
/+
 (h
et
er
oz
yg
ou
s 
fo
r 
th
e 
m
ut
a t
io
n)
 m
/m
 (h
om
oz
yg
ou
s 
fo
r 
th
e 
m
ut
a t
io
n)
 
W
ild
 t
yp
e 
 
Fi
gu
re
 1
2 
C
u
rr
e
n
t 
ag
gr
e
ca
n
 m
o
d
e
l s
ys
te
m
s
  A
19
46
V
 A
ca
n
   
   
   
  
      C4st1
gt/gt 
   
m
/+
  
 m
/m
 
 A
 
 B
 
 C
 
 D
 
 F
 
 G
 
E 
71
1.8. Project Aims 
In recent years, several patients have been reported with disproportionate short 
stature caused by mutations in the proteoglycan aggrecan. Preliminary research has indicated 
that although many of these disorders are due to haploinsufficiency, several of the mutations 
are likely to exert an antimorphic effect. The phenotypes of all but one of the aggrecan animal 
models currently available (cmd, nanomelia) are also due to haploinsufficiency. The remaining 
model (A1946V Acan mouse) is not a disease causing mutation found in humans. To this end, 
two mouse models were generated for two skeletal disorders: OCD (dominant V2303M ACAN 
mutation) and SEMD (recessive D2267N ACAN mutation). These mutations are only a few base 
pairs apart and are both found in the CLD of the G3 domain, but are phenotypically very 
different. The aims of this project were therefore:  
 To analyse the phenotypes of two knock-in mouse models with disease causing mutations
in the major proteoglycan aggrecan.
 To assess and compare the pathomolecular mechanisms of spondyloepimetaphyseal
dysplasia aggrecan type and familial osteochondritis dissecans with analysis of
cartilaginous tissues.
 Further elucidate the disease mechanisms of these disorders with transcriptomic analysis
and pathway validation.
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Chapter 2. Materials and Methods 
All steps were performed at room temperature unless specified otherwise. 
2.1 Materials 
All chemicals and solvents were obtained from Sigma Aldrich unless otherwise stated. 
Antibody suppliers are detailed in Appendix B. 
Primers were synthesised by Eurofins Scientific Ltd. 
Restriction enzymes were obtained from New England Biolabs. 
Image J was obtained from www.imagej.net (Schneider, Rasband et al. 2012). 
Adobe Photoshop CS3 and Graphpad Prism software were obtained on licence from Adobe 
Systems and Graphpad Software respectively. 
LICOR image studio lite software and REVERT total protein stain were obtained from LI-COR 
Biosciences. 
Bovine serum albumin, dithiothreitol (DTT) DNAse I, ethidium bromide, fetal bovine serum, 
glycerol, isopropanol, non-essential amino acids, Novex 3-8% tris-acetate precast gradient 
gels, Novex 4-12% Bis-Tris precast gradient gels, NuPAGE MES SDS Running Buffer, paraffin 
wax, Pierce BCA protein assay kit, penicillin-streptomycin and sodium dodecyl sulfate were 
obtained from ThermoFisher Scientific. 
Acetic acid, coverslips, Dulbecco’s modified eagle medium/nutrient mixture (DMEM) F-12, 
ethanol, hydrochloric acid, methanol, sterile phosphate-buffered saline (PBS) Superfrost Plus 
slides, tissue culture plates and xylene were obtained from VWR International. 
ImmEdge hydrophobic barrier pen, normal rabbit serum, normal goat serum, Nuclear Fast Red 
and VectaMount permanent mounting medium were obtained from Vector Laboratories. 
Dead End Fluorimetric TUNEL system, ethylenediaminetetraacetic acid (EDTA) and ReliaPREP 
RNA tissue miniprep system were obtained from Promega. 
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Cell proliferation labelling reagent bromodeoxyuridine (BrdU) was obtained from GE 
Healthcare. 
Donkey serum and Precision plus protein standards were obtained from Bio-Rad Laboratories. 
Fluoroshield mounting medium with DAPI and Picro-Sirius Red kit were obtained from Abcam. 
25% E.M. grade glutaraldehyde and epoxy embedding resin kit were obtained from TAAB 
Laboratory Equipment Ltd. 
Non-skirted PCR 96 well plates were obtained from Cell projects. 
BioMix red was obtained from Bioline Reagents. 
Qiagen DNA extraction kit was obtained from Qiagen Ltd. 
Agarose was obtained from Melford Laboratories Ltd. 
2% aqueous uranyl acetate and lead citrate were obtained from Leica UK Ltd 
Osmium tetroxide and pioloform were obtained from Agar Scientific. 
RNA 6000 nano kit was obtained from Agilent Technologies. 
Epoxomicin was obtained from Merck Milllipore. 
Nitrocellulose membranes were obtained from Scientific Laboratory Supplies Ltd. 
2.2 Reagents and solutions 
All solutions referenced in the methods section are described in Appendix C. 
Primer sequences are detailed in Appendix D. 
Information on the antibodies and their dilutions can be found in Appendix B. 
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2.3 Generation of mutant mice 
The generation of mutant mice was performed by Polygene Transgenetics in 
Switzerland. The D2267N and V2303M aggrecan mutations were introduced into the 
C57BL/6N inbred mouse line using gene targeting. The mouse aggrecan protein is very similar 
to the human aggrecan protein. Human aggrecan is encoded by 19 exons found on 
chromosome 15. The mouse aggrecan gene contains 18 exons and is found on murine 
chromosome 7. This change from the 19 exons of human ACAN to 18 exons in the mouse Acan 
is because murine exon 13 (encoding 1 of the Type II EGF-like repeats) is a pseudoexon. The 
murine ortholog for the human aspartic acid (D) residue in position 2267 is D1983 on exon 
14 (Figure 13A). The murine ortholog for the human valine 2303 residue is V2019 on exon 15 
(Figure 13B). As the two mutations are located in the adjacent exons, Polygene generated 
targeting vectors with the same homology regions. The final targeting vectors were identical 
apart from the D1983N and V2019M point mutations. The bacterial artificial chromosome BAC 
RP23-390O18 has an insert length of 188 kb and contains exons 2-17 of mouse Acan (but not 
exon 1 or the promoter region) was used to generate the targeting construct. The identity of 
the BAC was confirmed by polymerase chain reaction (PCR) to amplify a fragment of Acan 
intron 14 (the neomycin cassette insertion site) using primer pair P12 and P13 (appendix D). 
PCR was used to generate the short (containing exons 13-14) and long (containing exons 15-
17) arms of homology (confirmed by sequencing). The PCR products were cloned into
PolyGene vector 0008.4a which contained an FRT-flanked neomycin resistance cassette. 
Restriction sites were added to the 5’ (NotI) and 3’ (BamHI) ends of the short arm of homology 
to insert it into the vector upstream of the neomycin cassette, which was placed in intron 14 
of the Acan gene (Figure 14A). A BsiWI restriction site was created to facilitate site directed 
mutagenesis. Restriction sites were added to the 5’ (SbfI) and 3’ (XhoI) ends of the long arm 
of homology to allow insertion into the vector downstream of the neomycin cassette (Figure 
14B). This vector (SY01.2, Figure 14C) was then used as the basis for the following targeting 
strategies. 
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2.3.1 SEMD (D1983N Acan) gene targeting strategy 
The D1983N mutation (G5947A) and an additional silent mutation to introduce a PvuI 
restriction site (T5955G) were introduced into the vector upstream of the neomycin cassette 
using the restriction enzymes BsmBI and BsiWI (Figure 15A). The PvuI restriction site was
created to facilitate confirmation of the presence of the D1983N point mutation by restriction 
digestion with the PvuI enzyme. The restriction enzyme SnaBI was then used to collapse the 
vector (SY01.3 CV) by removing the sequence between the two restriction sites to produce 
the final targeting vector (SY01.4 TV) (Figure 15B-C). The vector sequence was confirmed by
Sanger sequencing of exonic regions and by restriction digestion with XmaI, NcoI, SphI, BglII, 
BspHI, PvuI (Figure 15C). The vector was linearised with the restriction enzyme SnaBI (Figure
15C).
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2.3.2 OCD (V2019M Acan) gene targeting strategy
The V2019M mutation (G6055A) and an additional silent mutation to introduce an 
AgeI restriction site (A6045T) were introduced into the vector (SY01.2) downstream of the 
neomycin cassette using the restriction enzymes SbfI and AgeI (Figure 16A). The AgeI
restriction site was created to facilitate confirmation of the presence of the V2303M point 
mutation (by restriction digestion with the AgeI enzyme). The restriction enzyme SnaBI was 
then used to collapse the vector (D115.4a CV) by removing the sequence between the two 
restriction sites to produce the final targeting vector (D115.5 TV) (Figure 16B-C). The vector
sequence was confirmed by Sanger sequencing of exonic regions and by restriction digestion 
with XmaI, NcoI, SphI, BglII and BspHI (Figure 16C). The vector was then linearised by
restriction digestion with NotI (Figure 16C).
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2.3.3 Screening of the ES cells 
The linearised targeting vectors were electroporated into 2.3 x 107 C57BL/6N-derived 
embryonic stem (ES) cells. The ES cells were then screened for the presence of either the OCD 
or SEMD targeting vectors as follows. The stably-transfected cells were selected for eight days 
with 0.3 mg/ml Geneticin and screened by polymerase chain reaction (PCR) using primer pair 
D115.2 (which bound outside the short arm of homology) and 5182LRPCR (which bound to 
the neomycin cassette) (Figure 17A). The positive clones were expanded and tested for
homologous recombination on both homology arms by long-range PCR using the primer pair 
SY01.14 (which bound upstream of the long arm of homology) and LRPCRneo1 (which bound 
to the neomycin cassette) (Figure 17A) followed by restriction digestion with AgeI and
BamHI. The restriction digestion of the PCR fragment with AgeI was also used to test for the 
presence of the V2019M mutation as an AgeI restriction digest site had been introduced into 
the vector with the mutation (Figure 17A). Semi-quantitative PCR (using primer pair D115.2
and 5182LRPCR) and restriction digestion with PvuI were used to test for the presence of the 
D1983N mutation as a PvuI restriction digest site had been introduced into the vector with 
the mutation (Figure 17A).
2.3.4 Blastocyst injection and implantation 
The screened C57BL/6N clones were then injected into blastocysts from grey C57BL/6 
mice and the surviving blastocysts implanted into CD-1 pseudopregnant foster mice. The 
offspring were assessed and the 100% chimeric mice (with 100% black coats) were mated to 
C57BL/6N based grey Flp-deleter mice. Flp-deleter mice express the site-specific recombinase 
FLP1 gene driven by the phosphoglycerate kinase 1 (Pgk1) promotor. Germline transmission 
was assessed based on coat colour (as black is dominant over grey) and offspring with black 
coats were screened by PCR (using primer pair SY01.P12 and SY01.P13) (Figure 17B-C) for Flp-
mediated deletion of the FRT-flanked neomycin resistance cassette. The neomycin resistance 
cassette had been required as a positive drug marker during the antibiotic selection of ES cells, 
however it was removed to prevent any off-target effects such as disrupted expression of 
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nearby genes. Semi-quantitative PCR (using primer pair D115.3 and D115.4) and restriction 
digestion with AgeI was used to test for germline transmission of the V2019M mutation 
(Figure 17). Semi-quantitative PCR (using primer pair SY01.15 and SY01.16) and restriction
digestion with PvuI was used to test for germline transmission of the D1983N mutation 
(Figure 17). Semi-quantitative PCR was used to screen for the presence of the FLP1-
transgene (primer pair SD24 and SD25) (Figure 17).
2.4 Establishment of the OCD and SEMD mouse lines 
Mice heterozygous for either 1) the SEMD (D1983N Acan) mutation or 2) the OCD 
(V2019M Acan) mutation (after Flp-mediated removal of the neomycin resistance cassette) 
and positive for the FLP1 transgene were transported to our facility for further breeding. 
2.4.1 Tissue and genomic DNA extraction 
An ear notcher was used to obtain ear tissue and allow identification of mice after 3 
weeks of age. Tail or skin tissue was obtained post-mortem from pups under 3 weeks of age. 
Genomic DNA was then isolated from tissue according to the following hotshot protocol: 75 
μl of cell lysis buffer was added to each tissue sample and incubated for 30 minutes at 95°C, 
followed by 10 minutes at 4°C; 75 μl of neutralising buffer was added and the samples
vortexed to homogenise.  
2.4.2 Semi-quantitative polymerase chain reaction (PCR) 
This standard protocol was used for all subsequent PCR. The reactions were performed 
in thin-walled PCR plates with the following reagents per reaction: 7.4 μl ddH2O, 10 μl of 2x 
Biomix red, 0.8 μl of 10nm forward oligonucleotide primer, 0.8 μl of 10nm reverse 
oligonucleotide primer. The master mix was briefly pipette mixed and 19 μl was added to each 
well. 1 μl of genomic DNA was then added per well. Genomic DNA extracted from a FLP1-
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positive colony founder mouse heterozygous for the targeted mutant Acan amplicon 
(previously genotyped by Polygene Transgenetics) was used as a positive control and 1 μl of 
distilled water was used as a template-negative control. The samples were placed in a 
Labnet Multigene Optimax thermocycler with the appropriate cycling protocol (Appendix D).
The DNA fragments were separated with horizontal gel electrophoresis. 
2.4.2.1 Flp-mediated removal of the neomycin cassette 
Semi-quantitative PCR with the primers P12 and P13 was used to check that Flp-
mediated removal of the neomycin cassette from the targeted Acan allele had occurred. This 
PCR protocol was also used for the routine genotyping of mice from the OCD and SEMD mouse 
colonies. The expected size of the wild type amplicon was 434 bp and the expected size of 
the targeted mutant Acan amplicon (with only one FRT site remaining) was 545 bp (Figure 
17).
2.4.2.2 Removal of the FLP transgene 
The FLP1 transgene had been used during the generation of the knock-in mice to 
remove the neomycin cassette from the targeted Acan allele. Semi-quantitative PCR with the 
primers SD24 and SD25 was used to identify mice positive for the FLP1 transgene (with an 
expected amplicon of 500bp). Mice which were negative for the FLP1 transgene were then 
selected for breeding. 
2.4.2.3 Confirming the presence of the point mutation 
In order to confirm presence of either 1) the SEMD (D1983N Acan) mutation or 2) the 
OCD (V2019M Acan) mutation, semi-quantitative PCR was used in combination with 
restriction digestion with either the 1) PvuI or 2) AgeI restriction enzymes (as restriction digest 
sites were introduced with the mutations of interest). PCR using DNA extracted from mice 
heterozygous or homozygous for the SEMD mutant Acan allele was performed with the 
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primers SY01.15 and SY01.16 (Figure 17B). The expected amplicon was 617bp. Semi-
quantitative PCR using DNA extracted from mice heterozygous or homozygous for the OCD 
mutant Acan allele was performed with the primers D115.3 and D115.4 (Figure 17C). The
expected amplicon was 662bp. 
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2.4.2.4 DNA extraction 
A Qiagen DNA extraction kit was used to obtain DNA from the agarose gel according 
to the manufacturer’s protocol. Briefly, the PCR products were separated using horizontal gel 
electrophoresis on a 1.5% agarose (w/v) gel at 30V for 30 minutes. The DNA bands were cut 
from the gel under UV light using a clean scalpel and weighed. 3 μl of QG buffer per mg of gel 
was added. The samples were incubated at 50°C for 10 minutes with vortexing every 2 minutes 
until the gel slice had dissolved. 1 μl of isopropanol per mg of gel was added in order to 
precipitate the DNA. The solution was then applied to a spin column and centrifuged at 13, 
000 x g for 1 minute to bind the DNA to the column membrane. The flow-through was 
discarded and 500 μl QG buffer was applied to remove remaining agarose. The column was 
centrifuged at 13, 000 x g for 1 minute and the flow-through discarded. The column was 
washed with 750 μl PE buffer and centrifuged at 13, 000 x g for 1 minute to remove residual 
buffer. The column was placed into a clean Eppendorf and the DNA eluted in 30 μl of distilled 
water. The resultant DNA was then digested with the appropriate restriction enzymes. 
2.4.2.5 Restriction digestion 
The DNA fragments originally extracted from mice heterozygous or homozygous for 
either  the 1) SEMD or 2) OCD mutant Acan allele were digested with the restriction enzyme 
1) PvuI or 2) AgeI, respectively. A reaction mastermix was made with the following reagents:
14 μl of distilled water, 5 μl of 10x NEBuffer3.1, 1 μl of 10U/μl restriction enzyme and 30 μl of 
DNA. The reactions were then incubated at 37°C overnight. The DNA fragments were 
separated with horizontal gel electrophoresis. The expected size of the undigested SEMD DNA 
fragment was 617 bp. The expected size of the digested DNA fragments (those containing the 
SEMD D1983N mutation) was 349 bp and 268 bp. The expected size of the undigested OCD 
DNA fragment was 662 bp. The expected sizes of the mutant digested DNA fragments (those 
containing the OCD V2019M mutation) were 314, 252 and 96 bp. The expected sizes of the 
wild type digested DNA fragments (those not containing the V2019M mutation) were 410 and 
252 bp. 
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2.4.3 Animal husbandry 
Heterozygote mutant crosses were established to enable preliminary phenotypic 
comparison of littermates of all three genotypes (heterozygous mutant, homozygous mutant 
and wild type). This minimised the effect of environmental factors such as quality and 
abundance of milk provided by the female in each breeding pair during the pre-weaning 
phase of development. Defined crosses which produced offspring of a single genotype ((wild 
type or homozygous for the OCD (V2019M) allele)) were established for the collection of 
tissue and cells for culture in vitro and to reduce animal usage in line with the 3Rs principal of 
animal research (Flecknell 2002). Unfortunately, it was difficult to establish a defined cross
for mice homozygous for the SEMD (D1983N) allele due to the high mortality rate during the 
first few days after birth. Breeding trios consisting of a homozygous mutant male, a 
homozygous mutant female and a heterozygous mutant female were more successful and 
pups born from each female survived to seven days of age. Pups were selected based on 
their visual appearance (relative size and craniofacial features) and the genotype confirmed 
by PCR analysis of DNA extracted from a tail tissue or skin biopsy. All mice were checked for 
teeth overgrowth upon weaning due to the high incidence of malocclusion in the C57BL/6 
background strain. In addition to this, skeletal dysplasias can affect tooth formation (Dressler, 
Meyer-Marcotty et al. 2010, Low, Ansari et al. 2017) and so mice were monitored for tooth 
abnormalities throughout life. Mice with malocclusion had their teeth clipped every week 
and were provided with hydrated diet pellets to reduce the impact of dietary differences on 
weight and skeletal growth phenotype. 
2.4.4 Generation of genotype ratios
The number of pups of each genotype per 100 pups born was counted from a minimum 
of five independent breeding pairs. The frequency of each genotype was then analysed 
statistically with a Chi-square test. 
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2.5 Phenotype analysis 
Wild type mice and mice heterozygous and homozygous for the mutant Acan alleles 
were included in the preliminary phenotype analysis. 
2.5.1  Generation of growth curves 
Male and female adult mice were weighed at 3, 6 and 9 weeks of age in order to 
measure the rate of growth. The difference in the average mass of each genotype was 
statistically analysed with a Student’s t-test. 
2.5.2 Radiographical analysis 
A Faxitron MX-20 digital X-ray machine was used to capture dorsal and lateral 
radiographs of mice at 1, 3, 6 and 9 weeks of age. Bone length measurements were obtained 
by analysing the original DICOM files using ImageJ (Schneider, Rasband et al. 2012) 
measurement tools in order to assess the length of the mandible, maxilla, tibia, femur, skull, 
pelvis (illium and ischium), the intercanthal distance (ICD) and the angle between the illium 
and the tuberosity of the ischium (Figure16A-B). The difference in the average bone length of 
each genotype was statistically analysed with a Student’s t-test. The dorsal angle of spine 
curvature was measured with an adapted version of the Diab method in order to assess 
scoliosis (Figure16A). This method was chosen as other more widely used techniques, such as 
the Cobb and Ferguson methods, rely on manual identification of the end vertebrae (Diab, 
Sevastik et al. 1995). The difference in the average dorsal angle of each genotype was 
statistically analysed with a Student’s t-test. The Grubbs’ test function in Graphpad Prism was 
used to detect significant outliers within the data set for each genotype. 
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2.5.3  Histological and morphometric analysis of skeletal preparations 
Neonatal skeletal preparations were generated to assess the number and organisation 
of early skeletal components. Newborn mice were culled by overdose of isoflurane 
anaesthetic and placed in tap water for 24 hours at 4°C. Each pup was scalded in 65-70°C tap 
water for 30 seconds and the skin and viscera removed. Preparations were placed into a 6 well 
tissue culture plate and fixed in 95% ethanol for 3 to 5 days. The pups were then stained 
with Alcian Blue (Appendix C) for 24 hours, rinsed twice with 95% ethanol and incubated 
in 95%ethanol for 48 hours. The preparations were cleared in 1% (w/v) potassium 
hydroxide for 6 hours, stained with Alizarin Red (Appendix C)  for 3 hours and  cleared 
in 2% (w/v) potassium hydroxide for 48 hours. The pups were then incubated in 80:20 2% 
KOH:glycerol for 24 hours followed by incubation in 60:40 2% KOH:glycerol for 24 hours 
and 40:60 2% KOH:glycerol for 24 hours. Each preparation was then stored in 20:80 2% 
KOH:glycerol. Images of the neonatal skeletal preparations were taken using a Zeiss 
Stemi SV6 dissecting microscope. Bone measurements were obtained by analysing the 
original ZVI files with ImageJ measurement tools to assess the length of the femoral and 
tibial bones (Figure 18C). The difference in the average bone length of each genotype was 
statistically analysed with a Student’s t-test. 
2.5.4 Histological and morphometric analysis of skull preparations 
Alizarin Red and Alcian Blue were used to stain the calcified bone and proteoglycans 
in the cartilage respectively in order to analyse the ossification patterns and the size and shape 
of the skull bones. Mice were culled by an appropriate Schedule 1 method. Skulls were 
dissected from male mice at 3 weeks of age, the skulls skinned and loose soft tissue and eyes 
removed. The skulls were then fixed in 4% paraformaldehyde for 48 hours at 4°C and 
incubated in Alcian blue for 24 hours. Samples were then post-fixed in 95% ethanol for 48 
hours and incubated in 1% potassium hydroxide to remove the remaining soft tissue, 
changing the solution every few days. Once the majority of soft tissues were removed, the 
skulls were incubated in Alizarin red for 24 hours. The samples were incubated in 1% 
potassium hydroxide to remove the remaining soft tissue, changing the solution every few 
days, until all the soft tissue was removed. The mandible was removed by severing the 
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attached ligaments in order to allow the skull to lie flat for imaging. Skulls were imaged with 
a Zeiss Stemi SV6 dissecting microscope. Bone measurements were obtained by analysing the 
original ZVI files with ImageJ measurement tools to assess the length and width of the nasal, 
parietal and frontal bones (Figure 18D, protocol modified from Kawakami and Yamamura 
2008). The difference in the average bone length or width of each genotype was statistically 
analysed with a Student’s t-test. 
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2.6 Histological analysis 
All staining was performed manually, except toluidine blue and haematoxylin and 
eosin staining which was performed using a Linistat linear automated stainer. Images of all 
tissue sections were taken using a Zeiss Axioplan or Z2 Axioimager microscope. 
2.6.1 Tissue dissection and preparation 
Mice were culled by an appropriate Schedule 1 method. Tissues were dissected and 
fixed in 95% ethanol and 5% acetic acid (immunohistochemistry) or 4% paraformaldehyde 
(histology) for 48 hours at 4°C. Skeletal samples were decalcified for 14 days in 20% 
ethylenediaminetetraacetic acid (EDTA, pH 7.4) and washed under running tap water for an 
hour to remove any residual EDTA. The samples were placed in a Thermo Scientific Spin 
Tissue Processor to infiltrate with paraffin before embedding (Appendix E). The tissue
samples were embedded in paraffin wax and sectioned on a sagittal (joint samples) or 
frontal (IVD samples) plane in 6μm thick sections with a Thermo Scientific Automatic Rotary 
microtome. The slides were air-dried, heated to 64°C to increase tissue adherence to the 
slide and then air dried again. 
2.6.2 Haematoxylin and Eosin staining 
Harris’ modified Haematoxylin and Eosin Y were used to investigate cell morphology 
and the structure of the growth plate, articular surface and intervertebral disc (IVD). A 
linistat linear automated stainer was used (Appendix F). The joint areas were matched by
morphological assessment of 5 slides per animal. Slides were dewaxed with two 5 minute 
washes of xylene. The tissue sections were then rehydrated with decreasing concentrations 
of ethanol and one wash of water. The slides were incubated in filtered Harris’ modified 
haematoxylin and rinsed with alkaline tap water. Differentiation was achieved by washing in 
1% acid alcohol. The tissue was then rinsed with water, counterstained with filtered Eosin Y 
and rinsed with water to remove the excess stain. The tissue sections were dehydrated with 
94
increasing concentrations of ethanol and then cleared with two 5 minute washes of xylene. 
The slides were then mounted using Vectamount mounting media and 22 x 55 mm coverslips 
and dried overnight.  
This method stains the cell nuclei blue, cytoplasm pink and the surrounding cartilage matrix a 
light purple/pink. 
2.6.3 Quantification of the growth plate
A Zeiss Z2 Axioimager microscope was used to take tiled images of the entire tibial 
growth plate which were then stitched together for analysis. At least one section from each 
of the three regions of the joint compartment was selected (3-5 mice per genotype). ImageJ 
measurement tools were used to measure the total growth plate height, the height of each 
zone (resting, proliferative and hypertrophic) (Figure 19A) and the mineralised area of the 
secondary ossification centre (Figure 19B). Height measurements were taken as an average 
of three measurements of the central section of the growth plate (avoiding the 
perichondrium). The difference in the average height or area of each genotype was 
statistically analysed with a Student’s t-test. 
2.6.4 Quantification of the thoracic vertebral column
A Zeiss Axioplan microscope was used to take overlapping images of the vertebral 
column and the Photoshop photomerge function was used to produce a reconstruction of the 
entire thoracic spine. ImageJ measurement tools were used to measure the height and width 
of each vertebral body, the height of the mid-region in each intervertebral disc and the 
height and width of the nucleus pulposus (Figure 1C). Measurements were taken as an 
average of five vertebral bodies or discs per mouse. The difference in the average of each 
parameter was statistically analysed with a Student’s t-test (4-5 mice per genotype).  
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2.6.5 Scoring for intervertebral disc degeneration
Intervertebral discs (IVD) were assessed for degenerative changes by one new and two 
experienced scorers using an established histo-morphometric technique (Tam, Chan et al. 
2018). The individual components of the IVD (annulus fibrosis, nucleus pulposus) were scored 
for morphological features associated with either normal disc structure or degenerative 
changes. Normal disc morphology was scored with a value of 0 and degenerative features 
scored according to severity. Morphological features associated with degeneration included 
the formation of fissures or clefts, loss of boundary between the annulus fibrosis and nucleus 
pulposus and cell loss within the nucleus pulposus. The average score was calculated for each 
disc component (maximum score of 6) the annulus fibrosis- nucleus pulposus boundary 
(maximum score of 2) and the entire IVD (maximum score of 14). The difference in the average 
of each score was statistically analysed with a Student’s t-test (3-5 mice per genotype).  
2.6.6 Toluidine Blue staining
The histological stain Toluidine Blue was used to look at the relative abundance of 
proteoglycans and glycosaminoglycans. A linistat linear automated stainer was used 
(Appendix F). Each slide was dewaxed with two 5 minute washes of xylene. The tissue
sections were then rehydrated with decreasing concentrations of ethanol and one wash of 
distilled water. The slides were incubated in Toluidine Blue (Appendix C) and rinsed with one
wash of distilled water. The tissue was counterstained with Nuclear Fast Red and rinsed with 
two washes of distilled water to remove the excess stain. The tissue sections were then 
dehydrated with increasing concentrations of ethanol and cleared with two 5 minute washes 
of xylene. The slides were then mounted using Vectamount mounting media and 22 x55mm 
coverslips and dried overnight.  
This method stains the cytoplasm blue and the cell nuclei and surrounding cartilage matrix 
purple. 
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2.6.7 Picro-Sirius Red staining
An Abcam Picro-Sirius Red kit was used to look at the relative abundance, orientation 
and diameter of collagen fibrils by exploiting the bifringence of collagen under polarised light. 
The manufacturer’s protocol was used as follows. Each slide was dewaxed with two 5 minute 
washes of xylene. The tissue sections were then rehydrated with decreasing concentrations 
of ethanol and two washes of distilled water. The slides were incubated in Picro-Sirius Red for 
one hour and rinsed with two changes of 0.5% acetic acid. The slides were shaken vigorously 
to remove excess water, dehydrated with 3 changes of 100% ethanol and cleared with two 5 
minute washes of xylene. The slides were then mounted using Vectamount mounting media 
and 22 x55mm coverslips and dried overnight. Images of tissue sections were taken using a 
Leica DM2700 microscope under polarised light. 
When observed under polarised light this method stains larger collagen fibers orange/red and 
thinner fibres green. 
2.6.8 Von Kossa staining
Von Kossa staining was performed on calcified tissue in order to assess calcium and 
calcium salt deposition as a marker of bone mineralisation. Each slide was dewaxed with two 
5 minute washes of xylene and rehydrated with decreasing concentrations of ethanol and two 
washes of distilled water. Tissue sections were incubated for 20 minutes in 1% (w/v) Silver 
Nitrate under ultra violet (UV) light. The sections were rinsed with distilled water, incubated 
in 1% (w/v) sodium thiosulphate for 5 minutes to remove unreacted silver and washed again 
with distilled water. Slides were counterstained with Nuclear Fast Red and dehydrated with 1 
change each of 90% and 100% ethanol. Slides were cleared with two 5 minute washes of 
xylene and mounted using Vectamount mounting media and 22 x55mm coverslips before 
drying overnight. 
This method stains calcium and calcium salts brown/black. 
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2.6.9 Tartrate-resistant acid phosphatase (TRAP) staining
A Sigma Aldrich acid phosphatase kit was used to assess the abundance of the 
osteoclast marker tartrate-resistant acid phosphatase and the manufacturer’s protocol was 
followed with a few modifications. In summary, each slide was dewaxed with two 5 minute 
washes of xylene and rehydrated with decreasing concentrations of ethanol and two washes 
of distilled water. The sections were incubated in pre-warmed (37oC) TRAP staining solution 
for 1 hour protected from light then rinsed in distilled water for 5 minutes and counterstained 
with Fast Green solution. The tissue sections were then rinsed thoroughly and dehydrated in 
95% and 100% ethanol. Slides were cleared with two 5 minute washes of xylene and mounted 
using Vectamount mounting media and 22 x55mm coverslips before drying overnight. 
This method stains cells containing tartrate acid-resistant phosphatase red/purple. 
2.6.10 Safranin O staining
Safranin O was used to assess relative proteoglycan loss in the articular cartilage. The 
growth plate was used as an internal control between individuals of the same genotype. Each 
slide was dewaxed with two 5 minute washes of xylene and rehydrated with decreasing 
concentrations of ethanol. The nuclei were stained with Weigert’s iron hematoxylin for 10 
minutes and excess staining solution removed by washing under running tap water for 10 
minutes. The slides were counterstained with 0.05% fast green for 5 minutes and briefly 
decolourised with 1% acetic acid for 10–15 seconds. Tissue sections were stained with 0.25% 
safranin O solution for 5 minutes and dehydrated with 2 changes of 95% ethanol and 100% 
ethanol for 2 minutes. Slides were then cleared with two 5 minute washes of xylene and 
mounted using Vectamount mounting media and 22 x55mm coverslips before drying 
overnight. 
This method stains cell nuclei black, cytoplasm grey/green and the proteoglycan in the 
cartilage matrix red. 
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2.6.11 Immunofluorescent analysis
Primary antibodies used for the analysis of tibial tissue were against aggrecan, COMP, 
matrilin 3, collagen type IX, collagen type X, collagen type II, LC3 and IHH (Appendix B). Each 
slide was dewaxed with two 5 minute washes of xylene. The tissue sections were then 
rehydrated with decreasing concentrations of ethanol and two washes of distilled water. The 
tissue sections were washed with two 3 minute washes of phosphate-buffered saline (PBS). 
An ImmEdge hydrophobic barrier pen was used to mark around the sections in order to 
reduce the volume of reagents required. All incubations after this point were performed with 
the slides in a humidified chamber in the dark. Tissue sections were incubated with bovine 
hyaluronidase (0.2% in 1x PBS) for 30 minutes (for antigen retrieval) and then rinsed with 
three 2 minute PBS washes. Further antigen retrieval was performed with incubation in 10 
μg/ml proteinase K for 5 minutes, followed by three 2 minute PBS washes. Sections were then 
incubated for one hour with 1% bovine serum albumin (BSA), 0.6% serum and 0.3% Triton X- 
100 in 1x PBS. The tissue sections were then incubated with primary antibody (in 1% BSA, 
0.3% Triton X-100, 1x PBS) overnight at 4°C. Slides were rinsed with two 5 minute washes of 
1% BSA in PBS and incubated with a fluorescent AlexaFluor secondary antibody (1% BSA, 0.6% 
serum, 1x PBS) for one hour at room temperature. The tissue sections were rinsed with three 
5 minute washes of PBS. The slides were then mounted using Fluoroshield mounting media 
(with DAPI to counterstain the cell nuclei) and 22 x55mm coverslips and dried overnight in the 
dark.
2.6.12 Bromodeoxyuridine labelling and detection
 The thymidine analog 5-bromo-2-deoxyuridine (BrdU) was used to analyse chondrocyte 
proliferation. 3 week old mice were injected subcutaneously with 0.1ml of BrdU reagent per 
10g of mouse mass. The mice were left for 130 minutes to allow the BrdU to incorporate into 
the DNA during S-phase and then culled. The legs were dissected out and the tissue processed 
as per the protocol for immunohistological analysis. Each slide was dewaxed with two 5 
minute washes of xylene. The tissue sections were then rehydrated with decreasing 
concentrations of ethanol and two washes of distilled water before three 5 minute washes of 
phosphate-buffered saline (PBS). The DNA in the tissue sections was denatured by a 15 minute 
incubation in 4M hydrochloric acid. The acid was then neutralised by incubation in 0.1M 
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borate buffer for 5 minutes, followed by three 2 minute washes of PBS. An ImmEdge 
hydrophobic barrier pen was used to mark around the sections in order to reduce the volume 
of reagents required. All incubations after this point were performed with the slides in a 
humidified chamber in the dark. Tissue sections were blocked with 4% donkey serum in 1x 
PBS for 20 minutes to prevent non-specific binding. The tissue sections were incubated with 
primary antibody (1% BSA in 1x PBS) for one hour and then rinsed with two 5 minute washes 
of PBS. The slides were then incubated with an Alexafluor fluorescent secondary antibody for 
1 hour and then rinsed with two 5 minute washes of PBS. The slides were mounted with 
Fluoroshield DAPI mounting medium (to counter-stain the nuclei) and 22 x55mm coverslips 
and dried overnight in the dark. A Zeiss Z2 Axioimager microscope was used to take images of 
the entire tibial growth plate which were then stitched together for analysis in ImageJ using 
the cell counter (Schneider, Rasband et al. 2012) and the Watershed plug-in (Soille and Vincent 
1990). The number of fluorescent cells was counted as a percentage of the total number of 
DAPI stained cells in the proliferative zone. The percentage of fluorescent proliferating cells in 
a mutant growth plate was then compared with that of a wild type mouse and statistically 
analysed with a Student’s t-test. 
2.6.13 Terminal deoxynucleotidyl transferase dUTP nick end labelling
(TUNEL) 
The Dead End Fluorimetric TUNEL system was used to assess apoptosis. The 
manufacturer’s protocol was followed with some modifications as follows. Each slide was 
dewaxed with two 5 minute washes of xylene. The tissue sections were then rehydrated with 
decreasing concentrations of ethanol, a five minute wash of 0.85% sodium chloride and a five 
minute wash of PBS. The tissue sections were then post-fixed with a 15 minute incubation in 
4% paraformaldehyde. The tissue sections were then rinsed with two 5 minute washes of PBS 
and boiled in citric buffer for 12 minutes to allow antigen retrieval. The slides were then rinsed 
in PBS for five minutes, post-fixed in 4% paraformaldehyde for five minutes and washed with 
PBS for five minutes. An ImmEdge hydrophobic barrier pen was used to mark around the 
sections in order to reduce the volume of reagents required. All incubations after this point 
were performed with the slides in a humidified chamber in the dark. In order to produce a 
positive control one slide was treated with DNase I in order to fragment the DNA. The slide 
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was incubated firstly in DNase I buffer for five minutes, then DNase I (in DNase buffer) for ten 
minutes and rinsed with three washes of dH2O. All of the slides were incubated for 5 minutes 
with equilibration buffer. The TdT master mix was then added and the slides incubated at 37C 
for 1 hour. The slides were incubated in SSC buffer for 15 minutes to stop the reaction and 
then washed with three 5 minute washes of PBS. The slides were then mounted in 
Fluoroshield (with DAPI to counterstain the nuclei) and 22 x 55mm coverslips and dried 
overnight. A Zeiss Z2 Axioimager microscope was used to take images of the entire tibial 
growth plate which were then stitched together for analysis in ImageJ using the cell counter 
and watershed plug-in. The number of cells with fluorescein-12-dUTP- labeled DNA in each 
zone was counted as a percentage of the total number of DAPI stained cells in each zone. The 
percentage of fluorescent cells per zone in a mutant growth plate was then compared with 
that of a wild type mouse and statistically analysed with a Student’s t-test. 
2.6.14 Transmission electron microscopy
The structure of the cartilage extracellular matrix was analysed with transmission 
electron microscopy. Mice were culled by neck dislocation at 7 days of age. The cartilage was 
dissected and cut into 1mm by 2mm pieces of tissue. The tissue was fixed in 2% glutaraldehyde 
in sodium cacodylate buffer at 4°C for 14 days. The following protocol was then performed by 
staff at Newcastle University Electron Microscopy Research Services. The samples were post-
fixed with 1% osmium tetroxide to preserve the lipid content and add contrast to the tissue. 
The tissue was dehydrated with increasing concentrations of acetone, impregnated with 
increasing concentrations of resin in acetone and embedded in resin at 60°C for 24 hours. 
0.5µm survey sections were cut and stained with 1% toluidine blue in 1% borax to visualise 
the growth plate. 70nm sections were then cut with a diamond knife on either an RMC MT-XL 
or Leica EM UC7 ultramicrotome. The sections were stretched with chloroform to prevent 
compression and mounted in pioloform-filmed copper grids. The tissue was then stained with 
2% aqueous uranyl acetate and lead citrate. The tissue was analysed with a Philips CM100 
Compustage (FEI) Transmission Electron Microscope and an AMT CCD camera (Deben). It is 
important to note that the fixation methods used here do not preserve the proteoglycan 
content of the cartilage (Hunziker, Lippuner et al. 2014). The Photoshop photomerge function 
was used to produce a growth plate reconstruction. 
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2.7 Transcriptome analysis 
2.7.1 Cartilage tissue extraction 
Mice were culled by neck dislocation at 5 days of age. Each leg was skinned, the 
femur severed 5mm above the knee and the tibia cut at the ankle. The muscle and fibrous 
tissues were removed if possible and the remaining tissue incubated in 250µl collagenase at 
37°C for 50 minutes. The tissue was then placed in warm phosphate-buffered saline (PBS) 
and dissected under a Leica MZ 12.5 stereomicroscope to remove any remaining muscle and 
fibrous tissue. A clean scalpel was then used to separate the cartilage from the bone by a 
single cut at the bone-cartilage interface. The cartilage was snap-frozen in liquid nitrogen 
and stored at -80°C until required for RNA isolation. 
2.7.2 Total RNA extraction 
Total RNA was isolated from the cartilage tissue using the Promega ReliaPREP RNA 
tissue miniprep system. The manufacturer’s protocol was used as follows. A Sartorius Mikro-
dismembranator S tissue homogeniser was used to disrupt the frozen cartilage’s tissue 
structure in flash frozen lysis buffer. The tissue was then allowed to thaw directly into the 
tissue lysis buffer in order to protect the integrity of the RNA and release the RNA into solution 
free of associated protein. The DNA was then sheared with pipetting and the sample diluted 
with an equal volume of RNA dilution buffer, vortexed and incubated for 1 minute. The sample 
was centrifuged for 3 minutes at 10, 000 x g to pellet insoluble cell debris and the cleared 
lysate transferred to a clean eppendorf. The RNA was precipitated with the addition of 340 μl 
isopropanol and applied to the minicolumn. The column was centrifuged for 1 minute at 13, 
000 x g to bind the RNA to the membrane and incubated with RNase-free DNase I in order to 
remove any genomic DNA. The column was then washed several times to remove any other 
contaminants. The RNA was eluted with Nuclease-Free Water and assessed with an Agilent 
2100 Bioanalyser for quantity and quality. Samples with an RNA integrity number (RIN) of 7 
or above were used for downstream transcriptome analysis (Appendix H).
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2.7.3 Next-generation sequencing and bioinformatic transcriptome 
analysis 
Next-generation RNA sequencing (RNA-seq) was performed in order to analyse the 
mutant transcriptome and identify possible disease mechanisms. In-house RNA-sequencing 
for differential gene expression analysis was performed by Newcastle University Genomics 
Core Facility using an Illumine NextSeq 500 sequencer. 220 ng of DNAse-treated total RNA was 
used per sample. Total RNA was pooled from two mice per sample and three samples (from 
three different litters) were sequenced per genotype to allow downstream statistical analysis. 
15-23,000,000 reads were obtained per sample. In-house transcriptome analysis was 
performed by the Newcastle University Bioinformatics Support Unit. The MultiQC (FastQC) 
tool was used for quality control. Alignment free quantification and counting were both used 
for mapping and quantification. Kallisto 0.43.0 was used for alignment free quantification. 
Alignment was finished with a STAR 1-Pass protocol and the features counted with HTSeq-
Count. Principal component analysis (PCA) was applied to normalised data (Appendix H). 
Differential gene expression modelling was performed with DESeq2. Further pathway 
enrichment analysis was then performed by myself using the database for annotation, 
visualisation and integrated discovery (DAVID) functional annotation tool to identify GO 
terms (Huang da, Sherman et al. 2009). REVIGO was then applied to cluster redundant GO 
terms (Supek, Bošnjak et al. 2011). 
2.8 Tissue culture 
All tissue culture was performed in Class II tissue hood. All tissue cultures were 
incubated at 37°C and 5% CO2 in a humidified atmosphere. Cartilage explants and cells were 
grown in maintenance media (Appendix C). L-ascorbic acid 2-phosphate sesquimagnesium
salt was used to enhance the chondrocytes’ collagen type II production at both a 
transcription and post-transcriptional level. Further to this, chondrocytes are stereo-
selective for the L-forms and ascorbic acid is unstable at 37°C (88-98% disappear within 24 
hours) and so fresh media was added every 24 hours (Anderson, McLean et al. 1991, 
McNulty, Vail et al. 2005). 
104
2.8.1 Chondrocyte extraction 
Mice were culled by neck dislocation at 7 days of age. The mice were dissected, the rib 
cages isolated and placed in warm PBS. The tissue was then dissected under a Leica MZ 12.5 
stereomicroscope to remove any remaining soft tissue. A clean scalpel was used to separate 
the cartilage from the bone by a single cut at the bone-cartilage interface. The pieces of 
cartilage were incubated in 3 mg/ml collagenase for 45 minutes at 37°C and 5% CO2 in a 
humidified atmosphere. The tissue samples were agitated with a 25 ml pipette to assist in the 
removal of soft tissue and the translucent cartilage transferred to a clean 6 well tissue 
culture plate. The cartilage was incubated in 0.5 mg/ml collagenase overnight at 37°C and 
5% CO2 in a humidified atmosphere to digest the extracellular matrix around the 
chondrocytes. 25 ml of maintenance media was added to dilute the collagenase and 
decrease the rate of digestion. The cell suspension was agitated through decreasing sizes of 
pipettes to disperse cell aggregates and filtered through a 48 μm cell strainer. The cell 
suspension was centrifuged for 10 minutes at 400 x g. The media was removed and the cell 
pellet washed with PBS and resuspended in 1 ml of maintenance media per animal. 5 μl of 
Trypan blue, which selectively stains dead cells, was added to 15 μl of cell suspension in 
order to assess cell viability. The suspension was pipetted into a FastRead 102 disposable 
haemocytometer and visualised under a Nikon Eclipse TS100 microscope. The number of live 
cells (those not stained dark blue) was counted in four squares and the total number of 
viable cells extracted was calculated according to the following calculation:   
counts/ml = total counts x 104 x sample dilution 
The chondrocytes were seeded in a 6 well plate at a density of 25 x 10
3 
cells/cm
2
. 
2.8.2 Drug treatment 
None of the drugs used were sterilised as they were all dissolved in 100% tissue-culture 
standard DMSO which has exhibited anti-microbial activity (Howard, William et al. 1969).
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2.8.2.1 Autophagy inhibition 
Drug treatment was performed in cartilage explants. Briefly, mice were culled by neck 
dislocation at 7 days of age. Each leg was skinned, the femur severed 5mm above the knee 
and the tibia cut at the ankle. The tissue was then placed in warm PBS and dissected under a 
Leica MZ 12.5 stereomicroscope to remove any remaining muscle and fibrous tissue. A clean 
scalpel was then used to separate the cartilage from the bone by a single cut at the bone-
cartilage interface. The cartilage explants were incubated overnight in maintenance media 
and then washed with PBS twice before transfer to a clean 24 well plate. To inhibit the 
autophagy pathway the end-stage autophagy inhibitor chloroquine was used. Chloroquine 
prevents the fusion of the lysosome with the autophagasome leading to the accumulation of 
the autophagic vesicles. Cartilage explants were incubated in maintenance media 
supplemented with 250μM chloroquine for 0, 1, 3 and 6 hours. After chloroquine treatment 
the cartilage tissue was rinsed twice in PBS and centrifuged at 800 x g for 5 minutes to 
remove any residual media. The cartilage was then snap-frozen and stored at -80°C until 
required for protein extraction. 
2.8.2.2 Carbamazepine 
Carbamazepine (CBZ) has been shown to reduce intracellular protein retention and 
endoplasmic reticulum stress in a mouse model of Schmid metaphyseal chondrodysplasia 
(MSDS) by stimulating the mTORC-independent autophagy and proteasomal protein 
degradation pathways (Mullan, Mularczyk et al. 2017). It was not possible to use an in vivo 
drug treatment protocol as mice homozygous for the OCD and SEMD mutations were below 
the minimum weight threshold (10 kg) for subcutaneous drug pellet implantation (using the 
pellets available). Tissue explants were therefore used as an alternative in order to assess 
tissue pathology and bone length. Mice were culled by neck dislocation at 7 days of age and 
the entire leg dissected out and skinned. Explants were incubated for two weeks in 
maintenance media supplemented with 200μM CBZ. After CBZ treatment the cartilage tissue 
was rinsed in dH2O, x-rayed to facilitate bone length measurements and processed for 
downstream histology. 
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2.9 Immunoblotting 
2.9.1 Sequential protein extraction 
Mice were culled by an appropriate Schedule 1 method at three weeks of age. Two 
femoral heads were dissected per mouse and three mice were used per genotype. Samples 
were snap-frozen in liquid nitrogen and stored at -80°C until required for use. The femoral 
heads were cut into small pieces with a scalpel, transferred to a pre-weighed clean eppendorf 
and weighed. All buffers were pre-chilled to 4°C before use. The appropriate amount of 
Buffer I (Appendix C) per weight was added and samples rotated at 4°C for six hours. The
samples were then centrifuged for 5 minutes at 13, 000 x g and 4°C. The supernatant was 
removed in 100     μl aliquots and stored at -20°C. The pellet was resuspended in an appropriate 
amount of Buffer II per weight, vortexed vigorously and rotated at 4°C overnight. The 
samples were then centrifuged for 5 minutes at 13, 000 x g and 4°C. The supernatant was 
removed in 100    μl aliquots and stored at -20°C. The pellet was resuspended in an appropriate 
amount of Buffer III per weight, vortexed vigorously and rotated at 4°C for six hours. The 
samples were then centrifuged for 5 minutes at 13, 000 x g and 4°C. The supernatant was 
removed in 100    μl aliquots and stored at -20°C. All protein samples were ethanol precipitated. 
Briefly, 1.4ml 95% ethanol was added to each supernatant aliquot, mixed with gentle 
agitation (without vortexing) and incubated overnight at 4°C. The samples were then 
centrifuged for 15 minutes at 13, 000 x g and 4°C and the supernatant removed with a 
syringe. 1 ml of wash solution (Appendix C) was added and the sample vortexed to dissociate
the pellet before incubation for one hour. The samples were centrifuged for 15 minutes at 
13, 000 x g and 4°C and the supernatant removed with a syringe. The samples were briefly 
centrifuged and the remaining wash solution removed with a syringe. The pellets were air 
dried, resuspended in 20  μl dH2O. 5 μl 5x SDS-PAGE loading buffer (Appendix C) and 1 μl 1M
dithiothreitol (DTT) (if under reducing conditions) were added and the samples incubated for 
10 minutes at 95°C before analysis by Western Blotting. 
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2.9.2 Total protein extraction and quantification: tissue 
A Sartorius Mikro-dismembrator S tissue homogeniser was used to disrupt the flash 
frozen cartilage. The vessel and ball bearing were pre-cooled in liquid nitrogen. The frozen 
cartilage tissue was then added to the vessels with 100μ    l flash frozen PBS and homogenised 
for 1 minute at a shaking frequency of 1500 rpm. The tissue was allowed to thaw directly into 
the PBS and stored at -20°C. A Pierce BCA protein assay was used to quantify the extracted 
protein and the manufacturer’s protocol was performed as follows. Bovine serum albumin 
(BSA) was diluted in the same diluent as the samples to produce a range of protein standards 
(Appendix G). 25 μl of the samples and protein standards were pipetted into a 96 well plate in 
duplicate. The BCA working reagent was prepared by adding 1 part of BCA reagent B to 50   
parts of BCA reagent A.  200    μl of working reagent was added to each well and vortexed for 
30 seconds. The plate was then incubated for 30 minutes at 37°C and allowed to cool to room 
temperature. A Thermoscientific Varioskan Lux plate reader was used to measure the 
absorbance at 562 nm wavelength. The average absorbance of protein standard I (the blank) 
was subtracted from the average absorbance of the standards and the samples. A standard 
curve was plotted of the average blank-corrected absorbance of the standards against the 
BSA standard concentrations (μg/ml). Polynomial regression was performed to produce a 
polynomial trendline. The coefficient of multiple determination was required to be above 
0.99 to ensure that the standard curve was a good fit to the data points. The resultant 
equation was used to determine the protein concentration of each sample.
2.9.3 Total protein extraction and quantification: cells 
The cell culture media was removed, centrifuged at 800 x g for 4 minutes to pellet any 
cell debris and then stored at -20°C. The cells were washed twice with pre-warmed PBS and 
incubated on ice with 1 ml radioimmunoprecipitation assay (RIPA) buffer (Appendix C) for 15
minutes to lyse the cells. A cell scraper and pipette were then used to remove the cells and 
the cell suspension was centrifuged at 13, 000 x g for 10 minutes at 4°C to pellet the cell debris. 
A Thermoscientific nanodrop 1000 spectrophotometer was used to quantify the protein 
extracted in the supernatant by measuring the absorbance of the sample at 280nm. Equal  
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volumes of media (100 μl) were concentrated to 20 μl using a Thermo Scientific Savant DNA 
120 speedvac concentrator. 15-25 μg cell lysate or 20 μl of media was added to 5 μl 5x 
sample buffer and 1 μl 1M DTT (to reduce disulfide bonds). Distilled water was then added 
to a total volume of 25 μl. The samples were denatured at 95°C for 10 minutes. 
2.9.4 SDS-PAGE 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
separate the extracted proteins according to their size (Blancher and Jones 2001). Novex 4-
12% Bis-Tris precast gradient gels were used and the electrophoresis was performed in MES 
buffer. 5 μl of pre-stained molecular weight marker or 25 μl of sample were loaded per well, 
with 5 μl of sample buffer added to empty wells to avoid lane distortion. The gel was run at 
200V for 60 minutes. The proteins were then transferred to a nitrocellulose membrane with 
the appropriate pore size (0.45μm or 0.2μm depending on protein size) to enable detection 
with antibodies. A Novex transfer module was assembled (Figure 20). Each of the
components was soaked in 1x transfer buffer and protein transfer was performed in 1x 
transfer buffer at 30V for 60 minutes. The membrane was incubated in REVERT total protein 
stain for 5-10 minutes with agitation in order to check equal protein loading and visualised 
with a LICOR Oyssey CLx (Appendix G). The membrane was blocked with blocking buffer
(Appendix C) for 1 hour with agitation. Primary antibodies were diluted as appropriate
(Appendix D) in blocking buffer and the membrane incubated overnight at 4°C with
agitation. The membrane was washed with six 5 minute PBS-T (Appendix C) washes and a
secondary antibody diluted in PBS-T applied. The membrane was incubated for 1 hour with 
agitation and then washed with three 5 minute PBS-T washes. The membrane was then 
placed in the LICOR Oyssey CLx for antibody detection. Densitometry was performed with 
LICOR image studio lite software according to the Novus biological loading control handbook 
(The Novus biologicals loading control handbook. Available at: https://
images.novusbio.com/design/BR_loadingcontrolsguide_101416.pdf (Accessed 21 July 2018). 
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Chapter 3. Validation and Phenotyping of Mutant Aggrecan 
Mouse Models
3.1. Establishment of the V2019M Acan and D1983N Acan knock-in mouse colonies 
The OCD and SEMD mouse models were generated by Polygene Transgenetics in 
Switzerland. The mouse colony founders (heterozygous for the FLP transgene and 
heterozygous for either 1) the OCD-causative V2019M Acan allele or 2) the SEMD-causative 
D1983N Acan allele) were then transferred to Newcastle University. The genotypes of these 
founder mice were validated by restriction digestion and PCR to ensure that the initial 
genotyping data provided by Polygene Transgenetics was correct. The DNA constructs, 
genotyping strategy and primers were designed and previously used by Polygene.  
3.1.1. Validation of the SEMD mouse colony by screening for the D1983N Acan 
mutation 
Founder mice were initially screened for the presence of the D1983N Acan mutation. 
PvuI restriction sites had previously been introduced with the D1983N Acan mutation during 
generation of the D1983N Acan knock-in mouse. These PvuI restriction sites enabled selective 
restriction digestion of the mutant allele but not the wild type allele. DNA was extracted from 
an ear biopsy and PCR was performed with primers P15 and P16 to amplify the region 
around the mutation producing an amplicon of 617bp (Figure 21). The PCR product was 
separated by horizontal gel electrophoresis and the 617bp DNA amplicon extracted from the 
agarose gel. This DNA was then digested with the PvuI restriction enzyme. Digestion of the 
wild type allele had no effect, whereas digestion of the mutant fragment produced two 
fragments of 349bp and 268bp respectively. The heterozygous founder mice therefore 
presented with three DNA fragments: a 617bp wild type amplicon and the additional 349bp 
and 268bp fragments from the mutant allele (Figure 21C). 
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3.1.2 Validation of the OCD mouse colony by screening for the V2019M Acan 
mutation 
Founder mice were initially screened for the presence of the V2019M Acan mutation. 
AgeI restriction sites had previously been introduced with the V2019M Acan mutation during 
generation of the V2019M Acan knock-in mouse. Firstly, DNA was extracted from an ear 
biopsy and PCR was performed using the primers P3 and P4 to amplify the region around the 
mutation, producing an amplicon of 662bp (Figure 22). The PCR product was separated by 
horizontal gel electrophoresis and the 662bp DNA amplicon extracted from the agarose gel. 
This DNA was then digested with the AgeI restriction enzyme. Digestion of the wild type 
fragment produced two fragments of 410bp and 252bp whereas digestion of the mutant 
fragment produced three fragments of 314bp, 252bp and 96bp. The heterozygous founder 
mice therefore presented with five DNA fragments: two wild type amplicons (410bp and 
252bp) and three fragments from the mutant allele (314bp, 252bp and 96bp) (Figure 22C). 
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3.1.3     Genotyping of the OCD and SEMD colonies by screening for the targeted Acan 
allele  
Once the founder mice had been validated for the presence of the relevant Acan 
mutation, routine genotyping was performed by screening mice in the OCD and SEMD colonies 
for the presence of the targeted Acan allele after deletion of the neomycin cassette. PCR was 
performed using the primers P12 and P13 to amplify the relevant region in the aggrecan gene. 
The wild type Acan allele produced an amplicon of 434bp whereas the mutant targeted allele 
(containing the remaining FRT site introduced with the gene targeting vector) produced a 
larger 545bp amplicon (Figure 23A-D). This PCR-based genotyping strategy was routinely 
used to distinguish mice heterozygous or homozygous for the mutation from their wild type 
littermates.  
3.1.4 Establishment of the OCD and SEMD colonies by removal of the FLP transgene 
The validated founder mice were bred at 6 weeks of age and the resultant pups (F1 
generation) were genotyped using PCR in order to select FLP-negative individuals for further 
breeding (F2 generation). The FLP transgene had previously been used in the deletion of the 
neomycin cassette from the targeted allele but was no longer required and so was selectively 
removed to avoid any off-target effects. PCR was performed to amplify the FLP transgene, 
producing an amplicon of 500bp (Figure 23E). Those mice whose DNA was negative for the 
FLP transgene were then selected for further breeding once they had reached sexual maturity 
at 6 weeks of age. 
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3.1.5 Genotype ratio analysis of the SEMD mouse colony 
Following genotyping the ratio of pups weaned with each genotype (wild type, 
heterozygous mutant, homozygous mutant) was analysed to assess the effect of the D1983N 
Acan mutation on pre-weaning lethality. Statistical analysis indicated Mendelian distribution 
of genotypes (p=0.2) and that heterozygous crosses produced normal sized litters (p=0.3). 
Crosses with a homozygous male and a heterozygous female also produced normal sized 
litters (p=0.8) (Figure 24A). These data indicated that the D1983N Acan mutation had no 
effect on pre-weaning mortality. Analysis of litter sizes produced by homozygous crosses was 
not performed due to high post-natal infanticide. Furthermore, in cages containing 
homozygous crosses with an additional heterozygous female, it was not always possible to 
confirm whether the pups used were the offspring of the homozygous or heterozygous 
female.  
3.1.6 Genotype ratio analysis of the OCD mouse colony 
The ratio of pups with each genotype (wild type, heterozygous mutant, homozygous 
mutant) was analysed to assess the effect of the V2019M Acan mutation on pre-weaning 
lethality. Statistical analysis indicated Mendelian distribution of genotypes (p=0.9) and that 
both heterozygous (p=0.2) and homozygous (p=0.7) crosses produced normal sized litters 
(Figure 24B). This data indicated that the V2019M Acan mutation had no effect on pre-
weaning mortality. 
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Figure 24 Genotype ratio of the OCD and SEMD mouse colonies
(A) Genotyping of 3 week old mice from the SEMD mouse colony showed Mendelian dis-
tribu  on (p=0.2, total number of li  ers = 19). Normal li  er sizes were produced by hetero-
zygous SEMD (p=0.3) and homozygous (male) heterozygous (female) SEMD crosses (p=0.8) .
(B) Genotyping of 3 week old mice from the OCD mouse colony showed Mendelian distri-
bu  on (p=0.9, total number of li  ers = 14). Normal li  er sizes were produced by heterozy-
gous OCD (p=0.2) and homozygous OCD (p=0.7) crosses.
Key: +/+ (wild type) S/+ (heterozygous for the SEMD mutation) S/S (homozygous for the 
SEMD mutation) O/+ (heterozygous for the OCD mutation) O/O (homozygous for the 
OCD mutation) Chi-square test (genotype ratio) Two-tailed T-test (litter sizes).  
Genotype +/+ O/+ O/O 
Expected number 
of pups 
25 50 25 
Observed number 26 53 24 
Genotype +/+ S/+ S/S 
Expected number 
of pups 
25 50 25 
Observed number 29 55 16 
A 
B 
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3.2 Phenotypic analysis of the SEMD mouse model
In order to assess the potential of the D1983N Acan knock-in mouse as a model for 
spondyloepimetaphyseal dysplasia (SEMD) aggrecan type, a range of phenotyping techniques 
were used. The morphology and skeletal development of the mice was assessed at birth and 
at key stages of their adult life, including 1) weaning at 3 weeks, 2) sexual maturity at 6 weeks 
and 3) cessation of bone growth at 9 weeks of age. SEMD aggrecan type is a recessive disorder; 
however, three family members who were heterozygous for the equivalant human D2267N 
ACAN mutation were reported to have mild proportionate short stature (Tompson, 
Merriman et al. 2009). Both homozygous and heterozygous mutant mice were therefore 
included in the phenotyping stage of this study to help resolve this question. The rate of 
growth was measured by weighing the mice over a 6 week time period to assess whether 
early growth cessation had occurred before 9 weeks of age. Skeletal morphology and the 
phenotypic onset of this bone disorder was assessed at birth by preparing skeletal 
preparations, using histological dyes which preferentially stain the cartilage and bone. This 
allowed the visualisation of the skeletal components, such as the ossification centres and 
quantitative measurement of the bone lengths. This assessed whether pre-natal 
development was affected by the disorder. The skeletal morphology and maturation of adult 
mice was assessed both radiographically and histologically. Patients with SEMD aggrecan 
type present with severe short stature and a broad range of skeletal defects (Tompson, 
Merriman et al. 2009). It was therefore decided that short stature, spine curvature,
brachydactyly and mid-face hypoplasia would be assessed in the mutant mice compared to 
wild type littermates.
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3.2.1 Morphological analysis of newborn SEMD mice 
At birth heterozygous and homozygous mutant mice were not overtly visually different 
in size or appearance from their wild type littermates. Neonatal skeletal preparations were 
prepared and stained with Alcian Blue (which preferentially dyes proteoglycan, a major 
component of the cartilage growth plate) and Alizarin Red (which preferentially stains calcified 
bone). There was no major visible difference in the arrangement of skeletal components of 
mice heterozygous or homozygous for the mutation compared to those of wild type 
littermates (Figure 25A-B, D). The total lengths of the femur and tibia bones were measured 
at birth. There was no statistical difference in the average femoral bone length of either 
homozygous or heterozygous mutant mice compared to wild type littermates. However, the 
average length of the tibia in homozygous mutant mice was reduced to 87.5% of wild type 
bone length (Figure 25C). This suggests that although the SEMD mutation does not severely 
affect pre-natal skeletal developmental patterning, bone growth is reduced and therefore the 
phenotypic onset of SEMD likely occurs before birth.  
3.2.2 Postnatal growth of SEMD mice 
Mice were weighed at 3, 6 and 9 weeks of age in order to assess the growth rate of 
heterozygous and homozygous mutant mice relative to wild type littermates. At 3 weeks of 
age both male and female mice homozygous for the mutation were visibly smaller and by 9 
weeks were 32.2% and 30.1% lighter than wild type littermates respectively (Figure 26). 
There was no statistical difference between the mass of heterozygous mutant mice and that 
of their wild type littermates (Figure 26).  
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Figure 25 Morphology of SEMD mice at birth.
Skeletal prepara tions stained with Alizarin Red (to visualise calci fied bone) and Alcian Blue 
(to visualise the car tilage).  Pups either heterozygous or homozygous for the muta  on were 
morphologically indis tinguishable from wild type li ttermates. (A) Hind limb (B) Fore limb (D) 
Sternum (C) Tibia and femur bone lengths were measured in mice of all 3 genotypes (black 
lines). There was no statistical difference in the average femur length but the average tibia 
length of homozygous mice was reduced, reaching 87.5% of wild type bone length. (E) Nu-
meric data used for the genera tion of graph A. 
Key: +/+ (wild type) S/+ (heterozygous for the muta  on) S/S (homozygous for the mutation) 
SEM (standard error of the mean) *p>0.05, Two tailed T-test, scale bars = 50μm, n≥3. 
A  B 
+/+  +/+ 
S/+  S/+ 
S/S  S/S 
C 
E 
+/+ S/+ S/S 
Femur (mm) ± SEM 3.60±0.09 3.89±0.10 3.45±0.21
Tibia (mm) ± SEM   4.08±0.09 4.19±0.07 3.57±0.21*
D 
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A  Male 
B  Female 
C 
Male Female 
Age (weeks) +/+ S/+ S/S +/+ S/+ S/S 
3 8.81±0.51 9.53±0.52 7.18±0.33 * 8.91±0.49 9.59±0.44 7.05±0.52 
Mass (g)
±SEM 
6 19.79±0.27 19.00±0.89 
14.06±0.57 
*** 
16.26±0.71 16.27±0.42 
12.25±0.78 
** 
9 23.77±0.65 22.89±0.98 
16.11±0.78 
*** 
19.01±0.56 19.25±0.74 
13.28±1.12 
** 
Figure 26 Growth rates of SEMD mice.
The body mass of mice of all 3 genotypes (wild type, heterozygous mutant and homozygous 
mutant) was measured at 3, 6 and 9 weeks of age. Male and female mice homozygous for 
the muta  on had reduced body mass, reaching  67.8% (A) and 69.9% (B) of wild type body 
mass respectivel  by 9 weeks. (C) Numeric data used for the genera  on of graphs A and B. 
Key: +/+ (wild type) S/+ (heterozygous for the muta  on) S/S (homozygous for the muta  on) 
SEM (standard error of the mean) *p>0.05, **p>0.01, ***p>0.001, Two tailed T-test, n≥3. 
*** 
*** 
* 
** 
** 
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3.2.3 Radiographic and morphological analysis of developing SEMD mice 
Mice were x-rayed in the dorsal plane and the length and angle of the appropriate 
bones were then measured (Figure 27). As the phenotype did not appear to be influenced by 
gender only data from male animals has been shown, but data from females is presented in 
Appendix I.
3.2.3.1 Long bones and the pelvic girdle 
Mice homozygous for the SEMD mutation exhibited a number of bone abnormalities, 
including a bell-shaped rib cage, brachydactyly and irregular epiphyses, all consistent with 
the human SEMD phenotype (Figure 27) (Tompson, Merriman et al. 2009). At 3 weeks of age 
the average femoral, tibial and pelvic bone length measurements of male (and female) mice 
homozygous for the mutation were already significantly reduced compared to those of wild 
type littermates (Figure 28). By 9 weeks male (and female) mice homozygous for the 
mutation were exhibiting a severe short stature phenotype; for example, the average femur 
and tibia lengths of male mice homozygous for the mutation were 27.4% and 24.6% shorter 
that that of wild type littermates. Similarly, the combined length of the pelvic girdle bones 
(ilium and ischium) was reduced by 22.5% compared to wild type bones (Figure 28). There 
was no statistical difference between the bone lengths of mice heterozygous for the 
mutation and those of wild type littermates at 3 weeks of age. However, by 6 weeks of age 
mice had significantly reduced femoral and tibial bone lengths compared to those of wild 
type littermates. By 9 weeks heterozygote mice displayed a short stature phenotype; for 
example, the average femur and tibia lengths of male mice heterozygous for the mutation 
were 8.2% and 8.3% shorter than that of wild type littermates. Similarly, the combined length 
of the pelvic girdle bones (ilium and ischium) was reduced by 5.5% compared to wild type 
bone lengths (Figure 28). There was a 4-fold increase in the average angle between the illium 
and the tuberosity of the ischium in 9 week old male mice homozygous for the mutation 
compared with that of wild type littermates (Figure 29) suggesting a hip dysplasia. 
Interestingly, heterozygote mice did not exhibit hip dysplasia (Figure 29). 
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5mm 
A 
B 
 +/+  S/+  S/S  
+/+  S/S 
Figure 27 Radiographic analysis of SEMD mice.
(A) Representative X-ray imaging of  3 week old male mice (dorsal view). Mice homozygous
for the mutation displayed irregular epiphyses (white star) hip dysplasia (black lines) bell-
shaped rib cage, disproportionately short limbs (blue line) and brachydactyly. Mice hetero-
zygous for the mutation exhibited disproportionately short limbs (blue line) but no other
skeletal abnormalities (B) Representative X-ray imaging of  9 week old male mice (dorsal
view). Homozygous mice exhibited brachydactyly.
Key: +/+ (wild type) S/+ (heterozygous for the mutation) S/S (homozygous for the 
mutation) n≥4, scale bars = 2mm
* 
 +/+  S/+  S/S  
125
A  Male 
B 
Age (weeks) +/+ S/+ S/S 
Femur (mm) 
± SEM   
3 9.99 ± 0.57 8.88 ± 0.18 7.10 ± 0.42 ** 
6 12.21 ± 0.16 10.60 ± 0.19 *** 8.30 ± 0.13 *** 
9 12.56 ± 0.23 11.53 ± 0.20 ** 9.12 ± 0.33 *** 
3 16.38 ± 0.10 12.60 ± 0.19 9.76 ± 0.37 * 
Tibia (mm) ± 
SEM    
6 16.38 ± 0.10 15.26 ± 0.16 *** 12.05 ± 0.11 *** 
9 17.27 ± 0.06 15.83 ± 0.08 *** 13.05 ± 0.23 *** 
Pelvis (mm) 
± SEM  
3 10.60 ± 0.29 10.47 ± 0.24 8.85 ± 0.26 *** 
6 15.77 ± 0.10 14.74 ± 0.24 *** 12.32 ± 0.12 *** 
9 17.14 ± 0.11 16.20 ± 0.10 *** 13.28 ± 0.29 *** 
 
Figure 28 Morphometric analysis of male SEMD mice.
Tibia and femur and pelvic (illium and ischium) bone lengths were measured at 3, 6 and 9 
weeks of age in male mice of all 3 genotypes. (A) The average femur,  tibia and 
pelvis lengths of mice homozygous for the muta tion was reduced, reaching 72.6%, 
75.6% and 77.5% of wild type bone lengths respectively by 9 weeks. The average femur,   
tibia and pelvis lengths of mice heterozygous for the muta tion was reduced to 91.8%, 
91.7% and 94.5% of wild type bone lengths respectively by 9 weeks. (B) Numeric data 
used for the generation of graph A. 
Key: +/+ (wild type) S/+ (heterozygous for the muta  on) S/S (homozygous for the muta  on) 
SEM (standard error of the mean) *p>0.05, **p>0.01, ***p>0.001, Two tailed T-test, n≥3. 
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A  Male 
B 
C 
Age (weeks) +/+ S/+ S/S 
Hip angle (°) 
± SEM  
3 10.47±0.63 8.46±0.59 13.43±0.84 
6 2.72±0.34 6.53±1.56 8.92±0.90 *** 
9 2.63±0.44 5.19±1.28 10.44±2.71 *** 
Figure 29 Hip dysplasia in male SEMD mice.
The angle of the hip was measured at 3, 6 and 9 weeks of age in male mice of all 3 
genotypes. (A) Representa tive X-ray imaging of  9 week old male mice (dorsal view). (B) 
There was a 4-fold increase in the average hip angle of mice homozygous for the 
muta tion compared with that of wild type li ttermates. (C) Numeric data used for the 
genera tion of graph B. 
Key: +/+ (wild type) S/+ (heterozygous for the muta  on) S/S (homozygous for the muta  on) 
SEM (standard error of the mean) ***p>0.001, Two tailed T-test, scale bars = 2mm, n≥3. 
 +/+  S/+  S/S  
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3.2.3.2 Skull 
       There was no statistical difference in the average inner canthal distance between the 
homozygous mutant and wild type mice of either gender at 3, 6 and 9 weeks of age. However, 
the length of the skull was already reduced at 3 weeks of age and by 9 weeks was decreased 
by 16.9% in female and 20.6% in male mice compared to wild type bone lengths (Figure 30). 
In order to further investigate the skull morphology and development, skulls were dissected 
from newborn pups and male mice at 3 weeks of age. Newborn pups were not separated by 
gender as the previous radiographic and morphometric analysis indicated that both male and 
female mice had comparable features. All skull preparations were stained with Alcian Blue and 
Alizarin Red in order to determine the proportion of cartilage relative to the calcified bone 
during early and adult development. There were no overt differences in the appearance of 
ossification centre formation or proportion of cartilage relative to the calcified bone between 
the skulls of homozygous mutant mice and wild type mice (Figure 31A). However, at 3 weeks 
of age the length of the nasal bone and the distance between the antero-lateral corners of 
the frontal bones were significantly reduced in mice homozygous for the mutation when 
compared to wild type littermates (Figure 31C). There was no statistical difference in the 
inner canthal distance between heterozygous mutant and wild type mice at 3, 6 and 9 weeks 
of age. There was a small (4%), but statistically significant, decrease in skull length at 6 weeks 
of age, whereas the 0.5% decrease at 9 weeks of age was not statistically significant, 
suggesting that the effect of the single mutant allele on skull development was minimal 
(Figure 30). In addition to the pathological changes in skull parameters it was noted that 
84.62% of the homozygous mice exhibited malocclusion by 3 weeks of age (Figure 32A,D). 
This represents a 1839-fold increase in the incidence of teeth overgrowth, as the recorded 
occurrence in the background strain of this model (C57BL/6) is only 0.046% (Garcia-Arocena). 
In contrast, wild type and heterozygous mutant littermates did not display any malocclusion. 
Rodent teeth grow continuously throughout life and the length of teeth is limited by tooth 
grinding. Malocclusion therefore often occurs when there is misalignment of the jaw, altering 
the bite of the animal and preventing efficient tooth grinding (Dontas, Tsolakis et al. 2010). 
SEMD patients display relative mandibular prognathism (Tompson, Merriman et al. 2009) and 
so mice were x-rayed in the lateral plane in order to assess the position and size of the 
mandible relative to the rest of the skull (Figure 32A). Unfortunately, due to the resolution of 
the radiographic images available, it was not possible to measure the maxilla. The size of the 
128
mandible was therefore expressed as a percentage of the total skull length. At 3 weeks of age 
male homozygous mutant mice exhibited a 5.08% increase in mandible length relative to 
skull length (Figure 32A-C). This indicates that the SEMD mouse model displays the relative 
mandibular prognathism observed clinically in the SEMD patients, leading to a change in jaw 
alignment and so likely causing an increased incidence of malocclusion in these animals. 
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A  Male 
B 
C 
Age (weeks) +/+ S/+ S/S 
ICD (mm) ± 
SEM 
3 6.60±0.08 6.64±0.08 6.57±0.07 
6 7.37±0.04 7.28±0.09 7.31±0.06 
9 7.71±0.04 7.57±0.05 7.09±0.32 
Skull (mm) 
± SEM  
3 16.49±0.20 17.08±0.24 15.09±0.18 *** 
6 18.97±0.15 18.22±0.16 ** 15.71±0.22 *** 
9 19.59±0.18 19.50±0.13 15.55±0.16 *** 
Figure 30 Morphometric analysis of the skull in male SEMD mice.
ICD (inner canthal distance) and skull length were measured at 3, 6 and 9 weeks of age in 
male mice of all 3 genotypes. (A) Representative X-ray imaging of  9 week old male mice 
(dorsal view). (B) There was no difference in ICD but the average skull length of ho-
mozygous mice was reduced to 79.4% of wild type bone length by 9 weeks. (C) Numeric data 
used for the generation of graph B. 
Key: +/+ (wild type) S/+ (heterozygous for the muta tion) S/S (homozygous for the muta tion) SEM 
(standard error of the mean) **p>0.01, ***p>0.001, Two tailed T-test, scale bars = 2mm 
  +/+  S/+  S/S 
        NS 
130
A  B 
C 
D 
Figure 31 Morphometric analysis of the cranial vault in SEMD mice.
(A) Skulls stained with Alizarin Red (to visualise calci fied bone) and Alcian Blue (to visualise 
the car tilage). Skull parameters (B) were measured at 3 weeks of age in both homozygous 
mutant and wild type male mice. (C) Graph showing skull measurements with standard error 
of the mean. The average nasal bone length was reduced by 20.4% and the distance between 
the anterolateral corners of the frontal bone reduced by 8.6% in mice homozygous for the 
muta tion compared with that of wild type mice. (D) Numeric data used for the genera tion of 
graph B.
Key: +/+ (wild type) S/S (homozygous for the muta tion) SEM (standard error of the mean) 
*p>0.05, ***p>0.001, Two tailed T-test, n≥4.
Genotype +/+ S/S 
interparietal bone length (IL) ± SEM 2.49±0.05 2.12±0.14 
sagi ttal length of parietal bone (PL) ± SEM 2.90±0.17 2.60±0.11 
frontal bone length (FL) ± SEM 5.43±0.12 5.16±0.06 
nasal bone (NL) ± SEM 4.36±0.05 3.47±0.12 *** 
interparietal bone width (IW) ± SEM 7.71±0.01 6.94±0.31 
frontal bone width (FW) ± SEM 4.97±0.34 5.15±0.17 
anterolateral distance of frontal bone (LR) ± SEM 3.82±0.14 3.49±0.06 * 
nasal bone width (NW) ± SEM 2.05±0.07 1.95±0.03 
 FW 
  LR 
  NW 
IL 
  PL 
  FL 
NL 
+/+    S/S 
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3.2.3.3 Spine 
SEMD patients exhibit mild thoracic scoliosis, cervical-vertebral clefts and lumbar 
lordosis (Tompson, Merriman et al. 2009). Heterozygous mutant mice were not assessed in 
this spinal study as their overall skeletal phenotype was relatively mild and the three 
heterozygous (carrier) members of the SEMD family did not exhibit any spinal malformations 
(Tompson, Merriman et al. 2009). Wild type mice did not exhibit abnormal spine curvature 
(Diab angle≥12); however, at 3 weeks of age 33.33% of homozygous mutant male mice 
exhibited mild thoracic scoliosis, with the incidence increasing to 57.14% with skeletal 
maturity at 9 weeks of age (Figure 33). At 9 weeks of age there was a two-fold increase in the 
angle of spinal curvature of the homozygous mutant mice, who displayed visible scoliosis 
compared to their wild type littermates. There was no statistical difference between the angle 
of spinal curvature in homozygous mice that presented without scoliosis and wild type mice. 
The angle of scoliosis was not significantly different between mice that presented with 
scoliosis at 3 and 9 weeks of age, indicating that although the incidence of scoliosis increases 
with age, there is not a further increase in severity during adult development (Figure 33).  
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3.3 Phenotypic analysis of the OCD mouse model
In order to assess the potential of the V2019M Acan knock-in mouse as a model for 
dominant familial osteochondritis dissecans (OCD) a range of phenotyping techniques were 
used. The morphology and skeletal development of the mice was assessed at birth and at key 
stages of their adult life, including 1) weaning at 3 weeks, 2) sexual maturity at 6 weeks and 
3) cessation of bone growth at 9 weeks of age. Familial osteochondritis dissecans (OCD) is a
dominantly inherited disorder and only heterozygous patients have been reported (Stattin,
Tegner et al. 2008, Stattin, Wiklund et al. 2010). Both homozygous and heterozygous mutant
mice were therefore included in the initial phenotyping stage of this study. The rate of
postnatal growth was measured by weighing the mice over a 6 week time period to determine
whether early growth cessation had occurred before 9 weeks of age. Skeletal morphology and
the phenotypic onset of this bone disorder was assessed at birth by preparing skeletal
preparations of neonates and applying histological dyes which preferentially stain the
cartilage and bone. This allowed the visualisation of the skeletal components, such as the
ossification centres, and quantitative measurement of the bone lengths. The skeletal
morphology of adult mice was assessed both radiographically and histologically. The
radiographic strategy was based on established skeletal mouse phenotyping techniques
(Suleman, Gualeni et al. 2012) protocols established in the literature for the assessment of
mouse models predicted to have similar phenotypic features and the clinical findings of
heterozygous patients carrying the equivalent human mutation (V2303M ACAN) (Stattin,
2010). Patients with dominant fOCD are characterised by mild disproportionate short stature
and the formation of osteochondrotic lesions in the knee, patella, hip or elbow which can lead
to the development of early-onset osteoarthritis. Some affected family members were also
found to have a variety of heterogenous bone abnormalities, such as scoliosis and low
invertebral discs in the thoracic- and lumbar-spine. It was decided to prioritise the study of
only a few of these bone abnormalities, focusing on the short stature and spine curvature
phenotype (Stattin, Tegner et al. 2008, Stattin, Wiklund et al. 2010).
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3.3.1 Morphological analysis of newborn OCD mice
At birth, homozygous mutant mice were not visually different in size or appearance 
from their wild type littermates. Heterozygous mutant mice were not studied due to the very 
mild nature of the adult skeletal phenotype (section 3.3.2). Neonatal skeletal preparations 
were prepared and stained with Alcian Blue (which preferentially dyes proteoglycan, a major 
component of the cartilage growth plate) and Alizarin Red (which preferentially stains calcified 
bone). There was no major visible difference in the number and organisation of the skeletal 
components of homozygous mutant mice compared to those of wild type littermates and all 
ossification centres were present (Figure 34A-B and D). Further to this, the total lengths of 
the femur and tibia bones were measured. There was no statistical difference in the average 
femoral or tibial bone lengths of homozygous mutant mice compared to wild type littermates 
(Figure 34C). This indicates that the OCD mutation does not severely affect pre-natal skeletal 
developmental patterning or growth and so the phenotypic onset of OCD occurs during post-
natal development.  
3.3.2 Postnatal growth of OCD mice. 
Mice were weighed at 3, 6 and 9 weeks in order to assess the growth of heterozygous 
and homozygous mutant mice relative to that of their wild type littermates. At 3 weeks of age 
there was no statistical difference between the mass of mice homozygous for the mutation 
and their wild type littermates. However, by 6 weeks of age the male mice homozygous for 
the mutation were 7.5% lighter, suggesting that their rate of growth had slowed, and by 9 
weeks were 16.2% lighter than wild type littermates. The female mice homozygous for the 
mutation were not statistically lighter at 6 weeks of age, but by 9 weeks the average mass 
was reduced by 10.5% compared to that of wild type littermates (Figure 35). There was no 
statistical difference between the mass of heterozygous mutant mice and that of their wild 
type littermates (Figure 35). 
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CC  D 
A B 
Figure 34 Morphology of OCD mice at birth.
Skeletal prepara tions stained with Alizarin Red (to visualise calci fied bone) and Alcian Blue 
(to visualise the cartilage).  Pups homozygous for the muta tion were morphologically indis-
  nguishable from wild type li  ermates. (A) Hind limb (B) Fore limb (D) Sternum (C) Tibia 
and femur bone lengths (black line) were measured in mice of all 3 genotypes. There was 
no statistical difference in the average length of the femur and tibia  bones in homozygous 
mice compared to those of wild type li ttermates. (E) Numeric data used for the genera tion 
of graph C.  
Key: +/+ (wild type) O/O (homozygous for the muta tion) SEM (standard error of the mean) 
NS (not significa t) Two tailed T-test, scale bars = 50μm, n≥3. 
+/+ O/O 
Femur (mm) ± SEM 3.60±0.09 3.74±0.10 
Tibia (mm) ± SEM   4.08±0.09 3.99±0.08
        NS 
        NS 
+/+  O/O 
+/+  O/O 
C          D
E
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Figure 35 Growth rates of OCD mice.
The body mass of mice of all 3 genotypes (wild type, heterozygous mutant and homozy-
gous mutant) was measured at 3, 6 and 9 weeks of age. Male and female mice homozygous 
for the muta tion had reduced body mass, reaching 83.8% (A) and 89.5% (B) of wild 
type body mass respectively by 9 weeks. (C) Numeric data used for the genera tion of 
graphs A and B. 
Key: +/+ (wild type) O/+ (heterozygous for the muta  on) O/O (homozygous for the muta-
  on) SEM (standard error of the mean). **p>0.01, Two tailed T-test, n≥10. 
Male Female 
Age (weeks) +/+ O/+ O/O +/+ O/+ O/O 
3 8.81±0.51 8.98±0.46 8.53±0.47 8.48±0.38 7.68±0.31 7.83±0.22 
Mass 
(g)
±SEM 
6 19.79±0.27 19.70±0.69 18.32±0.51 * 16.26±0.71 15.58±0.40 14.79±0.20 
9 23.77±0.65 23.24±0.64 
19.92±0.40 
*** 
19.01±0.56 17.73±0.39 
17.02±0.32 
** 
A  Male 
B  Female 
C 
** 
*** 
* 
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3.3.3 Radiographic and morphological analysis of developing OCD mice 
Radiographs were taken of the mice in the dorsal plane in order to measure the 
length and angle of the appropriate bones (Figure 36). As the phenotype did not appear to be 
affected by gender, only data from male animals has been shown and all data from females 
is presented in Appendix I. Mice heterozygous for the mutation were analysed in order to 
assess whether there was a milder intermediate phenotype. 
3.3.3.1 Long bones and the pelvic girdle 
At 3 weeks of age the average femoral and tibial length bone measurements of female 
mice homozygous for the mutation were already statistically reduced compared to those of 
wild type littermates (Appendix I). By 9 weeks both male and female mice homozygous for 
the mutation were exhibiting mild disproportionate short stature; for example, the average 
femur and tibia lengths of male mice homozygous for the mutation were 10% and 8.5% 
shorter that that of wild type littermates (Figure 37). Similarly the combined length of the 
pelvic girdle bones (ilium and ischium) was reduced by 7.3% compared to wild type bone 
lengths (Figure 37). There was a clear trend of reduced average tibial, femoral and pelvic 
bone length measurements, in both male and female heterozygote mice compared to those 
of wild type littermates; however, there was only one statistically significant difference 
(Figure 37). This indicates that any putative skeletal phenotype is very mild. There was no 
difference in the angle between the illium and the tuberosity of the ischium (and therefore 
no suggestion of hip dysplasia) in mice either homozygous or heterozygous for the mutation 
and wild type controls (Figure 38).  
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Figure 37 Morphometric analysis of male OCD mice.
Tibia, femur and pelvic (illium and ischium) bone lengths were measured at 3, 6 and 
9 weeks of age in male mice of all 3 genotypes. (A) The average femur, tibia and 
pelvis lengths of mice homozygous for the muta tion was reduced, reaching 90.0%, 
91.5% and 92.7% of wild type bone lengths respectively by 9 weeks. The average femur 
length of mice heterozygous for the muta tion was reduced to 88.3% of wild type femur 
length at 6 weeks but there was no sta tis tical di fference at 9 weeks. (B) Numeric data used 
for the genera tion of graph A. 
Key: +/+ (wild type) O/+ (heterozygous for the muta  on) O/O (homozygous for the muta-
 tion) SEM (standard error of the mean) **p>0.01, ***p>0.001, Two tailed T-test, n≥10. 
A  Male 
B 
Age (weeks) +/+ O/+ O/O 
Femur (mm) ± 
SEM   
3 9.99 ± 0.57 10.20± 0.58 9.72± 0.54 
6 12.21 ± 0.16 11.48± 0.19 ** 10.78± 0.24 *** 
9 12.56 ± 0.23 12.18± 0.23 11.30± 0.17 *** 
Tibia (mm) ± 
SEM    
3 12.17 ± 0.63 11.61± 0.53 11.30± 0.49 
6 16.38 ± 0.10 15.65± 0.12 15.17± 0.10 *** 
9 17.27 ± 0.06 16.60± 0.17 15.80± 0.10 *** 
3 10.60 ± 0.29 10.42 ± 0.26 9.91 ± 0.21
Pelvis (mm) ± 
SEM    
6 15.77 ± 0.10 15.34 ± 0.20 15.02 ± 0.12
9 17.14 ± 0.11 16.57 ± 0.17 15.89 ± 0.09 *** 
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A  Male 
B 
C 
Age (weeks) +/+ O/+ O/O 
Hip angle (°) 
± SEM  
3 10.47±0.63 9.30±0.69 9.89±0.84 
6 2.72±0.34 4.32±0.59 3.34±0.38 
9 2.63±0.44 2.27±0.48 3.22±0.53 
Figure 38 Hip dysplasia in male OCD mice.
The angle of the hip was measured at 3, 6 and 9 weeks of age in male mice of all 3 
genotypes. (A) Representa tive X-ray imaging of 9 week old male mice (dorsal view). (B) 
There was no sta tistical di fference in the average hip angle of mice either heterozygous or 
homozygous for the muta tion compared with that of wild type li ttermates. (C) Numeric 
data used for the genera tion of graph B. 
Key: +/+ (wild type) O/+ (heterozygous for the muta tion) O/O (homozygous for the muta-  
on) NS (non-significant) SEM (standard error of the mean) Two tailed T-test, scale bars = 
2mm, n≥10. 
 +/+  O/+  O/O 
        NS 
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3.3.3.2 Skull 
There was no statistical difference in the inner canthal distance or skull length between 
either the heterozygous or homozygous mutant and wild type mice at 3, 6 and 9 weeks of 
age (Figure 39) indicating that the V2019M Acan mutation has no overt effect on skull 
development or intramembranous ossification. 
3.3.3.3 Spine 
OCD patients exhibit a variety of heterogenous spine abnormalities such as scoliosis 
and low invertebral discs in the thoracic- and lumbar-spine (Stattin, Tegner et al. 2008, Stattin, 
Wiklund et al. 2010). In order to assess spine curvature, mice were sacrificed by terminal 
injection in order to avoid the spinal distortion that can occur with schedule one methods 
involving inhalation. Male mice were x-rayed in both the dorsal and lateral planes. 
Homozygous mutant mice did not display any signs of scoliosis up to 9 weeks of age (data 
not shown) and no further research was conducted.  
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A  Male 
B 
C 
        NS 
Age (weeks) +/+ O/+ O/O 
ICD (mm) ± 
SEM 
3 6.60±0.08 6.60±0.09 6.60±0.07 
6 7.37±0.04 7.28±0.09 7.38±0.03 
9 7.71±0.04 7.63±0.04 7.61±0.05 
Skull (mm) 
± SEM 
3 16.49±0.20 16.93±0.17 16.92±0.22 
6 18.97±0.15 18.73±0.11 18.48±0.17 
9 19.59±0.18 19.55±0.28 18.91±0.18 
Figure 39 Morphometric analysis of the skull in male OCD mice.
ICD (inner canthal distance) and skull length were measured at 3, 6 and 9 weeks of age in 
male mice of all 3 genotypes. (A) Representative X-ray imaging of 9 week old male mice 
(dorsal view). (B) There was no di fference in ICD or skull length between  male li ttermates of 
all 3 genotypes. (C) Numeric data used for the genera tion of graph B. 
Key: +/+ (wild type) O/+ (heterozygous for the muta tion) O/O (homozygous for the muta-
tion) SEM (standard error of the mean) NS (not significant) Two tailed T-test, scale bars = 
2mm, n≥10. 
  +/+  O/+  O/O 
        NS 
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3.4 Summary 
The aim of this chapter was to validate and describe the skeletal phenotype of two knock-
in mouse models of skeletal dysplasia with causative mutations in the C-type lectin domain of 
aggrecan. Morphometric and histological techniques were used to analyse the relative growth 
rates and skeletal development of mice homozygous or heterozygous for either the SEMD 
mutation (D1983N Acan) or fOCD mutation (V2019M Acan) relative to their wild type 
littermates. Once this radiographic and morphometric analysis of mutant mice was complete 
it demonstrated that both male and female mice replicated the human phenotype of the 
relevant skeletal disorder. All subsequent studies of adult skeletal development were 
therefore only conducted on mutant male mice since any phenotypic effect could be 
reasonably extrapolated to mutant female mice. This strategy increased the number of 
females available for the breeding programme and reduced the number of mice required in 
line with the principle of the 3Rs (Flecknel 2002). The initial establishment of both the SEMD 
and OCD mouse colonies was successful. PCR and restriction digestion was used to confirm 
the presence of germline transmission of the relevant Acan mutation in the founder mice 
provided by Polygene Transgenetics. PCR was also used to verify the presence of the targeted 
aggrecan allele after deletion of the neomycin cassette (previously used for antibiotic 
selection of C57Bl/6-derived embryonic stem (ES) cells used during the gene-targeting 
process). The use of selective breeding removed the FLP transgene (used to remove the 
neomycin resistance cassette during the generation of the two knock-in mice) within the F1 
generation as assessed by PCR analysis. All mutant mice used for the subsequent phenotypic 
analysis were therefore validated as FLP-negative, with germline transmission of the relevant
Acan mutation and deletion of the neomycin cassette. Initial phenotyping of the homozygous 
D1983N Acan knock-in mouse confirmed that it replicates the human SEMD aggrecan type 
phenotype. The D1983N Acan mutation had no effect on pre-natal skeletal developmental 
patterning as the arrangement of skeletal components in homozygous mutant (SEMD) mice 
was no different from that of their wild type littermates at birth. However, the average bones 
length of newborn SEMD mice were reduced compared to wild type controls, suggesting that 
onset of the short stature skeletal phenotype occurs during pre-natal development. Mice 
homozygous for the SEMD mutation displayed a reduced growth rate during post-natal 
development and by 9 weeks of age exhibited severe disproportionate short stature. SEMD 
mice also displayed a number of bone abnormalities which had been reported in the patient 
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clinical data, including bell-shaped rib cage, hip dysplasia, mild scoliosis, irregular epiphyses 
and brachydactyly. In addition to this, the morphology of the skull was altered, indicating mid-
face hypoplasia and relative mandibular prognathism (all characteristic of the human SEMD 
phenotype). The distance between the antero-lateral corners of  the frontal bone was also 
slightly reduced, showing a decrease in the size of the cranial vault. Although the bones that 
form the cranial base and caudal cranial vault ossify via endochondral ossification, the 
craniofacial and rostral cranial vault bones are formed by intramembranous ossification 
(Percival and Richtsmeier 2013). These data suggest that both intramembranous and 
endochondral ossification are perturbed in the SEMD mouse model. Mice who were 
heterozygous for the SEMD mutation did not display a reduced growth rate but exhibited a 
mild disproportionate short stature phenotype by 9 weeks of age. In contrast to the mice 
homozygous for the mutation, heterozygous mice did not exhibit any additional skeletal 
abnormalities such as hip dysplasia or brachydactyly. This is in line with patient clinical data in 
which it was reported that the heterozygous parents and half-sister of the proband 
appeared to have reduced proportionate short stature but no other bone abnormalities. It is 
worth noting, however, that the only family member with two wild type aggrecan alleles was 
thought to be above average height for the indigenous Mexican population and the region 
from which the family had originated (Krakow, personal communication, 2017). Initial 
phenotyping of homozygous V2019M Acan knock-in mice confirmed that they replicated the 
human familial OCD disproportionate short stature phenotype. The V2019M Acan mutation 
had no overt effect on pre-natal skeletal developmental patterning or growth. At three 
weeks of age female OCD mice were already exhibiting mild disproportionate short stature 
and by 9 weeks of age both male and female mice had a disproportionate short stature 
phenotype. OCD mice did not display a hip dysplasia often seen in mouse models of skeletal 
dysplasia disorders and radiographic analysis did not reveal any of the heterogenous skeletal 
abnormalities recorded in the patients’ clinical data (such as scoliosis) apart from the mild 
short stature phenotype. Unfortunately, due to the resolution of the radiographic images 
obtained it was not possible to definitively say whether the other noted abnormalities (such 
as platyspondyly or osteochondrotic lesions) were present. Further to this, mice 
heterozygous for the V2019M Acan mutation appeared to exhibit an extremely mild 
intermediate skeletal phenotype. There was a clear non-statistical trend in the 
morphometric data indicating a decrease in pelvic, tibial and femoral bone lengths compared 
to those of the wild type mice.  
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In conclusion, morphometric analysis of both the SEMD and OCD mouse models accurately 
replicates the skeletal phenotypes reported in patients with these very different skeletal 
disorders. These mouse models formed a phenotypic disease spectrum from the very severe 
SEMD to the milder OCD and were promising models for the study of these conditions 
(Figure 40). Subsequent to this phenotypic study, analysis of the resultant tissue pathology 
was conducted.  
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Chapter 4. Qualitative Tissue Pathology Analysis of the SEMD 
and OCD Mouse Models
The morphometric and radiographic analysis performed in Chapter 3 indicated that 
the homozygous D1983N Acan knock-in mice replicated the severe disproportionate short 
stature phenotype of the recessive human skeletal disorder spondyloepimetaphyseal 
dysplasia (SEMD) aggrecan type (Tompson, Merriman et al. 2009). Thus far, no analysis of 
patient tissue has been performed due to the rarity of SEMD aggrecan type in the population 
and because the three known patients have not undergone surgical intervention. In vitro 
studies of a recombinant aggrecan G3 domain demonstrated that the secretion of aggrecan is 
unaffected by the human D2267N mutation. The mutation is, however, predicted to affect 
the interaction of aggrecan with other extracellular matrix proteins and surface-plasmon-
resonance studies showed that the D2267N ACAN G3 domain had altered binding with 
tenascin C (Tompson, Merriman et al. 2009). The homozygous V2019M Acan knock-in mouse 
also appeared to replicate the moderate disproportionate short stature phenotype 
of dominant familial OCD (Stattin, Wiklund et al. 2010). Familial osteochondritis dissecans 
is more common in the population than SEMD, with five causative mutations reported so 
far (Aspberg, personal communication, Gkourogianni, Andrew et al. 2017, van der Steen, 
Pfundt et al. 2017); however, little is known about the downstream effects exerted by 
these mutations. Due to the formation of osteochondrotic lesions and the resultant early-
onset osteoarthritis, OCD patients often undergo arthroplasty to remove loose bodies 
from the joint space. Mass spectral analysis of arthro-plasty samples suggested that the 
V2303M ACAN mutation did not affect secretion or glycosaminoglycan sulfation (Stattin, 
Wiklund et al. 2010). In vitro analysis of patient MSC and iPSC pellet cultures indicated 
mutant aggrecan was retained within the ER with very little secretion into the inter-
territorial matrix (Xu, Stattin et al. 2016). These two studies and an in vitro model system 
expressing recombinant mutant G3 domain in mammalian cells also suggested there was 
altered matrix composition and reduced binding with other extracellular matrix proteins 
(Stattin, Wiklund et al. 2010, Xu, Stattin et al. 2016). In addition to this, the C-type lectin do-
main of aggrecan is involved in both secretion of the aggrecan core protein and the 
binding of aggrecan to other ECM molecules (Day, Olin et al. 2004). The investigation of the 
tissue pathology for the OCD and SEMD mouse models was therefore performed as a 
broad analysis of the growth plate structure, mutant aggrecan secretion and the 
localisation of key extracellular matrix proteins. Wild type C57/BL6 mice and 
heterozygous and homozygous mutant mice were included in the initial histological 
analysis of tissue pathology. Tissue analysis was performed on mice at birth, 3 weeks, 9 
weeks, 6 months and 9 months of age to reflect the onset and progression of the 
disorders.  150
4.1. Histological analysis of growth plate structure 
Haematoxylin and Eosin staining was used to assess the structure of the tibial growth 
plate and cell morphology in male mice either heterozygous or homozygous for the OCD or 
SEMD mutations and their wild type littermates. Toluidine Blue staining was used to investi-
gate the relative abundance of proteoglycans in the growth plate. Chondrocytes in the wild 
type growth plate were arranged into three distinct zones (resting, proliferating and hyper-
trophic) and proliferating chondrocytes were arranged in columns parallel to the direction of 
growth.  
4.1.1. The SEMD mouse model 
The organisation of tibial growth plates from mice homozygous or heterozygous for 
the SEMD mutation was comparable to those from wild type littermates although the 
growth plates of mice homozygous for the mutation appeared visually smaller (n=2) (Figure 
41A). At birth there was no visible difference in toluidine blue staining intensity (and 
therefore proteoglycan abundance) in growth plates from wild type and mutant mice 
(Figure 41B). At three weeks of age there was a 23.7% reduction in the growth plate height 
of mice homozygous for the SEMD mutation compared to wild controls (Figure 42A-B). 
Further to this, the relative proportion of zones within the growth plate was abnormal, with 
a 16.0% decrease in the proliferative zone and an 11.8% proportional increase in the 
hypertrophic zone in SEMD growth plates compared to wild type controls (Figure 42C). The 
formation of the secondary ossification centre in the wild type murine tibial growth plate 
occurs after 7-10 days of age. At three weeks of age the secondary ossification centre is well-
formed with a pronounced mineralized area. In growth plates from mice homozygous for the 
SEMD mutation there was a 49.9% reduction in the mineralised area of the secondary 
ossification centre (Figure 42A and D) suggesting that the formation of the secondary centre 
was delayed.  
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 +/+  S/+  S/S 
Figure 41 Tibial growth plate structure in newborn SEMD mice.
(A) H&E and (B) toluidine blue staining of sec  ons from heterozygous and homozygous
mice and wild type controls. There were no visible di  erences in growth plate structure  and
all zones were present. Further to this, there were no visible di  erences in toluidine blue
staining intensity observed.
Key: +/+ (wild type) S/+ (heterozygous mutant) S/S (homozygous mutant) RZ (resti g zone) 
PZ (prolifera  ve zone) HZ (hypertrophic zone) n≥2 (except S/+) scale bar = 20μm. 
RZ 
PZ 
HZ 
A 
B 
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B  C  D 
E 
Figure 42 Tibial growth plate structure in 3 week old SEMD mice.
(A) H&E staining of matching sec tions from heterozygous and homozygous mutant mice 
and wild type controls. Homozygous mice had very disorganised growth plates (B) with a 
23.7%  reduc tion in height. (C) All zones were present, but there was a 16% decrease in the 
prolifera tive zone, an 11.82% increase in the hypertrophic zone and (D) a 49.9% decrease in 
the mineralised area of the secondary ossifica tion centre (black outline). Heterozygous mice 
had slightly disorganised growth plates and a well-formed secondary ossifica tion centre. (E) 
Table showing the numeric data used for the genera tion of graphs B, C and D.
Key: +/+ (wild type) S/+ (heterozygous mutant) S/S (homozygous mutant) RZ (resting zone) PZ 
(prolifera tive zone) HZ (hypertrophic zone) NS (not significant) *P≤0.05, **P≤0.01, Two tailed 
T-test, scale bar = 50μm, n≥3.  3 joint regions analysed from each animal. 
RZ 
PZ 
HZ 
+/+ S/+ S/S 
Growth plate height (mm) ± SEM  0.51±0.01 0.46±0.05 0.39±0.03** n≥3
% of total growth plate height ± 
SEM    
RZ 0.08± 0.01 0.10±0.01 0.11±0.004 n≥3
PZ 53.18± 1.23 48.98±1.69 44.67±1.49** n≥3
HZ 34.25± 0.47 36.05±1.52 38.30±1.49* n≥3
4.71±0.54 4.61±0.65 2.36±0.11* Area of secondary centre (mm2) ± SEM n=3 
NS (p=0.07)  
+/+  S/+  S/S 
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Growth plates of mice homozygous for the SEMD mutation also exhibited an altered 
cellular organisation. The separation between zones was visibly less distinct and chondrocytes 
were variable in size and arranged in irregular columns which were not always in the 
direction of growth (Figure 43). In addition to this, the intensity of toluidine staining of the 
ECM was slightly reduced, indicating a reduction in either proteoglycan abundance or 
sulfation (n=3) (Figure 43). There was no statistical difference in the parameters measured in 
the growth plates of mice heterozygous for the SEMD mutation and the secondary 
ossification centre was well-formed (Figure 42). Cellular organisation in the growth plate was 
slightly altered, alt-hough chondrocytes were generally arranged in columns parallel to the 
direction of growth and all zones were present. There was also no difference in toluidine 
blue staining intensity when compared with wild type controls (Figure 43). 
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+/+                                                                     S/+       
Figure 43 Growth plate structure and proteoglycan abundance in SEMD mice.
Toluidine blue staining of matching  tibial growth plate sec tions from 3 week old male mice heterozygous or homozygous for the muta tion and wild 
type controls. The growth plates of homozygous mice were very disorganised with less distinct zone separation, reduced columnar organisation and a 
slight reduction in the intensity of toluidine blue staining. The growth plates of heterozygous mice were slightly disorganised with all zones present. 
There were no visible di fferences in toluidine blue staining observed.   
Key: +/+ (wild type) S/+ (heterozygous for SEMD muta tion) S/S (homozygous for SEMD muta tion) RZ (resting zone) PZ (prolifera tive zone) HZ 
(hypertrophic zone) scale bar = 100µm, 3 joint regions analysed from 3 individual animals. 
 S/S 
Resting zone 
Prolifera tive zone 
Hypertrophic zone 
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4.1.2. The OCD mouse model 
The tibial growth plates of newborn mice homozygous or heterozygous for the OCD 
mutation were well organised with normal cell morphology. The chondrocytes were arranged 
in three distinct zones (resting, proliferative and hypertrophic) with well-formed columns in 
the proliferative zone (Figure 44A). Furthermore, there was no visible difference in the inten-
sity of toluidine blue staining (Figure 44B). By three weeks of age growth plate height in mice 
homozygous for the OCD mutation was reduced by 13.7% (Figure 45A-B) although there was 
no statistical difference in the relative proportion of each zone when compared to that of 
wild type controls (mutant mice analysed ≥5) (Figure 45C). The mineralized secondary 
ossification centre appeared visually smaller, suggesting a delay in formation of the 
secondary ossification (Figure 45A). Quantitative analysis indicated a trend in decreasing size 
of the mineralised centre in OCD growth plates compared to wild type controls; however, 
this difference was not statistically significant (mutant mice analysed ≥4, P=0.6) (Figure 45D). 
The growth plates of mice homozygous for the OCD mutation were disorganised with a slight 
reduction of toluidine blue staining in the interterritorial ECM (Figure 46). The growth plates 
of mice heterozygous for the mutation were comparable to those of wild type controls with 
only a slight reduction in extracellular toluidine blue staining in some areas (Figure 46).
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+/+  O/+  O/O 
Figure 44 Tibial growth plate structure in newborn OCD mice.
(A) H&E and (B) toluidine blue staining of sec  ons from heterozygous and homozygous 
mice and wild type controls. There were no visible di fferences in growth plate structure 
and all zones were present. Further to this, there were no visible di fferences in toluidine 
blue staining intensity observed.
Key: +/+ (wild type) O/+ (heterozygous mutant) O/O (homozygous mutant) RZ (resting zone) 
PZ (prolifera tive zone) HZ (hypertrophic zone) H&E n=3, toluidine blue n≥2, scale bar = 
20μm.  
A 
B 
RZ 
PZ 
HZ 
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+/+  O/+  O/O 
Figure 45 Tibial growth plate structure in 3 week old OCD mice.
(A) H&E staining of matching sec tions from heterozygous and homozygous mutant mice 
and wild type controls. Homozygous mice had disorganised growth plates (B) with a 13.7%
reduc  on in height. (C) There was no sta tis tical di fference in the propor tion of the zones in 
the growth plate (D) or the mineralised area of the secondary ossi fica tion centre (black out-
line). Heterozygous mice had slightly disorganised growth plates with a well-formed second-
ary ossifica tion centre. (E) Table showing the numeric data used for the genera tion of graphs 
B, C and D.
Key: +/+ (wild type) O/+ (heterozygous mutant) O/O (homozygous mutant) RZ (res ting zone) 
PZ (prolifera tive zone) HZ (hypertrophic zone) NS (not significant) *P≤0.05, Two tailed T-test, 
scale bar = 50μm, 3 joint regions analysed from each animal. 
+/+ O/+ O/O 
Growth plate height (mm) ± SEM  0.51±0.01 0.50±0.01 0.44±0.02* n≥5 
% of total growth plate height ± 
SEM    
RZ 0.08± 0.01 0.08±0.005 0.09±0.007 n≥5 
PZ 53.18± 1.23 54.51±1.59 53.06±1.42 n≥5 
HZ 34.25± 0.47 33.20±1.23 33.35± 1.04 n≥5 
4.71±0.54 4.52±0.43 4.39±0.36 Area of secondary centre (mm2) ± SEM n≥3 
NS 
NS 
NS 
NS 
RZ 
PZ 
HZ 
A
C             D
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4.2. Histological analysis of collagen fibril orientation 
Picrosirius red staining visualised under polarised light was used to visualise the orien-
tation and thickness of collagen fibrils in growth plate and articular surface cartilage of tibias 
from wild type and mutant male mice at 3 weeks of age. Growth plate cartilage from wild type 
mice contained thinner green-coloured collagen fibrils with some regions of increased fibril 
thickness which appeared red under polarized light (Figure 47A).  
4.2.1. The SEMD mouse model 
Growth plate cartilage from mice heterozygous for the SEMD mutation were visually 
similar to those of wild type mice. In contrast, collagen fibrils in growth plate cartilage from 
homozygous mice had an irregular appearance with a greater number of fibrils with 
increased thickness compare to the control (Figure 47A). Articular cartilage from wild type 
mice contained thinner green-coloured or yellow-coloured collagen fibrils which were 
orientated according to zone. Collagen fibrils in the superficial zone were arranged parallel 
to the articular surface, whereas those in the transitional and deep zones were orientated 
perpendicular to the joint surface (Figure 47B). Articular cartilage from mice homozygous for 
the SEMD mutation contained thicker red-coloured collagen fibrils. In addition to this, and 
although collagen fibril orientation in the superficial zone was maintained, the organisation 
of fibrils in the transitional and deep zones was completely disrupted (Figure 47B). There 
was no overt difference in fibril thickness in articular cartilage from heterozygous mice and 
the orientation of fibrils in the superficial zone was similar to that in the wild type control. 
The organization of fibrils in the transitional and deep zones was slightly disrupted; however, 
some fibrils were still per-pendicular to the joint surface (Figure 47B). 
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4.2.2. The OCD mouse model 
There was no overt difference in fibril orientation or thickness in the cartilage growth 
plate of mice either heterozygous or homozygous for the OCD mutation and their wild type 
controls (data not shown). There was also no visual difference between the articular 
cartilage of mice heterozygous for the OCD mutation and wild type controls (Figure 48). In
contrast, articular cartilage from homozygous mice exhibited thicker red-coloured fibrils. The 
orienta-tion of fibrils in the superficial zone was comparable to that of wild type controls and 
although the organisation of fibrils in the transitional and deep zones was slightly disrupted, 
some fibrils were still perpendicular to the joint surface (Figure 48).
Due to the mildness of the skeletal phenotype and lack of overt tissue pathology, mice 
heterozygous for either the OCD or SEMD causative mutations were not analysed further. 
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4.3. Ultrastructural analysis of the cartilage growth plate 
Transmission electron microscopy (TEM) was used to study the ultrastructure of tibial 
growth plates in seven day old mice. This allowed an in depth assessment of growth plate 
structure, chondrocyte morphology and composition of the extracellular matrix. Overlapping 
images were taken at low magnification and used to generate a reconstruction of the entire 
growth plate (using the Photoshop “photomerge” function). 
4.3.1. The SEMD mouse model 
The growth plate of the mouse homozygous for the SEMD mutation appeared rela-
tively well organised with all zones present; however, the proportion of the zones within the 
growth plates appeared altered with an increase in the resting zone and a decrease in the 
proliferative zone (Figure 49, n=1). Proliferating chondrocytes were arranged in chondrons,
but they were more rounded in shape than those in the wild type growth plate and were not 
always parallel to the direction of growth (Figure 49). At higher magnification chondrocytes
exhibited a severely distended endoplasmic reticulum indicative of intracellular protein 
reten-tion (Figure 50A-B). There was no overt difference in the appearance of the pericellular
matrix; however, the inter-territorial matrix had a granular appearance (Figure 50B-C). Pre-
hyper-trophic chondrocytes exhibited abnormal morphology with an enlarged endoplasmic 
reticu-lum  (Figure 51A). Cells also displayed single-membraned vesicular bodies containing
electron-dense granular material with electron-lucent areas  (Figure 51B-C). Chondrocytes in
the hy-pertrophic zone contained remnants of a distended ER (Figure 52A-B) but the
extracellular matrix appeared normal (Figure 52C).
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Figure 49 Reconstruction of the SEMD tibial growth plate
Transmission electron microscopy of secti ns from a seven day old homozygous SEMD 
mouse and a wild type li  ermate.  The SEMD growth plate exhibited all zones  but was dis-
propor  onate, with an enlarged res  ng zone and reduced prolifera  ve zone compared to 
that of the wild type sample. The chondrocytes were arranged in chondrons which were 
not always parallel to the directi n of growth (arrowheads). 
Key: +/+ (wild type) S/S (homozygous for the muta  on) n=1, scale bar = 50 µm. 
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Figure 50 Ultrastructure of the proliferative zone in the SEMD tibial growth plate. 
TEM of sectio s from a seven day old SEMD mouse and a wild type control. (A-B) Wild type 
chondrocytes contained an endoplasmic re  culum (ER) with a fi e ribboned structure 
(white arrows) whereas mutant chondrocytes exhibited an enlarged ER (black arrows). 
There was no di  erence in the composi  on of the (B) pericellular or (C) inter-territorial ex-
tracellular matrix.       
Key: +/+ (wild type) S/S (homozygous for the muta  on) (A) scale bar = 2µm, (B,C) scale bars 
= 500nm, n=1. 
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Figure 51 Ultrastructure of the pre-hypertrophic zone in the SEMD growth plate. 
TEM of secti ns from a seven day old SEMD mouse and a wild type control. Pre-
hypertrophic SEMD chondrocytes exhibited abnormal morphology including (A) an enlarged 
endoplasmic re  culum (black arrows) and (B-C) electron-dense intracellular vesicles (white 
arrows) with electro-lucent areas (*).  
Key: +/+ (wild type) S/S (homozygous for the muta  on) (A,B) scale bars = 2µm (C) scale bar = 
500nm, n=1. 
   +/+  S/S 
 P
re
-y
p
er
tr
o
p
h
ic
 z
o
n
e 
 (
C
) 
 (
B
) 
 
 (
A
) 
C
h
o
n
d
ro
cy
te
s 
* 
*
168
Figure 52 Ultrastructure of the hypertrophic zone in the SEMD growth plate. 
TEM of sec  ons from a seven day old SEMD mouse and a wild type control. (A-B) Hyper-
trophic SEMD chondrocytes exhibited abnormal morphology with remnants of an enlarged 
endoplasmic re  culum (black arrows). (C) There was no overt di  erence in the appearance 
of the extracellular matrix. 
Key: +/+ (wild type) S/S (homozygous for the muta  on) (A-B) scale bar = 2µm (C) scale bar = 
500nm, n=1. 
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4.3.2. The OCD mouse model 
The growth plate obtained from the mouse homozygous for the OCD mutation was 
well organised with all zones (resting, proliferative and hypertrophic) present (Figure 53). 
However, the relative proportion of the individual zones was altered with an overall reduction 
in the hypertrophic zone. Proliferative zone chondrocytes were arranged in chondrons 
parallel to the direction of growth (Figure 53). Under higher magnification proliferative 
chondrocytes contained an enlarged endoplasmic reticulum, suggesting intracellular 
retention of protein, and some cells displayed large electron-lucent vacuoles of 
undetermined origin (Figure 54A-B). The pericellular and inter-territorial matrix appeared 
normal (Figure 54D-E). Both proliferative and pre-hypertrophic chondrocytes contained a 
variety of vesicles 200-500 nm in diameter, which were not present in the wild type cells  
(Figures 54C and 55B-C). Vesicles containing electron-dense aggregates or microvesicles 
(50-150 nm in diameter) were surrounded by a double membrane and 
resembled autophagosomes or multivesicular bodies, which are associated with 
autophagic pathways (Li, Li et al. 2012). Vesicular structures without electron-dense 
contents were also observed (Figure 55C). In addition to this, cells in the pre-hyper-
trophic and hypertrophic zones displayed irregular morphology and contained an 
enlarged ER (Figures 55A-B and 56A). There was no difference in the appearance of the 
extracellular and inter-territorial matrix in the pre-hypertrophic and hypertrophic zones 
(Figures 56B). 
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Figure 53 Reconstruction of an OCD tibial growth plate 
Transmission electron microscopy of secti ns from a seven day old homozygous OCD 
mouse and a wild type li  ermate. All zones were present in the growth plate of the mouse 
homozygous for the muta  on, although the hypertrophic zone appeared propor  onally re-
duced compared to that of the wild type sample.  
Key: +/+ (wild type) O/O (homozygous for the muta  on) n=1, scale bar = 50 µm. 
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Figure 54 Ultrastructure of the proliferative zone in the OCD growth plate (A-C). 
+/+  O/O 
M
id
-p
ro
lif
er
ati
ve
 z
o
n
e
 
 (
C
) 
 (
B
) 
4
-c
e
ll 
ch
o
n
d
ro
n
 
 (
A
) 
4
-c
e
ll 
ch
o
n
d
ro
n
 
172
Figure 54 Ultrastructure of the proliferative zone in the OCD growth plate (D-E). 
TEM of sectio s from a seven day old OCD mouse and a wild type control. (A-B) Mutant 
chondrocytes have an enlarged endoplasmic re  culum (black arrows) and exhibit large 
electron-lucent vacuoles (white arrows) and (B-C) vesicles containing electron-dense mate-
rial (white arrows). There was no overt di  erence in the appearance of the (D) pericellular 
or (E) interterritorial extracellular matrix.  
Key: +/+ (wild type) O/O (homozygous for the muta  on) (A-B) scale bar = 2µm, (C-E) scale 
bars = 500nm, n=1. 
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Figure 55 Ultrastructure of the pre-hypertrophic zone in the OCD growth plate. 
TEM of secti ns from a seven day old OCD mouse and a wild type control. Pre-hypertrophic 
OCD chondrocytes exhibited abnormal morphology with (A) an enlarged re  culum (black 
arrows) and (B-C) intracellular vesicles containing punctate electron-dense material (white 
arrows) which appeared to have a double-membrane (arrowheads). Vesicles  with  uniden-
  fi d electron-lucent contents  were also observed (white arrows). 
Key: +/+ (wild type) O/O (homozygous for the muta  on) (A,B) scale bars = 2µm (C) scale bar 
= 250nm, n=1. 
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Figure 56 Ultrastructure of the hypertrophic zone in the OCD growth plate. 
TEM of sections from a seven day old OCD mouse and a wild type control. Hypertrophic 
OCD chondrocytes exhibited (A) remnants of a distended ER (black arrow). (B) There was 
no overt di  erence in the appearance of the extracellular matrix. 
Key: +/+ (wild type) O/O (homozygous for the muta  on) (A) scale bar = 2µm (B) scale bar = 
500nm, n=1. 
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4.4. Immunohistochemical analysis of the ECM 
Immunohistochemistry was used to analyse the localisation and relative abundance of 
the major extracellular matrix proteins in the tibial growth plate cartilage of male mice at 3 
weeks of age. The relative intensity of staining for collagen types II (Figure 57A) IX (Figure 
57B) and X (Figure 57C) was decreased overall in growth plates from mice homozygous for 
the SEMD mutation (n=3). Moreover, the localisation of collagen was altered compared to 
the wild type controls with staining for collagen type II in the secondary ossification centre 
(Figure 57A). Reduced staining for collagen type IX was found throughout the growth plate 
and secondary ossification centre of mutant mice (Figure 57B). Staining for the hypertrophy 
marker collagen type X was localised to not only the hypertrophic zone but to the secondary 
ossification centre, suggesting the presence of hypertrophic chondrocytes (n=3, Figure 57C). 
In contrast, the localisation of these same collagens was only slightly altered in the growth 
plate cartilage of mice homozygous for the OCD mutation, but with a reduction in staining 
intensity for collagen types IX (Figure 57B) and X (Figure 57C). There was no statistical 
difference in the proportion of the growth plate stained for collagen type X in tissue from 
either the OCD or SEMD mouse (n =3, Figure 57D). The intensity of staining for the adaptor 
proteins COMP (Figure 56A) and matrilin 3 (Figure 58B) was decreased and localised 
throughout the growth plate and secondary ossification centre in mice homozygous for the 
SEMD mutation and was slightly reduced in growth plates from mice homozygous for the 
OCD mutation (n=3, Figure 58). The abundance of aggrecan in the extracellular matrix was 
reduced in growth plates from both OCD and SEMD mice with an increase in intracellular 
staining (Figure 59). 
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Figure 57 Localisation and abundance of collagen in OCD and SEMD mice (A-B). 
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Figure 57 Localisation and abundance of collagen in OCD and SEMD mice (C-D). 
Immuno  uorescent staining of matching   bial growth plate sec  ons from male 3 week old 
wild type, OCD and SEMD mice. The intensity of staining for collagens type  IX (B) and X (C)
was reduced in the prolifera  ve zone of growth plates from OCD mice. The growth plates of 
SEMD mice exhibited decreased staining intensity for collagens type II (A) IX (B) and X (C). 
Staining for collagens type IX (B) was  not restricted to the prolifera  ve zone and staining for 
collagen type X (C) was localised to both the secondary centre and hypertrophic zone. (D) 
There was no sta  stica  di  erence in the propor  on of the growth plate stained for collagen 
type X. 
Key: +/+ (wild type) O/O (homozygous for the OCD muta  on) S/S (homozygous for the SEMD 
muta  on) scale bar = 50µm, n=3, NS (not significa t). 
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Figure 58 Localisation and abundance of ECM molecules in OCD and SEMD mice. 
Immuno  uorescent staining of matching   bial growth plate secti ns from male 3 week old 
wild type, OCD and SEMD mice. The intensity of staining for (A) COMP and (B) matrilin 3 in 
growth plates from OCD mice was slightly reduced. Staining intensity for (A) COMP and (B) 
matrilin 3 was both decreased and also localised to the secondary ossifica  n centre in the 
growth plates of SEMD mice.  
Key: +/+ (wild type) O/O (homozygous for the OCD muta  on) S/S (homozygous for the SEMD 
muta  on) scale bar = 50µm, n=3. 
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Figure 59 Mutant aggrecan is retained intracellularly in OCD and SEMD mice. 
Immuno  uorescent staining for aggrecan in matching ti ial growth plate secti ns from male 
3 week old wild type, OCD and SEMD mice.  The intensity of extracellular staining in the 
growth plates of OCD and SEMD was visibly reduced, whereas the intracellular staining was 
increased, sugges  ng that mutant aggrecan is retained within the cell (scale bar = 20µm, 
n=3).  
Key: +/+ (wild type) O/O (homozygous for OCD muta  on) S/S (homozygous for SEMD muta-
  on)  
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4.5. Histological analysis of the articular cartilage of OCD mice 
Haematoxylin and Eosin staining was used to assess the morphology of the tibial and 
femoral articular surface in male mice homozygous for the OCD mutation and their wild type 
littermates at 3 weeks (n=3), 9 weeks (n = 3), 6 months (n = 2) and 9 months (n = 1) of age. 
The articular cartilage in wild type controls at all ages studied formed a distinct layer over the 
subchondral bone and had a smooth surface with no obvious lesions present.  The morphology 
of the articular surface was unaffected in mice homozygous for the mutation up to 6 months 
of age in both the lateral and medial compartments of the knee joint (Figure 60A-C). Safranin
O staining was used to assess proteoglycan abundance in the articular cartilage.  The 
extracellular staining intensity was markedly reduced in the superficial and transitional zones 
of 9 week (data not shown) and 6-9 month old OCD mice in both the lateral and medial 
compartments of the knee joint (Figure 60D-E).
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Figure 60 The structure of knee articular cartilage in OCD mice (A-C)
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Figure 60 The structure of knee articular cartilage in OCD mice (D-E)
Histological staining of matched secti ns from male mice at 3 weeks, 9 weeks and 6 months 
of age. Haematoxylin and eosin staining showed no di  erence in the integrity of the ar  cular 
car  lage surface or underlying sub-chondral bone at (A) 3 weeks (B) 9 weeks or (C) 6 months 
of age. Safranin O staining was reduced in the superficial and transi  onal zones in both the 
(D) lateral and (E) medial joint compartments of mice by 6 months of age. 
Key: +/+ (wild type) O/O (homozygous for OCD muta  on) SZ (superficial zone) TZ (transiti nal 
zone) DZ (deep zone) CC (calcifie  car  lage) SB (subchondral bone) scale bar = 20µm, n=3  
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4.6. Summary 
The aim of this chapter was to investigate and compare the tissue pathology of two 
knock-in mouse models with missense mutations in the C-type lectin domain of aggrecan 
which  result in two  distinct  conditions, the mild familial OCD and the more severe SEMD 
aggrecan type. Transmission electron microscopy and a range of histochemical techniques 
were used to analyse cell morphology and growth plate structure during the growth and 
maturation of mice either homozygous or heterozygous for the aggrecan mutations 
compared to wild type controls. Histological analysis of mice homozygous for the SEMD 
mutation showed that growth plate height appeared reduced at birth. At three weeks of 
age, the mineralised area of the secondary ossification centre was significantly reduced in 
size, indicating a delay in the formation of the secondary ossification centre. In addition to 
this, the SEMD growth plate was reduced in height and disorganised, with rounded 
chondrocytes arranged into abnormal chondrons which were not always parallel to the 
direction of bone growth. The individual growth plate zones were disproportionate, with a 
significant increase in the height of the hypertrophic zone. Interestingly, however, the area 
of staining for the hypertrophic marker collagen type X was not statistically different in mice 
homozygous for the SEMD mutation compared with wild type controls, suggesting 
premature hypertrophy or impaired maturation. In contrast to the SEMD mouse, at birth 
there were no overt differences in tissue morphology between mice homozygous for the 
OCD mutation and their wild type littermates. However, by three weeks of age the growth 
plate was disorganised and significantly reduced in size, although the secondary ossification 
centre was well-formed and within normal limits. Histological and ultrastructural analysis of 
the growth plate showed that the murine OCD and SEMD Acan mutations delay secretion of 
the mutant aggrecan protein, causing protein retention within the endoplasmic reticulum 
and reduced abundance of aggrecan in the ECM. It is important to note that the secretion of 
mutant aggrecan was not completely impaired in these models, as weak extracellular 
staining for aggrecan was observed in the OCD and SEMD growth plates of 3 week old mice. 
Furthermore, aggrecan-null models such as the Cmd mouse are known to be embryonic 
lethal (Rittenhouse, Dunn et al. 1978) and the OCD and SEMD mutations do not impair pup 
survival (see Chapter 1) confirming that the mutant aggrecan must be secreted  into the
ECM. Interestingly, ultrastructural analysis indicated a variety of intracellular  vesicles in both
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OCD and SEMD chondrocytes from growth plate cartilage. Vesicular bodies in the pre-
hypertrophic zone of the SEMD growth plate had electron-lucent regions and contained 
electron-dense granular material, therefore displaying many of the features associated with 
autolysosomes (Ishikawa, Furuno et al. 1983). In contrast, vesicles in the proliferative and 
pre-hypertrophic zones of the OCD growth plate were electron-lucent, exhibited a double-
membrane and contained electron-dense microvesicles or aggregates. These structures 
resemble autophagosomes or multivesicular bodies. Autolysosomes, autophagosomes and 
multivesicular bodies are structures associated with the macro- and micro-autophagy 
pathways and suggest that autophagy may play a role in the disease mechanisms in the OCD 
and SEMD mouse models. Ultrastructural analysis did not show any overt differ-ences in the 
appearance of the pericellular or inter-territorial extracellular matrix in growth plates from 
seven week old OCD or SEMD mice compared to a wild type control (n=1). In contrast to this, 
immunohistochemical analysis of 3 week old mice homozygous for the SEMD mutation 
indicated irregular collagen fibril thickness, mislocalisation and an overall reduction in the 
abundance of key ECM proteins such as COMP, matrilin 3 and type II collagen (n=3). Collagen 
fibril thickness in the articular cartilage was also increased and fibril orientation was 
disrupted in the transitional and deep zones. ECM matrix composition was also altered in the 
cartilage of OCD mice, with reduced abundance of collagen IX in the growth plate and in-
creased collagen fibril thickness in the articular cartilage. Histological analysis of articular car-
tilage from mice homozygous for the OCD mutation prior to growth cessation did not show 
necrosis (a classic hallmark of osteochondritis latens) or focal areas of disrupted endochondral 
ossification (osteochondritis manifesta). In addition to this, there was no formation of fissures 
in the cartilage and subchondral bone (osteochondritis dissecans) lesions in OCD animals up 
to six months of age either in the lateral or medial part of the joint. However, proteoglycan 
abundance in the superficial and transitional zones of articular cartilage from mice homozy-
gous for the OCD mutation appeared reduced at nine weeks of age (upon growth cessation). 
Staining intensity for proteoglycan in these zones was further reduced by 6 months of age, 
indicating that proteoglycan loss progressed with age.The growth plates of mice heterozygous 
for the OCD mutation were not visually different from the wild type mice. Similarly, the growth 
plates of mice heterozygous for the SEMD mutation were only slightly disorganized. This sug-
gested that the presence of one copy of the wild type aggrecan allele was enough to reduce 
the tissue pathology of both SEMD and OCD. This observation is consistent with published 
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patient clinical data (on the single family reported) in which SEMD aggrecan type is found to 
be a recessive disease (Tompson, Merriman et al. 2009). 
In conclusion, both the OCD and SEMD mouse models exhibited a disorganised growth 
plate with impaired trafficking of mutant aggrecan from the endoplasmic reticulum, altered 
matrix composition and a variety of intracellular vesicles. Histological analysis of the articular 
cartilage showed that this model of familial OCD does not exhibit the lesion formation ob-
served in classical osteochondrosis. However, mice homozygous for the OCD mutation did 
exhibit signs of cartilage degradation, displaying progressive proteoglycan loss from the artic-
ular cartilage with age. OCD mice exhibited a clear tissue pathology at three weeks of age, but 
the onset of pathology occurred at an earlier age in SEMD mice with growth plates visibly 
reduced in height at birth. The growth plate tissue pathology displayed by SEMD mice at 3 
weeks of age was also more severe, with irregular collagen fibril thickness, delayed formation 
of the secondary ossification centre, decreased proliferation zone and an increased hyper-
trophic zone.  In order to further eludicate the downstream effects of these aggrecan muta-
tions, a quantitative analysis of tissue pathology was performed and these data are presented 
in the following chapter. 
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Chapter 5. Quantitative Tissue Pathology Analysis of the SEMD 
and OCD Mouse Models
The qualitative analysis performed in Chapter 4 indicated that growth plates from
SEMD and OCD mice are smaller than those of wild type controls and exhibit altered cellular 
organisation. In addition to this the relative proportion of each zone in growth plates from 
the SEMD mice was also altered. Further in-depth histological analysis was performed to 
quantitatively assess a number of parameters including chondrocyte number, chondrocyte 
proliferation rate and programmed cell death. In order to assess whether the extended 
hypertrophic zone observed in the SEMD mouse growth plate was due to a defect in cartilage 
mineralisation or matrix resorption, bone calcification and osteoclast number were 
determined. Histological analysis in Chapter 4 had demonstrated alterations in matrix
composition and so RNA-seq and immunoblotting were used to assess the expression and 
secretion of key extracellular matrix proteins. Phenotypic analysis performed in Chapter 3
found that SEMD mice exhibited variable scoliosis, whilst intervertebral disc degeneration is 
often associated with short stature conditions caused by aggrecan mutations (Tatsi, 
Gkourogianni et al. 2017). Histo-morphometry techniques were therefore used to assess the 
morphology of the vertebrae and intervertebral discs. Wild type C57/BL6 mice and 
homozygous mutant mice were included in this quantitative analysis of tissue pathology. Mice 
were assessed at 5 days, 7 days, 3 weeks and 9 weeks of age to further investigate the tissue 
pathology of these conditions.  
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5.1 Chondrocyte number in the OCD and SEMD growth plates 
      In order to determine whether the altered relative proportion of the individual zones in 
the growth plates of SEMD mice was due to a change in cell number, rather than volume, 
individual chondrocytes were counted in each zone. The number of DAPI-positive cells in each 
zone was then expressed as a percentage of the total cell number. There was a 6.8% decrease 
in the number of chondrocytes in the resting and proliferative zones of mice homozygous for 
the mutation compared to wild type controls (n=3, Figure 61). In addition to this, the number 
of cells in the hypertrophic zone and on the vascular invasion front was increased by 30.6% 
and 41.2%, respectively. This suggested that the change in the relative proportion of the 
zones in the SEMD growth plate was most likely to be due to a difference in the number of 
cells at each stage of maturation. There was no difference in the number of cells per zone in 
mice homozygous for the OCD mutation compared to wild type controls (n=3, Figure 61).  
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Genotype +/+ O/O S/S 
% cells in the RZ-PZ/total cell number ± SEM  82.56±1.11 81.40±1.97 76.95±1.19* 
% cells in the HZ/total cell number ± SEM   14.87±0.87 15.66±1.64 19.42±1.01* 
% cells on the VIF/total cell number ± SEM   2.57±0.25 2.94±0.34 3.63±0.18* 
A 
B 
Figure 61 Cell number in the tibial growth plates of OCD and SEMD mice.
The number of cells per zone was analysed in the growth plates of 3 week old male OCD, 
SEMD and wild type mice. (A) Graph of the number of cells per zone expressed as a per-
centage of the total cell number. There was no di  erence in the percentage of cells per 
zone in the growth plates of OCD mice. In contrast, there was a 6.8% decrease in the aver-
age cell number in the combined res  ng and prolifera  ve zones of SEMD mice compared 
with wild type controls.  There was also a 30.6% and a 41.2% increase in the average cell 
number in the hypertrophic zone and vascular invasion front, respectiv ly. (B) Table show-
ing numeric data used for the genera  on of graph A. 
Key: +/+ (wild type) O/O (homozygous for the OCD muta  on) S/S (homozygous for the 
SEMD muta  on) RZ (resti g zone) PZ (prolifera  ve zone) HZ (hypertrophic zone) VIF 
(vascular invasion front) *P≤0.05, Two tailed T-test, n=3. 
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5.2 Proliferation rate of OCD and SEMD growth plate chondrocytes 
     The proliferation rate of chondrocytes in the tibial growth plate was analysed using in 
vivo BrdU labelling in mice at 3 weeks of age, followed by immunohistochemistry on nine 
matched sections per mouse (n=3, Figure 62A). There was a 50% decrease in the number of 
BrdU-positive labelled cells present in the proliferative zone of mice homozygous for the 
SEMD mutation when compared to wild type littermates. In contrast, there was no statistical 
difference in the proportion of BrdU-labelled cells in the growth plates of mice homozygous 
for the OCD mutation when compared to wild type littermates (Figure 62B-C).  
5.3 Apoptosis in OCD and SEMD growth plates 
Fluorescent TUNEL (Terminal dUTP Nick End-Labelling) labelling of fragmented DNA was 
used to analyse chondrocyte apoptosis in tibial growth plates from 3 week old male mice 
(Figure 63A). Growth plates from wild type mice contained very few apoptotic cells with only 
0.2% TUNEL-positive chondrocytes in the resting and proliferative zones. The number of 
apoptotic cells in the hypertrophic zone and on the vascular invasion front was 2.5% and 
14.3%, respectively. In the growth plates of mice homozygous for the SEMD mutation 
however, there was a 135.3% increase in the proportion of apoptotic cells in the hypertrophic 
zone compared to wild type littermates (P=0.02, Figure 63). Growth plates from mice 
homozygous for the OCD mutation exhibited a 77.7% at the vascular invasion front (P=0.05, 
Figure 63).  
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Figure 62 Chondrocyte proliferation in tibial growth plates of OCD and SEMD mice.
The chondrocyte prolifera  on rate was analysed with immunohistochemistry of BrdU-
labelled growth plates in 3 week old male OCD and SEMD mice and their wild type li  erma-
tes. (A) Representative pseudo-coloured images of BrdU-labelled cells in the growth plate. 
(B) Graph of BrdU–labelled cells expressed as a percentage of the total number of cells in 
the prolifera  ve zone. There was a 48.9% decrease in chondrocyte prolifera  on in the 
growth plates of SEMD mice but no sta  stical di  erence in that of OCD mice when com-
pared with wild type controls. (C) Table showing the numeric data used for the genera  on 
of graph B.
Key: +/+ (wild type) O/O (homozygous for OCD mutation) S/S (homozygous for SEMD muta-
tion) PZ (proliferative zone) SEM (standard error of the mean) scale bar = 100μm,  *P≤0.05, 
Two tailed T-test,  3 joint regions analysed from 3 individual animals. 
A 
B 
C 
Genotype +/+ S/S O/O 
% of BrdU labelled posi  ve cells in the PZ ± SEM  11.53±0.60 5.89±1.77 * 12.51±0.95 
100μM 
+/+  S/S
(P=0.04) 
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Figure 63 Chondrocyte apoptosis in tibial growth plates of OCD and SEMD mice.
The number of apopto tic cells was analysed with fluorescent TUNEL of fragmented DNA in 3 
week old male OCD, SEMD and wild type mice. (A) Representa tive images of  fluorescent 
TUNEL labelled apopto tic cells (white arrows) in the growth plate. Cell nuclei were detected 
with DAPI staining (B) Graph of TUNEL posi tive cells expressed as a percentage of the total 
number of cells in each growth plate zone. There was a 135.3% increase in the number of 
apopto tic cells in the hypertrophic zone of SEMD mice and a 77.7% increase in apopto tic 
cells at the vascular invasion front of OCD mice compared with wild type controls. (C) Table 
showing numeric data used for the genera  on of graph B. 
Key: +/+ (wild type) O/O (homozygous for the OCD muta  on) S/S (homozygous for the SEMD 
muta tion) RZ (resting zone) PZ (prolifera tive zone) HZ (hypertrophic zone) VIF (vascular 
invasion front) scale bar = 50µm, *P≤0.05, Two tailed T-test, 3 joint regions analysed from 3 
individual animals.  
A 
B 
C 
Genotype +/+ O/O S/S 
% of TUNEL posi  ve cells in the RZ-PZ ± SEM  0.22±0.12 0.28±0.13 0.66±0.17 
% of TUNEL posi  ve cells in the HZ ± SEM   2.49±0.87 1.59±0.33 5.86±0.30 * 
% of TUNEL posi  ve cells at the VIF ± SEM   14.25±3.08 25.32±2.51 * 19.48±0.98 
VIF 
D
A
P
I    (Y
FP
) TU
N
EL 
+/+      O/O  S/S 
VIF 
RZ/PZ 
HZ  
(P=0.02) 
(P=0.05) 
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5.4 Histological analysis of bone formation in OCD and SEMD mice
      Von Kossa staining was used to visualise calcium deposition in the cartilage growth plate 
and underlying bone of wild type and mutant newborn mice. There was no overt difference in 
the deposition of calcium in the cartilage matrix or trabecular bone of mice homozygous for 
either the SEMD (n=2) or OCD (n=3) mutation when compared to wild type controls (Figure 
64). Staining for the osteoclast marker tartrate-resistant acid phosphatase (TRAP) was 
performed on mice at three weeks of age (Figure 65A). There was no statistical difference in 
the total number of osteoclasts on the chondro-osseous border in either OCD (P=0.31) or 
SEMD (P=0.23) mice compared to wild type controls (n=3, Figure 65). In addition to this, 
there was no difference in the number of large mature multinucleate osteoclasts on the 
chondro-osseous border in OCD (P=0.24) or SEMD (P=0.23) mice (Figure 65).  
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Figure 65 Osteoclast density in OCD and SEMD mice. 
(A) TRAP staining for osteoclasts (black arrows) on matched sec  ons from male mice at 
three weeks of age (scale bar = 100μm). Representa  ve images of  (B) mul  nucleate and (C) 
mononucleate osteoclasts. Nuclei are indicated with arrows (scale bar = 50μm). (D) There 
was no sta  stical di  erence in the number of osteoclasts on the chondro-osseous border in 
OCD or SEMD mice. (E) Table showing the numeric data used for the genera  on of graph . 
Key: +/+ (wild type) O/O (homozygous for OCD muta  on) S/S (homozygous for SEMD muta-
tion) NS (not significant) SEM (standard error of the mean) n=3, scale bar = 100μm
+/+ O/O S/S 
Average mononucleate osteoclast number/mm2 ± SEM 0.02±0.01 0.02±0.01 0.04±0.01 
Average mul  nucleate osteoclast number/mm2 ± SEM  0.06±0.02 0.10±0.03 0.12±0.03 
Average total osteoclast number/mm2 ± SEM   0.08±0.02 0.13±0.03 0.14±0.04 
+/+  O/O  S/S 
A 
B D 
C 
E 
NS 
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5.5 Transcriptional analysis of the ECM 
       RNA-sequencing was used to compare the transcriptomic profile of chondrocytes from 
femoral and tibial cartilage extracted from 5 day old mice homozygous for either the SEMD or 
OCD mutation with that of wild type littermates. There was no statistical difference in the 
transcript levels of genes encoding the major ECM proteins including collagens (type II, V, VI, 
IX, X, XI and XXVII) proteoglycans (aggrecan, biglycan, perlecan) and glycoproteins (COMP, 
matrilin 1 and matrilin 3) in mice homozygous for either the SEMD or OCD mutation 
compared to wild type controls (Table 4). Gene expression of the SLRPs decorin (fold change
= -1.5) and lumican (fold change = -0.46) was statistically decreased in cartilage from mice
homozygous for the SEMD mutation compared to the wild type controls. However, gene 
expression levels were not below the -1.5 log fold change required for a biologically
meaningful change. There was increased gene expression of tenascin X (fold change = 1.85)
in cartilage from mice homozygous for the OCD mutation (Table 4).  
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Protein Gene symbol 
OCD SEMD 
FC P value FC P value 
Aggrecan Acan -2.01 0.18 -1.40 0.49 
Asporin Aspn 1.01 0.94 -1.02 0.92 
Biglycan Bgn -1.13 0.56 -1.35 0.17 
Chondroadherin Chad -1.71 0.24 -1.24 0.63 
Collagen type II α1 Col2a1 -2.30 0.16 -1.17 0.77 
Collagen type V α1 Col5a1 -1.13 0.70 -1.37 0.31 
Collagen type V α2 Col5a2 -1.12 0.67 -1.39 0.23 
Collagen type V α3 Col5a3 1.48 0.06 1.01 0.94 
Collagen type VI α1 Col6a1 1.06 0.80 -1.20 0.41 
Collagen type VI α2 Col6a2 1.05 0.84 -1.26 0.35 
Collagen type VI α3 Col6a3 1.04 0.86 -1.16 0.55 
Collagen type IX α1 Col9a1 -2.22 0.24 -1.01 0.98 
Collagen type IX α2 Col9a2 -2.44
 
0.12 -1.02 0.97 
Collagen type IX α3 Col9a3 -2.62 0.08 1.02 0.96 
Collagen type X α1 Col10a1 -1.67 0.45 -1.28 0.71 
Collagen type XI α1 Col11a1 -2.00 0.15 -1.65 0.28 
Collagen type XI α2 Col11a2 -2.07 0.14 -1.24 0.64 
Collagen type XXVII α1 Col27a1 -1.91 0.09 -1.47 0.14 
COMP comp -1.43 0.28 -1.42 0.28 
Decorin Dcn -1.10 0.56 -1.51 0.04* 
Epiphycan Epyc -2.71 0.25 1.17 0.85 
Fibromodulin Fmod -0.37 0.34 -1.59 0.11 
Perlecan Hspg2 -1.40 0.19 -1.47 0.14 
Lumican Lum -1.32 0.11 -1.46 0.04* 
Matrilin 1 Matn1 -2.99 0.13 1.34 0.67 
Matrilin 3 Matn3 -2.83 0.23 -1.06 0.94 
PRELP Prelp -1.30 0.37 -1.36 0.31 
Tenascin X Tnxb 1.85 0.02* 0.34 0.32 
Table 4 Differential gene expression of extracellular matrix molecules. 
Transcriptomics analysis was performed on   bial and femoral car  lage of   ve day old mice homozygous for 
either the SEMD or OCD muta  on and wild type controls. Mice homozygous  for the OCD muta  on exhibit-
ed increased gene expression of tenascin X (n=3, *P ≤ 0.05). Mice homozygous for the SEMD mutation dis-
played statistically decreased gene expression of decorin and lumican; however, the fold change was not
below the standard –1.5 required for a biologically meaningful change.
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5.6 Immunoblotting analysis of the ECM
       4-12% Bis-Tris SDS-PAGE Western blotting (under reducing conditions) was used to 
analyse the relative abundance of major extracellular matrix proteins in femoral head cartilage 
dissected from male mice at 3 weeks of age and rib chondrocytes extracted from mice at 7 
days of age. There was a 36% decrease in the total abundance of COMP (P=0.01) in femoral 
head cartilage extracted from mice homozygous for the SEMD mutation, but no statistical 
difference in the abundance of collagen type II (n=3, Figure 66A). Mice homozygous for the
OCD mutation exhibited a 61% and 47% decrease in the expression of COMP (P=0.03) and 
collagen type II (P=0.04) respectively (n=3, Figure 66A). Rib chondrocytes were isolated from
cartilage of 7 day old mice and cultured in maintenance medium for 48 hours before lysis. 4-
12% Bis-Tris SDS-PAGE Western blotting of culture medium (under reducing conditions) 
showed delayed secretion of mature collagen type II (120kDa) by OCD and SEMD 
chondrocytes. Immunoblotting of cell lysate from OCD and SEMD mice showed no overt 
difference in the band intensity for collagen type II but increased abundance of two higher 
molecular weight bands corresponding to uncleaved (proα1, 200kDa) and partially cleaved 
(pNα1, 150kDa) procollagen (Figure 66B) (Aubert-Foucher, Mayer et al. 2014, Wieczorek,
Rezaei et al. 2015). It was not possible to perform statistical analysis due to the low number 
of replicates (n=1) but this initial data suggested there may be a delay or impairment in the 
processing of procollagen II to the mature form.  
      Sequential protein extraction of femoral head cartilage dissected from male mice at 3 
weeks of age did not show any overt difference in the abundance of collagen type II in 
buffers I and II from mice homozygous for the SEMD mutation. There was however a 44% 
decrease in the abundance of collagen type II in the final extraction buffer (buffer III) 
suggesting that the extractability of collagen type II maybe slightly altered in SEMD cartilage 
compared to wild type controls (n =3) Figure 67).
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proα1 (II) 
pNα1 (II) 
Mature (II) 
GAPDH 
Total 
protein 
+/+      O/O   S/S    +/+      O/O   S/S  
Cell lysate    Medium  
Figure 66 Protein expression of extracellular matrix molecules
(A) Reduced Western blot of femoral head car  lage from 3 week old mice homozygous for either the 
SEMD or OCD muta  on and wild type li  ermates. Mice homozygous for the OCD or SEMD muta  on exhib-
ited a 61% and 36% decrease in COMP abundance rela  ve to GAPDH, respectively (n=3). OCD mice also dis-
played a 47% decrease in COMP expression. (B) Reduced Western blot of culture medium and cell lysate 
indicated that the secre  on of collagen type II into the medium was reduced and the ra  o of procollagen 
type II to the mature form was increased in SEMD and OCD chondrocytes compared to wild type controls. 
This suggested that collagen processing may be impaired in mice homozygous for either the SEMD or OCD 
muta  on (n=1).  
Key: +/+ (wild type) O/O (homozygous for OCD muta  on) S/S (homozygous for SEMD muta  on) *P ≤ 0.05, 
**P ≤ 0.01, Two tailed T-test. 
+/+      O/O      S/S  
Collagen type II 
COMP 
GAPDH 
120kDa 
100kDa 
37kDa 
200kDa 
 
120kDa 
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Figure 67 The extractability of collagen type II from the extracellular matrix
Reduced Western blot of sequentially extracted protein from femoral head cartilage in 
3 week old mice homozygous for the SEMD mutation and wild type littermates. There was 
no statistical difference in the extractability of collagen type II from the extracellular 
matrix of SEMD mice (compared to wild type controls) in buffers I and II. There was a 
44% decrease in the average amount of collagen type II (in protein extracted in buffer 
III) in mice homozygous for the SEMD mutation compared to the wild type controls (n=3).  
Key: +/+ (wild type) S/S (homozygous for SEMD muta tion) **P ≤ 0.01, Two tailed T-test. 
+/+    S/S    +/+    S/S   +/+     S/S  
120kDa 
Bu ffer I   Buffer II   Buffer III 
Collagen type II 
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 5.7 Histo-morphometric analysis of the thoracic vertebral column 
       Haematoxylin and eosin staining, safranin O staining and histo-morphometry were used 
to assess the morphology of the thoracic spine in 9 week old mice homozygous for the OCD 
and SEMD mutations and their wild type littermates. The vertebral bodies of OCD mice were 
proportionally smaller compared to wild type mice, with an 8.3% decrease in height (P=0.04) 
but no statistical difference in the width/height ratio (Figure 68). In contrast, SEMD mice 
displayed platyspondyly with a 13.2% decrease in vertebral body height (P=0.02) and an 
increased width/height ratio (P=0.0008, Figure 68). Interestingly, although the majority of 
SEMD mice analysed (n=3) exhibited flattened vertebrae, the SEMD mouse with the greatest 
spinal curvature (Diab angle of 30⁰) also displayed the classical wedge-shaped vertebrae 
associated with developmental scoliosis (n=1) (Scherrer, Begon et al. 2013). Morphological 
analysis of the invertebral disc (IVD) indicated that the height of the IVD in OCD mice was 
unaffected (Figure 69). The nucleus pulposus was flattened, however, with an increase in the 
width to height ratio (P=0.0003, Figure 69C). There was no statistical difference in the shape 
of the nucleus pulposus in SEMD mice, although the total height of the IVD was decreased by 
18.4% (P=0.04, Figure 69B-D).  
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Figure 68 Histological analysis of the thoracic vertebral bodies in OCD and SEMD mice.
The height and weight to height ra  o of the vertebral bodies were measured in 9 week old 
male OCD and SEMD mice and their wild type litter ates. (A) Representa  ve image of  ver-
tebral bodies from wild type, OCD and SEMD mice stained with haematoxylin and eosin. (B) 
Vertebral body wedging at the site of spinal curvature in an SEMD mouse (do  ed lines). (C) 
Graph of vertebral body height. Each colour denotes individual measurements from one 
mouse. The average vertebral body height was decreased by 8.3% and 13.2% in OCD and 
SEMD mice, respectively, compared to wild type littermates. (D) Graph of the width to 
height (W/H) ra  o of the vertebral body. The W/H ra  o was not sta  sti ally di  erent in the 
vertebral bodies of OCD mice. (E) Table showing the average of the numeric data used for 
the genera  on of graphs C and D. 
Key: +/+ (wild type) O/O (homozygous for OCD muta  on) S/S (homozygous for SEMD muta-
  on) W (width) H (height) SEM (standard error of the mean) scale bar = 100μm,  *P≤0.05, 
***P≤0.001 , Two tailed T-test, n≥3. 
Genotype +/+ O/O S/S 
Average vertebral body height  (mm) ± SEM 1.21±0.04 1.11±0.01* 1.05±0.03* 
Average vertebral body width/height ra  o ± SEM 1.30±0.08 1.44±0.05 1.88±0.03*** 
+/+    O/O   S/S    S/S 
A    B 
C  D 
E 
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Figure 69 Morphometric analysis of the thoracic spine in OCD and SEMD mice.
The height and weight to height ra  o of the en  re intervertebral disc (IVD) and nucleus pul-
posus were measured in 9 week old male OCD and SEMD mice and their wild type li  erma-
tes. (A) Representa  ve image of a wild type intervertebral disc. (B) Graph of intervertebral 
disc height. Each colour denotes individual measurements from one mouse. The average 
intervertebral disc height was decreased by 18.4% in SEMD mice compared to wild type 
li  ermates. There was no sta  stical di  erence in IVD height in OCD mice. (C) Graph of the 
width to height (W/H) ratio of the nucleus pulposus. The W/H ratio was not statistically 
different in SEMD mice. In OCD mice, however, the height of the nucleus pulposus was re-
duced compared to its width, indicating that the nucleus pulposus has a flattened morpholo-
gy. (D) Table showing the average of the numeric data used for the generation of graphs B
and C. 
Key: +/+ (wild type) O/O (homozygous for OCD mutation) S/S (homozygous for SEMD muta-
tion) NP (nucleus pulposus) IVD (intervertebral disc) SEM (standard error of the mean) scale 
bar = 50μm,  *P≤0.05,  ***P≤0.001 Two tailed T -test, n≥4. 
A 
B C 
D 
Genotype +/+ O/O S/S 
Average intervertebral disc height  (mm) ± 0.38±0.02 0.36±0.01 0.31±0.01* 
Average nucleus pulposus width/height ra  o± 
SEM   
2.82±0.08 3.51±0.07*** 3.53±0.35 
100μM 
IVD
height 
NP width 
NP height 
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5.7.1 Degenerative changes in the thoracic intervertebral disc 
       Histo-morphometric analysis using an established scoring system was performed to 
assess intervertebral disc (IVD) degeneration (Tam, Chan et al. 2017). IVD were scored for 
morphological features associated with either normal disc structure or degenerative changes. 
Normal disc morphology was scored with a value of 0 and degenerative features scored with 
a value between 1 and 2-4 according to severity. The average score was taken for the 
boundary between the annulus fibrosis and nucleus pulposus (maximum score of 2) each disc 
component (maximum score of 6) and as a total IVD score with a maximum potential score of 
14. Wild type intervertebral discs consisted of a single cell mass surrounded by extracellular
matrix known as the nucleus pulposus (n=3, Figure 70A). This inner structure was distinctly 
separate from the annulus fibrosis, an outer fibrous ring comprised of concentric lamellae with 
flattened or slightly rounded cells. Normal discs did not have any clefts or fissures. 
Intervertebral discs (IVD) from OCD mice (n=5) were either indistinguishable from wild type 
IVD (Figure 70B) or exhibited a number of morphological changes including reduced cell 
mass, increased matrix and cell cleft formation in the nucleus pulposus (Figure 70C). The 
separation between the nucleus pulposus and annulus fibrosis was less defined with some 
discs exhibiting complete boundary loss. Changes in the annulus fibrosis were more variable 
with serpentine lamellae and more rounded cells. Quantification of these degenerative 
changes showed a 1.6 point increase in the average total degeneration score (P=0.002, Figure 
70F). Statistically significant changes were observed in scoring for the boundary (P=0.02, 
Figure 70G) nucleus pulposus (P=0.004, Figure 70H) but not the annulus fibrosis (P=0.06, 
Figure 70I) indicating that the nucleus pulposus is the primary site of degeneration. SEMD 
mice displayed moderate to severe intervertebral disc degeneration (IDD). Annulus fibrosis 
lamellae were undefined and often protruded into the nucleus pulposus (n=4, Figure 70D-E). 
In severely degenerated discs the boundary between the annulus fibrosis and nucleus 
pulposus was absent (Figure 70E). The matrix-rich nucleus pulposus exhibited complete cell 
loss and the formation of small clefts. Quantification of these changes showed a 5.1 point 
increase in the average total degeneration score (P=0.00005, Figure 70F). Significant changes 
were observed in both the nucleus pulposus (P=0.004) and annulus fibrosis (P=0.0004, Figure 
70H-I).  
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Figure 70 Intervertebral disc degeneration in OCD and SEMD mice (A-E).
The severity of intervertebral disc degenera tion (IDD) in the thoracic spine was 
quan titatively assessed in 9 week old male OCD and SEMD mice and wild type li ttermates. 
Intervertebral discs (IVD) were stained with safranin O and images randomly numbered to 
remove bias. IVD morphology was scored blind for degenera tive changes (with a maximum 
possible score of 14). (A) Representa tive image of wild type IVD with normal morphological 
features. IVD from OCD mice exhibited both (B) relatively normal morphological features and 
(C) degenera tive changes such as cell loss and the presence of cle fts in the nucleus pulposus.
IVD from SEMD displayed (D) moderate and (E) severe degenera tive changes including loss of
the AF/NP boundary, fissures and loss of annulus fibrosis structure.
Key: +/+ (wild type) O/O (homozygous for OCD muta tion) S/S (homozygous for SEMD mutation) 
AF (annulus fibrosis) NP (nucleus pulposus) scale bar = 50µm, n≥3.
 
A
 
 
B 
 
 
C 
100μM 
 Single nucleus pulposus cell mass surrounded by 
matrix (arrow) with no   ssures 
Concentric lamellar (indicted with black line) AF 
with no cle  s  
Clear AF-NP boundary  
Single nucleus pulposus cell mass with no  fissures 
Serpentine annulus  fibrosis with rounded cells 
(arrow) 
Clear AF-NP boundary 
Total score = 0 
Total score = 1 
>50% cell loss in the nucleus pulposus with mild
cle fts <50% of NP compartment (arrow)
Serpentine annulus  fibrosis with rounded cells  
Loss of AF/NP boundary 
Total score = 6 
Single nucleus pulposus cell mass with no  fissures 
Undefined AF lamellae penetrating into the nucle-
us pulposus (arrow) 
Clear AF-NP boundary 
Matrix-rich NP with few cells and mild cle fts <50% 
of NP compartment (arrow) 
Undefined AF lamellae but no  fissures 
Loss of AF/NP boundary 
Total score = 9 
Total score = 3 
 
B 
C 
 
D 
E 
+/+ 
O/O 
O/O 
S/S 
S/S 
NP 
AF 
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F    G   
H  I 
J 
Genotype +/+ O/O S/S 
Average total degenera  on score±SEM 1.35±0.21 2.98±0.21*** 6.44±0.30*** 
Average AF-NP boundary score ±SEM 0.09±0.05 0.56±0.11* 1.15±0.08*** 
Average AF degenera  on score ±SEM 1.26±0.16 1.64±0.09 3.12±0.15*** 
Average NP degenera  on score ±SEM 0.00±0.00 0.78±0.13*** 2.17±0.22*** 
100μM 
Figure 70 Intervertebral disc degeneration in OCD and SEMD mice (F-J).
The average score of three independent scorers was plotte  for each disc. Each colour de-
notes individual measurements from one mouse. (F) The average degenera  on score was 
increased by 1.6 and  5.1 points in the OCD and SEMD mice respectively, compared to wild 
type controls. Interestingly, discs from OCD mice exhibited degeneration of the (H) nucleus
pulposus but scoring for the (I) annulus fibrosis was not statistically different. In contrast,
significantly different degenerative changes were observed in both the (H) nucleus pulpo-
sus and (I) annulus fibrosis of SEMD discs. (J) Table showing the average of the numeric
data used for the generation of graphs F, G, H and I. 
Key: +/+ (wild type) O/O (homozygous for OCD muta  on) S/S (homozygous for SEMD muta-
  on) SEM (standard error of the mean) NS (not significa t) *P≤0.05, ***P≤0.001, Two tailed 
T-test, n≥3. 
Total score                  AF-NP boundary 
Nucleus pulposus Annulus   brosis  
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       There was no correlation between the severity of these degenerative changes and the 
degree of scoliotic curvature, indicating that IDD in the SEMD model is distinct from the 
scoliotic phenotype (Figure 71). There was however an association with the position of the 
IVD, with disc degeneration correlating with distance from the head (n=4, Figure 72). A 
similar trend was not observed in OCD (n=5, Figure 72C) or wild type mice (n=3, data not 
shown). 
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Figure 71 Severity of scoliosis does not correlate with IDD in SEMD mice.
The rela  onship between the degree of spinal curvature and intervertebral disc degenera-
  on (IDD) was assessed in 9 week old male SEMD mice. (A) Radiographic image of a 9 week 
old SEMD mouse exhibiting scoliosis. The severity of the spine curvature was quantified by 
measuring the Diab angle(θ). Mice exhibiting scoliosis had a Diab angle≥12 (B) Graph of the 
degeneration scores of individual intervertebral discs plotted against the Diab angle (the 
degree of spinal curvature). Each colour denotes individual measurements from one mouse. 
There was no overt association between the severity of scoliotic curvature and IDD in SEMD 
mice. (C) Table showing the average of the numeric data used for the generation of graph B. 
Key: SEM (standard error of the mean) scale bar = 5mm, n=4. 
A   B 
C 
Diab angle (⁰) 9.47 30.06 15.68 4.75 
Average degenera  on score±SEM 7.33±1.13 6.17±1.25 6.00±1.36 6.25±0.99 
10θ 
+/+
S/S 
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Figure 72 Association between disc level and IDD in OCD and SEMD mice.
The associati n between the degree of intervertebral disc degenera  on and the level of the 
disc within the thoracic spine was assessed in 9 week old male SEMD mice. (A) Schematic of 
the numbered intervertebral discs in the murine spine. Diagram adapted from LifeMap Dis-
covery, accessed May 2018 (Edgar et al. 2013). (B) Graph of the degeneration scores of
intervertebral discs at levels T1-4, T5-7 and T8-10. The average degeneration score 
increased by 2 points at each stage measured as the distance from the head increased. Each 
colour denotes individual measure-ments from one mouse. (C) There was no correlation 
between disc level and severity of disc degeneration in OCD mice. (D) Table showing the 
average of the numeric data used for the generation of graphs B and C. 
Key: SEM (standard error of the mean) *P≤0.05, ***P≤0.001,Two tailed T -test, n≥4. 
A  B 
 C 
D 
Disc level 1-4 8-10 5-7 
Average degeneration score (SEMD) ±SEM 4.14±0.49 8.11±0.18 6.21±0.33 
Average degeneration score (OCD) ±SEM 3.06±0.53 2.78±0.22 2.62±0.40 
100μM 
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5.8 Summary
       The aim of this chapter was to further investigate and compare the tissue pathology of the 
OCD and SEMD mouse models, compared to wild type controls, using quantitative 
methodology. In vivo cell labelling and a range of histochemical techniques were used to 
analyse cell number, apoptosis and proliferation in the tibial growth plate and osteoclast 
number and degree of mineralisation of the underlying bone. RNA-seq and immunoblotting 
were used to assess the expression and composition of the extracellular matrix. The structure 
and degeneration of the spine was analysed using histo-morphometry. Histochemical analysis 
of tibial growth plate cartilage from SEMD mice indicated that the proliferative zone contained 
a reduced number of cells due to a reduction in the chondrocyte proliferation rate. This 
analysis also indicated that the expansion of the hypertrophic zone was due to increased cell 
number rather than greater cellular volume. In addition to this, dysregulated apoptosis was 
observed, with an increase in programmed cell death in the hypertrophic zone. In contrast, 
the relative proportion of cells in each zone and the chondrocyte proliferation rate were 
unaffected in growth plates from OCD mice. There was a difference in programmed cell death 
however, with increased apoptosis observed on the chondro-osseous border between the 
growth plate cartilage and bone. Analysis of the calcified cartilage and underlying trabecular 
bone indicated no difference in bone calcification or osteoclast number in tissue from OCD 
and SEMD mice compared to wild type controls. This suggested that the removal of 
extracellular matrix and subsequent mineralisation during bone formation were not affected 
in these mouse models. Transcriptomic and immunoblotting analysis confirmed that the 
composition of the cartilage extracellular matrix is altered in both the OCD and SEMD mouse 
models as cartilage from mice homozygous for the OCD mutation showed increased gene 
expression of tenascin X. There was no change in the transcript level of COMP in mutant 
cartilage compared to wild type controls; however, SDS-PAGE Western blotting showed 
decreased abundance of the COMP protein in cartilage from both OCD and SEMD mice. 
Transcript levels of type II collagen were also unaffected in OCD and SEMD; however, SDS-
PAGE Western blotting analysis of femoral head cartilage indicated that collagen type II 
expression is decreased in OCD cartilage. Furthermore, Western blotting analysis of OCD and 
SEMD chondrocytes suggested that the processing of procollagen to the mature form may be 
affected in these models. Histo-morphometric analysis of the vertebral column indicated that 
both the OCD and SEMD mouse models exhibit reduced vertebral body height and 
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morphological changes associated with intervertebral disc degeneration. Pathological 
changes in the SEMD spine were more severe, with platyspondyly and degenerative changes 
in both the annulus fibrosis and nucleus pulposus.  
       In conclusion, both the OCD and SEMD mouse models exhibit dysregulated apoptosis, 
altered matrix composition and intervertebral disc degeneration. Pathological changes in both 
the tibial growth plate and vertebral column of SEMD mice were noticeably more severe, with 
decreased proliferation, increased hypertrophy and greater disc degeneration. In order to 
explain why these two mutations in the G3 globular domain of aggrecan elicit such different 
tissue pathologies, the potential disease mechanisms of autophagy and cellular stress were 
investigated in the following chapter.  
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Chapter 6. Disease Mechanisms of the SEMD and OCD Mouse 
Models
In order to identify potential disease mechanisms, a biased and non-biased approach 
was used. RNA-seq was used to generate a transcriptomics profile of both mouse models for
a broad spectrum analysis. In parallel to this a more biased approach was used based on the 
data obtained in the previous two chapters. The analysis of the tissue pathology performed 
in Chapter 4 indicated that both the SEMD and OCD causative mutations cause delayed
secretion of aggrecan and retention of mutant protein within the endoplasmic reticulum. 
Retention of mutant protein in mouse models of other chondrodysplasias has been shown to 
cause endoplasmic reticulum stress (Briggs, Bell et al. 2015) as the ER upregulates 
chaperones to try and re-fold the misfolded protein. The classical ER stress pathway is the 
unfolded protein response (UPR) and so the genes and proteins involved in this pathway 
were selected as candidates for investigation of the disease mechanism using transcriptomics 
analysis and Western Blotting. In addition to this, the UPR has also been shown to interact 
with a number of pathways involved in protein degradation such as autophagy and the 
proteasome. Immunofluorescent staining for autophagic markers, chemical autophagy 
inhibition and Western blotting were therefore used to investigate potential dysregulation of 
autophagy.  
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6.1 Transcriptomic analysis of growth plate cartilage 
RNA-sequencing was used to investigate and compare the transcriptomics profile of 
mice homozygous for either the SEMD (D1983N) or OCD (V2019M) Acan mutation with those 
of wild type littermates. Total mRNA was extracted from femoral and tibial cartilage at 5 days 
of age. Samples were submitted for RNA-sequencing in triplicate. RNA-sequencing and the 
subsequent initial transcriptomics analysis were performed in house by the Newcastle 
University Genomics Core Facility and the Bioinformatics Support Unit. Differentially 
expressed genes which exhibited a biologically meaningful change (fold change ≥1.5 or ≤-1.5) 
were used for subsequent DAVID analysis (Huang, Sherman et al. 2009) to identify enriched 
biological themes. REViGO was then used to summarise the resultant gene ontology (GO) 
terms by clustering functionally redundant terms (Huang, Sherman et al. 2009). Cluster 
representatives or ‘umbrella terms’ were selected based on p-values supplied by DAVID. A 
SimRel semantic similarity measure (C) of 0.5 was used. This reduced the similarity between 
the GO terms in each cluster but still indicated a 99% chance of above-background similarity. 
A lower SimRel semantic similarity measure was not used to avoid the removal of non-
redundant GO terms from the analysis (Huang, Sherman et al. 2009, Supek, Bošnjak et al. 
2011). A uniqueness score was provided to assess the similarity of each GO term to the 
overall group. A dispensability score was also given, with a higher value indicating greater 
redundancy with other GO terms. 
2318 genes were significantly differentially expressed in cartilage extracted from mice 
homozygous for the SEMD mutation compared to wild type controls with 1484 exhibiting a 
biologically meaningful change (Figure 73). The most significantly enriched terms in REViGO 
analysis of the SEMD transcriptome were ‘flagellated sperm motility’ and 'anterior/posterior 
pattern specification' (Table 5).
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Term ID Description P-value Uniqueness Dispensability 
GO:0030317 flagellated sperm motility 1.38E-03 0.79 0.00 
GO:0032259 methylation 9.12E-02 0.95 0.00 
GO:0035456 response to interferon-beta 3.16E-02 0.90 0.00 
GO:0061025 membrane fusion 2.45E-02 0.87 0.02 
GO:0009952 anterior/posterior pattern 
specification 
3.09E-03 0.69 0.05 
GO:0051781 positive regulation of cell division 2.88E-03 0.80 0.11 
GO:0051321 meiotic cell cycle 3.20E-02 0.76 0.13 
GO:0070050 neuron cellular homeostasis 3.24E-03 0.79 0.14 
GO:0000012 single strand break repair 3.85E-02 0.91 0.18 
GO:0010807 regulation of synaptic vesicle 
priming 
1.92E-02 0.63 0.30 
GO:0003333 amino acid transmembrane 
transport 
3.40E-02 0.74 0.32 
GO:0015937 coenzyme A biosynthetic process 4.61E-02 0.76 0.36 
GO:0006468 protein phosphorylation 4.82E-02 0.85 0.37 
GO:0006355 regulation of transcription, DNA-
templated 
9.33E-03 0.78 0.38 
GO:0042391 regulation of membrane potential 3.53E-02 0.84 0.39 
GO:0055085 transmembrane transport 3.16E-03 0.83 0.41 
GO:0010459 negative regulation of heart rate 3.85E-02 0.63 0.43 
GO:0070286 axonemal dynein complex 
assembly 
3.85E-02 0.77 0.48 
GO:0070207 protein homotrimerisation 4.86E-02 0.86 0.48 
Table 5 REViGO GO terms in the SEMD transcriptome. 
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1157 differentially expressed genes were found in cartilage extracted from mice 
homozygous for the OCD mutation compared to wild type controls, with 990 differentially 
expressed genes exhibited a biologically meaningful change (Figure 74). The most 
significantly enriched terms in REViGO analysis of the OCD transcriptome were ‘ion 
transport' and 'cell adhesion' (Table 6).
218
219
Term ID Description P-value Uniqueness Dispensability 
GO:0002376 immune system process 2.77E-03 0.97 0.00 
GO:0006629 lipid metabolic process 2.06E-03 0.85 0.00 
GO:0006816 calcium ion transport 2.21E-02 0.87 0.00 
GO:0007155 cell adhesion 3.63E-04 0.87 0.00 
GO:0031639 plasminogen activation 2.34E-02 0.95 0.04 
GO:0007283 spermatogenesis 2.42E-03 0.64 0.08 
GO:0007169 transmembrane receptor protein tyrosine 
kinase signalling pathway 
3.05E-03 0.79 0.08 
GO:0005975 carbohydrate metabolic process 1.64E-03 0.95 0.09 
GO:0016126 sterol biosynthetic process 3.89E-03 0.73 0.15 
GO:0030317 flagellated sperm motility 2.49-E02 0.83 0.18 
GO:0006954 inflammatory response 2.17E-02 0.90 0.28 
GO:0006811 ion transport 2.39E-04 0.90 0.31 
GO:0072166 posterior mesonephric tubule 
development 
4.81E-02 0.71 0.37 
GO:0034625 fatty acid elongation, monosaturated fatty 
acid 
3.32E-02 0.75 0.51 
GO:0045453 bone resorption 2.22E-02 0.63 0.45 
GO:0008202 steroid metabolic process 1.66E-02 0.78 0.47 
GO:1901381 positive regulation of potassium ion 
transmembrane transport 
4.43E-02 0.71 0.50 
Table 6 REViGO GO terms in the OCD transcriptome. 
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2414 differentially expressed genes were found in cartilage extracted from mice 
homozygous for the OCD mutation compared to SEMD cartilage, with 1685 differentially 
expressed genes exhibited a biologically meaningful change (Figure 75A). Only 2.5% of the 
differentially expressed genes were downregulated in both OCD and SEMD cartilage and 9.3% 
upregulated (Figure 75B) indicating that the OCD and SEMD trancriptomes have distinct 
disease signatures. The most significantly enriched terms in REViGO analysis were ‘cilium 
movement’ and 'transmembrane transport' (Table 7). 
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Term ID Description P-value Uniqueness Dispensability 
GO:0002376 immune system process 9.42E-03 0.97 0.00 
GO:0003341 cilium movement 4.96E-04 0.80 0.00 
GO:0006821 chloride transport 5.74E-03 0.86 0.00 
GO:0010923 negative regulation of phosphatase 
activity 
5.37E-03 0.83 0.02 
GO:0071773 cellular response to BMP stimulus 1.39E-02 0.88 0.02 
GO:0009952 anterior/posterior specification 7.40E-04 0.55 0.05 
GO:0045110 intermediate filament bundle assembly 2.30E-02 0.81 0.10 
GO:0071502 cellular response to temperature 
stimulus 
1.58E-02 0.92 0.19 
GO:0009607 response to biotic stimulus 4.18E-02 0.91 0.28 
GO:0055085 transmembrane transport 6.13E-04 0.88 0.31 
GO:0035990 tendon cell differentiation 9.72E-03 0.61 0.37 
GO:0045662 negative regulation of myoblast 
differentiation 
2.11E-02 0.56 0.42 
GO:0046676 negative regulation of insulin secretion 6.46E-03 0.69 0.43 
GO:0002024 diet induced thermogenesis 1.48E-02 0.63 0.43 
GO:2000543 positive regulation of gastrulation 3.39E-03 0.54 0.45 
Table 7 REViGO GO terms between the OCD and SEMD transcriptomes. 
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6.1.1 The unfolded protein response and apoptosis 
Histological analysis in Chapter 4 had shown that mutant aggrecan was intracellularly 
retained in both OCD and SEMD cartilage. In order to assess whether this protein retention 
elicited the unfolded protein response a panel of 66 genes was assembled (Appendix J). 
These genes were known to be associated with the three branches of the UPR (PERK, ATF6 
and IRE1) the ER overload response (Kong, Li et al. 2015) and regulated IRE1-dependent 
decay of mRNA (RIDD) (Maurel, Chevet et al. 2014). There was no statistical difference in the 
gene expression of either canonical (Hspa5, Atf6, Ern1, Eif2ak3) or non-canonical stress 
sensors (Creb3, Creb3l2, Creb3l3, Creb3l4). However, there was a difference in the expression 
of 11 downstream stress-associated genes in SEMD cartilage, including a 3-fold increase in 
the ERAD component Derl3 and a 2-fold increase in the chaperone Hspa12a. This 
transcriptomic data suggested that SEMD chondrocytes may exhibit mild ER stress but that 
the classical UPR is not upregulated in either OCD or SEMD cartilage. Histological analysis in 
Chapter 5 had indicated that apoptosis is upregulated in both OCD and SEMD cartilage. This
was also suggested by transcriptomic analysis, with increased gene expression of Bcl2l15 and 
decreased expression of the anti-apoptotic Bcl2a1d in OCD cartilage and both a 7-fold
decrease  in Bcl2a1d and 2-fold increase in the pro-apoptotic Trib3 in SEMD cartilage.
6.1.2 Autophagic flux 
Transmission electron microscopy in Chapter 4 had suggested that autophagy may 
be either increased or dysregulated in OCD and SEMD cartilage. Transcriptional analysis 
indicated that the aggresome-autophagy pathway may be upregulated in SEMD cartilage, 
with increased expression of Park2, a known mediator of aggresome formation, and Ulk3, an 
ULK1-independant autophagy inducer (Chin, Olzmann et al. 2010, Braden and Neufeld 2016). 
In contrast, there was decreased gene expression of the alternative autophagy markers Eva1a 
and Rab9b (which is involved in autophagosome-lysosome fusion) in OCD cartilage, 
suggesting that autophagy may be dysregulated (Hirota, Yamashita et al. 2015, Hu, Li et al. 
2016) (Appendix J). This indicates that the regulation of alternative autophagy pathways
(which selectively degrade protein aggregates or organelles) may be altered between OCD 
and SEMD cartilage. 
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Upregulated genes in SEMD cartilage (including those annotated with the GO term 
‘membrane fusion’) encoded for SNARE complex components and vesicle transport 
regulators (Appendix J). These included motor proteins (Kif5a, Kifc2, Kif17) syntaxins (Stx1a,
Stx1b, Stx16) SNAPs (Napb) and synaptobrevin (Vamp1) (Fukuda 2007). In contrast, genes 
associated with vesicular transport were downregulated in OCD cartilage, such as 
synaptotagmins (Syt8, Syt14, Sytl2) syntaphilin (Snph) and Rab GTPases (Rab3c, Rab9b, 
Rab25). Vesicle trafficking also regulates the assembly and organisation of primary cilia 
(Hsiao, Tuz et al. 2012) REViGO analysis indicated that cilia organisation (under the umbrella 
term 'axonemal dynain complex assembly') is an enriched biological theme in SEMD
cartilage with increased gene expression of Kif motor proteins, Fam161a and Msn1. 
6.1.4 Regulatory signalling and differentiation 
The GO term ‘anterior/posterior pattern specification’ was enriched in SEMD cartilage 
compared to both OCD and wild type cartilage. Further analysis of the 65 genes under this 
umbrella term revealed that many upregulated genes belonged to the HOX transcription 
factor family with the Hoxa (Hoxa5, Hoxa9, Hoxa13) Hoxc (Hoxc4, Hoxc5, Hoxc6, Hoxc8) and 
Hoxd (Hoxd3, Hoxd4) gene clusters represented (Appendix J). The role of Hox genes in 
developmental patterning is well-characterised; however, they have also been shown to 
have a regulatory role in postnatal chondrocyte maturation (González-Martín, Mallo et al. 
2014). The highest upregulated gene Hoxd3 (12-fold increase) may be a marker of terminal 
chondrocyte differentiation and promote angiogenesis (Charboneau, East et al. 2005, 
Okuma, Hirata et al. 2015). WNT signalling also appeared to be perturbed in SEMD cartilage 
with decreased gene expression of WNT signalling components (Wnt4, Wnt5b, Fzd1) and 
increased expression of the WNT signalling inhibitor Wt1 (Kim, McGarry et al. 2009).
In contrast, Wt1 and another WNT signalling inhibitor Dkk1 were downregulated in
OCD cartilage, with a 17-fold decrease in OCD cartilage compared to SEMD samples. Bmp8a, 
Gdf1, Runx2, Runx3, and the IHH/PTHRP signalling receptors Ptch1 and Pth1r were also
significantly downregulated in OCD cartilage compared to wild type controls, suggesting that 
6.1.3 Vesicle trafficking and cilia formation 
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regulatory signalling may be altered. Gene expression changes in OCD cartilage were also
associated with osteoblast differentiation and bone formation, with decreased expression of 
Satb2 and mineralisation regulators such as the SIBLING phosphoproteins osteopontin (Spp1) 
bone sialoprotein (Ibsp) and Dmp1. Osteoclasts/chondroclasts markers such as tartrate-
resistant phosphatase (Acp5) and the osteoclast fusion mediator Ocstamp were also 
downregulated, suggesting that cartilage remodelling and bone formation may be
perturbed in OCD cartilage.  
6.2 Immunoblotting analysis of the unfolded protein response 
Transcriptomics profiling had indicated that gene expression of BIP, the master 
regulator of the classical UPR, was not upregulated in either SEMD or OCD chondrocytes at 
five days of age. In order to validate this finding at protein level Western blotting was 
performed on protein extracted from OCD, SEMD and wildtype femoral head cartilage at 3 
weeks of age. There was no statistical difference in the protein levels of BiP in cartilage 
extracted from either SEMD or OCD mice when compared with wild type littermates (Figure 
76).
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6.3 Immunofluorescent analysis of indian hedgehog signalling
Transcriptional analysis had indicated that regulatory signalling pathways such as the 
IHH/PTHRP feedback loop may be altered in OCD cartilage. Furthermore, the hedgehog 
signalling pathway is known to involve the primary cilium and gene expression associated 
with cilium organisation was unregulated in SEMD cartilage. Immunofluorescence was 
therefore used to assess the relative abundance and localisation of the secreted mature form 
of IHH in the growth plates of mice at three weeks of age. IHH is known to be highly expressed 
by pre-hypertrophic chondrocytes (Gualeni, Facchini et al. 2010) and staining for secreted 
IHH was greatest in the pre-hypertrophic and hypertrophic zones of wild type cartilage 
(Figure 77). There was no overt difference in staining intensity for indian hedgehog in OCD
cartilage. Staining for indian hedgehog was reduced in SEMD cartilage, with the greatest 
staining intensity observed on the chondro-osseous border and in the forming secondary 
ossification centre, indicating that the distribution or anchoring of secreted indian hedgehog
may be altered in the SEMD growth plate.  
228
In
d
ia
n
 h
e
d
ge
h
o
g 
+/+                                                        O/O                                                          S/S 
Figure 77 Localisationt and abundance of indian hedgehog in OCD and SEMD mice.
Immuno  uorescent staining of matching   bial growth plate secti ns from male 3 week old 
wild type, OCD and SEMD mice. The intensity of staining for indian hedgehog was reduced 
in growth plates from SEMD mice. There was no di  erence in staining intensity in growth 
plates from OCD mice compared to wild type controls. 
Key: +/+ (wild type) O/O (homozygous for the OCD muta  on) S/S (homozygous for the 
SEMD muta  on) scale bar = 50µm, n=3 
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6.4 Analysis of autophagic flux 
The relative abundance of autophagic vesicles in the growth plates of mice at three 
weeks of age was assessed with immunofluorescence. LC3B is a well-characterised marker of 
autophagy, which undergoes lipidation for recruitment to the autophagosome. 
Immunofluorescent staining for LC3B in wild type controls was mainly cytosolic, with some 
punctate staining observed, particularly in the early hypertrophic zone (Figure 78) (Srinivas, 
Bohensky et al. 2008). Resting, proliferative and early hypertrophic chondrocytes in SEMD 
cartilage exhibited increased punctate staining for LC3B (n=3) compared to wild type 
controls. In contrast, only proliferative OCD chondrocytes displayed the increased punctate 
LC3B staining associated with autophagosomes (n=3).  
Western blotting and autophagy inhibition was used to assess autophagic vesicle 
accumulation. Femoral and tibial cartilage was extracted from seven day old mice 
homozygous for either the OCD mutation and wild type controls. Cartilage explants were 
treated with the end-stage autophagy inhibitor chloroquine for 0, 1, 3, and 6 hours and 
analysed by Western blotting and densitometry. The scaffold protein p62 acts as a cargo 
receptor for ubiquitylated substrates and so is degraded by autophagy (Navone, Genevini et 
al. 2015). It can therefore be used as a marker of autophagic flux. Western blotting of wild 
type protein extracts showed significantly increased accumulation of P62 at 3 and 6 hours of 
chloroquine treatment, consistent with inhibition of basal macroautophagy (Figure 79). The 
expression level of P62 (relative to GAPDH) was increased in OCD cartilage compared to the 
wild type control in untreated samples, but P62 abundance did not statistically increase with 
chloroquine-treatment. This indicated that the increase in autophagosomes in OCD 
chondrocytes may be due to defective rather than upregulated autophagy or that P62 is not 
involved in the OCD autophagic pathway. 
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6.5 Summary 
The aim of this chapter was to identify and compare potential disease mechanisms of 
the OCD and SEMD disorders. Transcriptomic analysis of RNA at 5 days of age and 
immunoblotting of protein at 3 weeks of age indicated that the classical UPR is not 
upregulated in OCD or SEMD cartilage but that SEMD chondrocytes exhibit gene changes 
associated with mild cellular stress. Comparison of the OCD and SEMD transcriptomes 
suggested that genes associated with vesicular transport, cilia organisation and regulatory 
pathways such as WNT signalling are differentially expressed between OCD and SEMD 
cartilage. Immunofluorescent staining for the secreted indian hedgehog also suggested that 
the distribution of this signalling molecule is altered in SEMD cartilage. OCD cartilage 
exhibited decreased expression of genes associated with osteoblast differentiation and 
cartilage mineralisation suggesting that cartilage calcification may be affected. Furthermore, 
immunoblotting and immunofluorescence suggested that autophagy may be impaired in OCD 
cartilage.  
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Chapter 7. Discussion 
 The aim of this thesis was to characterise and compare two knock-in mouse models 
with mutations in the C-type lectin domain of aggrecan. These two mutations are only 36 base 
pairs apart but result in two very different phenotypes; one with severe short stature and a 
range of skeletal abnormalities (spondyloepimetaphyseal dysplasia) and one with mild short 
stature and osteochondritis dissecans (familial osteochondritis dissecans). There are a number 
of well-studied aggrecan models in the literature, however all (except the A1946V Acan 
mouse) are known to be caused by either reduced aggrecan abundance or defective 
proteoglycan sulfation in the growth plate. Therefore, although they provide an invaluable 
insight into aggrecan’s roles in growth plate organization, regulatory signalling, chondrocyte 
survival and differentiation (Wai, Ng et al. 1998, Lauing, Cortes et al. 2014) they cannot be 
used to assess the effect of human aggrecan mutations. The work presented in this thesis is 
therefore the first in-depth in vivo study of aggrecan mutations known to cause human genetic 
disorders. 
 
7.1. The homozygous D1983N Acan mouse recapitulates the SEMD phenotype 
 
 Mice homozygous for the D1983N Acan mutation exhibited extreme short stature 
from birth indicating that the onset of SEMD occurs during foetal development, although 
interestingly there was no overt effect on skeletal patterning at birth and no statistical effect 
on pup viability. SEMD is recessive in the human population, consistent with the mouse SEMD 
model in which homozygosity for the D1983N Acan allele was required to recapitulate the 
SEMD phenotype (Tompson, Merriman et al. 2009). The SEMD mouse replicated the human 
SEMD disproportionate short stature phenotype with characteristic skeletal abnormalities 
such as a bell-shaped rib cage, brachydactyly, irregular epiphyses, hip dysplasia, mid-face 
hypoplasia and relative mandibular prognathism (Tompson, Merriman et al. 2009). The 
reduction in size of both the long bones and craniofacial bones indicated that the SEMD 
mutation affects both endochondral and intramembranous ossification. The mouse 
phenotype did differ from the human phenotype in the degree of spinal involvement. All three 
of the human patients exhibited mild thoracic scoliosis and a range of other spinal 
malformations including cervical-vertebral clefts. Radiographs and skeletal preps of the SEMD 
mouse did not display any visible cervical-vertebral clefts. However, a third of the mice 
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displayed mild thoracic scoliosis at three weeks of age, with the incidence of spine curvature 
increasing to 3 in 5 by 9 weeks of age. The degree of spine curvature was very variable and 
although vertebral wedging was observed in the most severely curved spine, it was not 
possible to assess a greater number of mice. A more in-depth analysis using in vivo micro CT 
imaging would therefore be necessary to assess the progression of scoliosis in individual mice 
throughout post-natal development. However, it was not within the scope of this initial study 
to investigate spinal abnormality during the aging process and so no further research was 
conducted after this point. The incomplete penetrance of the spinal phenotype may be due 
to the difference in posture and gait between bipedal upright humans and quadrupedal mice, 
which will alter the physical force and pressure placed on the spine during development. As 
examples, severe kyphoscoliosis is not observed in 100% of FGFR3 null mice and there is great 
debate as to whether rodent tail models accurately model the human lumbar spine in 
intervertebral disc degeneration (Gao, Chen et al. 2015, Daly, Ghosh et al. 2016). 
 It was not possible to use homozygous mutant breeding crosses during this study due 
to a high level of infanticide. The increased pup survival which occurred in crosses which had 
an additional heterozygote mutant female suggested that homozygous breeding pairs 
struggled to care for their offspring. Furthermore, the jaw misalignment caused by the 
mandibular prognathism resulted in a very high incidence of malocclusion. Mouse incisors 
(unlike humans) have an open root and grow continuously throughout the animal’s lifetime. 
Rodents must therefore gnaw in order to grind these teeth down, which is impaired when the 
jaw is not aligned correctly. Malocclusion impairs the animal’s ability to eat, impacting survival 
and growth unless the teeth are clipped upon weaning and softer food provided. This provides 
an important example of the need to be aware of species-specific downstream effects of a 
mutation.  
 
7.2. The homozygous V2019M Acan mouse recapitulates the short-stature OCD 
phenotype 
 
 Homozygosity for the OCD mutation (V2019M Acan) also had no effect on pre-natal 
lethality, consistent with clinical observations of human fOCD patients who do not report 
higher incidence of miscarriage (Stattin personal communication 2017). However, in contrast 
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to SEMD mice, mice homozygous for the OCD mutation were not statistically smaller at birth 
and did not exhibit altered cranial vault morphology, indicating that this missense aggrecan 
mutation does not grossly affect skeletal development or intramembranous ossification. 
Furthermore, although this disorder is dominantly-inherited in the human population (Stattin, 
Wiklund et al. 2010) homozygosity for the OCD mutation was necessary to replicate the short 
stature fOCD phenotype in mice. This has previously been reported in other mouse models of 
skeletal dysplasia such as the homozygous D469del COMP mouse model of dominantly-
inherited human pseudoachondroplasia (Suleman, Gualeni et al. 2012). In contrast to the 
human fOCD phenotype, the homozygous V2019M Acan mouse did not display any other 
skeletal abnormalities, such as hip dysplasia, scoliosis or loose bodies in the joint spaces, 
although radiographic assessment was limited by the resolution of the X-ray machine 
available. Histological analysis also did not indicate the development of characteristic OCD 
lesions in mice homozygous for the mutation. However, proteoglycan content in the articular 
cartilage progressively declined up to 6 months of age, suggesting that these mice may be 
susceptible to joint degeneration due impaired resistance to mechanical loading. It is 
therefore possible that OCD or early-onset osteoarthritis may occur in aged OCD mice as 
observed with genetically-susceptible OA models such as the STR/ort mouse (Staines, Poulet 
et al. 2017). It may also be necessary to mechanically-challenge the mice by providing 
treadmills (Kotwal, Li et al. 2012) in order to cause the formation of lesions in the articular 
surface.  
 
7.3. OCD and SEMD mice exhibit intervertebral disc degeneration 
 
 Interestingly, both the OCD and SEMD mouse models exhibited early-onset 
intervertebral disc degeneration, which has not previously been reported in human patients 
but has been shown in other conditions in the aggrecanopathy phenotypic spectrum (Nilsson, 
Guo et al. 2014, Gkourogianni, Andrew et al. 2017, Tatsi, Gkourogianni et al. 2017). Scoring 
for changes in IVD structure indicated that the nucleus pulposus was the primary source of 
degeneration, consistent with current literature in this area (Inoue and Espinoza Orías 2011). 
Initial degeneration of the aggrecan-rich nucleus pulposus is characterised by proteoglycan 
loss, which causes decreased resistance to mechanical loading in the spine (Inoue and 
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Espinoza Orías 2011). It is therefore unsurprising that mice homozygous for mutations which 
cause delayed secretion of aggrecan would be susceptible to IVD degeneration. 
 
7.4. Aggrecan trafficking is impaired in OCD and SEMD cartilage 
 
 Histological and ultrastructural analysis indicated that both the OCD and SEMD 
mutations cause retention of mutant aggrecan within the endoplasmic reticulum, delaying 
trafficking of the core aggrecan protein to the Golgi. This is not surprising as the G3 domain is 
known to facilitate the secretion and folding of aggrecan and mutations in this domain have 
previously been shown to cause abnormal trafficking of the aggrecan polypeptide to the 
nucleus (Chen, Wang et al. 2001). This is however not consistent with previous in vitro analysis 
which suggested that the SEMD mutation does not affect aggrecan secretion (Tompson, 
Merriman et al. 2009). However, this analysis was performed using recombinant G3 domains 
rather than full length aggrecan and so the data presented in this thesis is likely to have greater 
biological relevance. Studies of the human V2303M ACAN OCD mutation have provided 
conflicting evidence on its effect on protein secretion. This appeared to vary depending on 
whether the study investigated early stage development in vitro (MSC or iPSC pellet culture, 
impaired secretion) or late-stage cartilage (arthroplasty cartilage, no effect on secretion) 
possibly reflecting that while aggrecan secretion is delayed by the OCD mutation it is not 
completely impaired. Transcriptomic analysis suggested that vesicle-mediated transport 
through exocytosis is altered in both OCD and SEMD cartilage. Aggrecan is known to be 
trafficked through the exocytotic pathway (Chen, Wang et al. 2001) and so this may reflect 
impaired constitutive or calcium-mediated regulated exocytosis trafficking (Kreutzberger, 
Kiessling et al. 2017). 
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7.5. Intracellular retention of mutant aggrecan does not elicit the UPR in OCD or SEMD 
cartilage 
 
 Studies of other skeletal dysplasia mouse models has shown that the intracellular 
retention of mutant protein often elicits the unfolded protein response (UPR) (Pirog-Garcia, 
Meadows et al. 2007, Nundlall, Rajpar et al. 2010). Transcriptional changes in SEMD cartilage 
suggested mild cellular stress and the rate of chondrocyte proliferation was decreased, a 
known downstream effect of ER stress (Gualeni, Rajpar et al. 2013). Furthermore, 
increased/spatially dysregulated cell apoptosis was observed in both OCD and SEMD cartilage. 
However, the classical UPR was not upregulated in either mouse model. This was confirmed 
by not only transcriptional and western blotting data but by ultrastructural analysis, which did 
not show any ER fragmentation or free ribosomes characteristic of endoplasmic reticulum 
stress (Kudelko, Chan et al. 2016). The master UPR regulator and chaperone BIP is known to 
preferentially bind hydrophobic residues, which may become exposed in misfolded proteins 
(Blond-Elguindi, Cwirla et al. 1993, Knarr, Gething et al. 1995). It is therefore possible that the 
OCD and SEMD mutations do not cause the exposure of hydrophobic residues and so do not 
cause the dissociation of BIP from ATF6, IRE1 or PERK. Mouse models of skeletal dysplasia 
without UPR have been reported (Suleman, Gualeni et al. 2012) and it is possible to 
hypothesise that cells may also be able to adapt to constant ER stress without eliciting the 
UPR.  
 
7.6. The macroautophagy pathway is altered in OCD and SEMD cartilage 
 
Histological and immunoblotting analysis suggested that autophagy may be dysregulated in 
OCD cartilage. Unfortunately due to difficulties in breeding mice homozygous for the SEMD 
mutation it was not possible to assess whether the increase in autophagosomes observed in 
SEMD cartilage was due to an upregulation or impairment of autophagy. Further work will 
therefore be required to determine whether autophagy is differentially regulated between 
OCD and SEMD chondrocytes. In order to assess whether increased mutant protein 
degradation might ease the metabolic burden of the cell and allow improved secretion of ECM 
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molecules, a brief pilot drug treatment study on limb explants was conducted. Carbamazepine 
(CBZ) treatment was previously shown to ameliorate the phenotype of metaphysical 
chondrodysplasia, Schmid type (MCDS) by acting through both autophagic and proteosomal 
pathways to degrade misfolded protein (Mullan, Mularczyk et al. 2017). CBZ treatment had 
no statistical difference on bone growth in either the OCD (n≥5) or SEMD (n=2) model 
(Appendix K). This suggested that drug amelioration of the autophagic and proteasomal 
pathways does not ameliorate the phenotype of these disorders. However, due to a lack of 
samples and a flawed experimental design, a larger more rigorous study would be required to 
make a scientific conclusion about the efficacy of this drug in these models. It was not possible 
to use commercial CBZ pellets for in vivo subcutaneous implantation due to restrictions on the 
minimum weight required for animals to undergo the procedure. However, it may be possible 
to utilise a gavaging technique to apply the drug in order to radiographically and histologically 
analyse post-natal bone growth in vivo. 
 
7.7. Altered matrix composition in OCD and SEMD cartilage may impair chondrocyte 
differentiation 
 
 In addition to the intracellular stress caused by the delayed secretion of mutant 
aggrecan it was also important to consider the extracellular effect of the mutant aggrecan 
once it was secreted into the matrix. Immunofluorescent and Western Blotting analysis had 
indicated that the expression of some key ECM structural proteins such as COMP was 
abnormal in both OCD and SEMD cartilage. This is consistent with current literature as the G3 
domain is known to mediate matrix organisation by the binding of aggrecan with other 
extracellular matrix molecules such as COMP and matrilin 3 (Olin, Morgelin et al. 2001, 
Lundell, Olin et al. 2004). A reduction in aggrecan abundance within the matrix and altered G3 
interactions are therefore likely to affect matrix composition. In addition to this, the SEMD 
mutation is situated in the CLD calcium coordinating loops, which facilitate calcium-
dependent binding (Tompson, Merriman et al. 2009) and the OCD mutation is found in the 
CLD ligand-interaction site (Tompson, Merriman et al. 2009, Stattin, Wiklund et al. 2010). In 
vitro studies have also shown that both the OCD and SEMD mutations disrupt binding with 
ECM molecules such as fibulin 1 and tenescin R (Tompson, Merriman et al. 2009, Stattin, 
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Wiklund et al. 2010). This altered matrix composition is likely to affect not only the structural 
integrity of the ECM but important regulatory signalling pathways necessary for correct 
differentiation within the growth plate. Aggrecan is particularly important for proper 
signalling as it binds to indian hedgehog through its GAG chains. The efficacy of this binding is 
affected by the degree of sulfation and so altered aggrecan abundance in the ECM would alter 
the distribution of secreted IHH within the growth plate. This is illustrated by mouse models 
with defects in proteoglycan sulfation such as the dtd mouse which exhibits altered IHH 
signalling and abnormal chondrocyte differentiation (Gualeni, Facchini et al. 2010). 
Furthermore, the aggrecan-null nanomelic chicken, which expresses a truncated aggrecan 
precursor, is characterised by altered IHH, BMP and FGF signalling causing reduced 
proliferation and premature hypertrophic maturation (Domowicz, Cortes et al. 2009). 
Interestingly, transcriptomic and immunofluorescent analysis of OCD and SEMD cartilage 
suggested that a number of signalling pathways including WNT and IHH/PTHRP may be altered 
between these two disorders. In addition to this, the formation of cilia (a fundamental 
structure in regulatory signalling such as hedgehog) was enriched in the SEMD transcriptome. 
Cell signalling and signal transduction can attenuate many downstream pathways including 
transcription, cell cycle and chondrocyte differentiation. Histological analysis indicated that 
both OCD and SEMD mice have a shortened growth plate compared to wild type controls. In 
addition to this, SEMD cartilage exhibited defective chondrocyte proliferation and a 
proportionally expanded growth plate, indicating that SEMD chondrocytes may exit the cell 
cycle early and enter hypertrophy prematurely. Histological analysis of OCD and SEMD 
cartilage at birth had indicated that mineralisation was not grossly affected. However, 
transcriptomic changes in 5 day old cartilage suggested that processes associated with 
cartilage ECM remodelling and bone formation such as osteoblast differentiation, 
chondroclast maturation and mineralisation may be disrupted in OCD cartilage. It is possible 
however that histological techniques may not be sufficiently sensitive to accurately assess 
calcium calcification. Future work could therefore be conducted using microCT to assess 
trabecular and cortical bone formation in mice after growth cessation. It would also be 
essential to assess the  gene expression of key markers such as collagen type II, collagen type 
X and osteopontin using in situ hybridisation in order to confirm whether chondrocyte 
differentiation is disrupted in OCD and SEMD cartilage. 
 In summary, this thesis characterises the first in vivo models of skeletal dysplasia 
caused by aggrecan mutations. Patho-molecular analysis thus far suggests that the disease 
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mechanisms of these two disorders are distinct, however, both are characterised by altered 
matrix organisation, disrupted signalling and impaired differentiation.  
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Appendix B (i) Antibodies and dilutions 
Primary antibody Dilution 
for IHC 
Dilution for 
Western Blot 
Supplier 
Monoclonal rabbit against 
aggrecan 
1:400 n/a Professor Tim Hardingham, 
University of Manchester 
Polyclonal goat against BIP n/a 1:500 Santa Cruz (SC105) 
Monoclonal rat against BrdU 1:100 n/a Abcam (AB6326) 
Polyclonal rabbit against collagen 
type II 
1:500 n/a Abcam (AB34712) 
Monoclonal mouse against 
collagen type II 
n/a 1:200 Abcam (AB185430) 
Polyclonal guinea pig against 
collagen type IX 
1:500 n/a Professor Frank Zaucke, 
Orthopedic University 
Hospital Friedrichsheim 
Polyclonal rabbit against collagen 
type X 
1:500 n/a Professor Karl Kadler, 
University of Manchester 
Polyclonal rabbit against COMP 1:100 1:1000 Genetex (GTX14515) 
Monoclonal mouse against 
GAPDH 
1:40 000 Millipore (MAB374) 
Polyclonal rabbit against indian 
hedgehog 
1:100 n/a Abcam (AB39634) 
Polyclonal rabbit against LC3B 1:100 n/a Cell signaling (2775S) 
Polyclonal goat against matrilin 3 1:500 n/a R&D (AF3357) 
Monoclonal mouse against P62 n/a 1:10 Abnova (H00008878-M01) 
n/a
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Secondary antibody Dilution 
for IHC 
Dilution for 
Western Blot 
Supplier 
Polyclonal goat anti-rabbit IgG 
(H+L) Alexafluor 594  
1:200 n/a ThermoFisher Scientific 
(A11012) 
Polyclonal donkey anti-goat IgG 
(H+L) Alexafluor 488 
1:200 n/a ThermoFisher Scientific 
(A11055) 
Polyclonal goat anti-guinea pig 
IgG (H+L) Alexafluor 488 
1:200 n/a ThermoFisher Scientific 
(A11073) 
Polyclonal donkey polyclonal 
anti-rat IgG (H+L) Alexafluor 488 
1:200 n/a ThermoFisher Scientific 
(A21208) 
IRDye 800CW goat anti-rabbit 
IgG (H + L) 
n/a 1:5000 Licor (P/N 925-32211) 
IRDye 680RD goat anti-mouse 
IgG (H + L) 
n/a 1:5000 Licor (P/N 925-68070) 
IRDye 800CW donkey anti-goat 
IgG (H + L) 
n/a 1:5000 Licor (P/N 925-32214) 
Appendix B (ii) Immunofluoresence secondary antibody controls (no primary antibody) 
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Appendix C Solutions 
 
Blocking buffer   5% bovine serum albumin in PBS-T 
 
Borate buffer (0.1M)   30.9g boric acid  
     13.5ml 10M NaOH 
dH2O to 1L 
pH adjusted to 8.5 
 
Buffer I   0.15M NaCl 
(Sequential extraction) 50mM Tris 
pH adjusted to 7.4 
    protein inhibitors added before use 
 
Buffer II    1M NaCl 
(Sequential extraction) 50mM Tris  
10mM EDTA 
pH adjusted to 7.4 
    protein inhibitors added before use 
 
Buffer III   4M GuHCl 
(Sequential extraction) 50mM Tris  
10mM EDTA 
ph adjusted to 7.4 
    protein inhibitors added before use 
 
Acid alcohol (1%)  990ml 70% ethanol 
    10ml hydrochloric acid 
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Alcian Blue    15mg Alcian Blue 8GX 
    80ml 95% EtOH 
    20ml glacial acetic acid 
    pH adjusted to 0.75 
 
Alizarin Red S   50mg/L Alizarin Red S 
2% (w/v) KOH) 
 
Citric buffer   10mM citric acid 
    0.05% Tween 20 
    pH adjusted to 6.0 
 
Lysis buffer    25 mM NaOH 
(hotshot)                   0.2 mM EDTA pH8.0 
 
                      
Neutralising buffer  40 mM Trizma Hydrochloride pH 5.0   
(hotshot)    
 
 
Maintenance media   500ml DMEM F-12  
    10% fetal bovine serum 
    50U/ml penicillin 
    50μg/ml streptomycin  
    50μg/ml non-essential amino acids 
    2μl/ml L-ascorbic acid 2-phosphate sesquimagnesium  
    salt 
 
PBS    1 PBS tablet/200ml 
 
PBS-T    1 PBS tablet/200ml 
    0.1% (v/v) Tween-20 
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RIPA buffer 10mM Tris pH7.4 
1% sodium deoxycholate 
150mM NaCl 
0.1% SDS 
SDS-PAGE loading buffer 4ml 1.5M Tris-Hcl (pH7 6.8) 
50% glycerol  
2g sodium dodecyl sulfate 
1ml 1% bromophenol blue 
dH2O to 20ml 
TAE buffer 242 g Tris-base 
57.1 mL glacial acetic Acid 
100 mL 0.5 M EDTA pH 8.0 
dH2O to 1L 
Toluidine Blue 0.04g Toluidine Blue 
100ml 0.1M sodium acetate buffer (pH3.75-4.25) 
Transfer buffer (20x) 1M Tris 
0.77M glycine 
25mM SDS 
Transfer running buffer 5% transfer buffer (20x) 
20% methanol 
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Trap staining      0.5ml Fast Garnet GBC base solution 
solution   0.5ml sodium nitrite solution 
    45ml pre-warmed (37oC) distilled water  
    0.5ml Naphthol AS-BI phosphate solution  
    2ml acetate solution  
    1ml tartrate solution 
 
Wash solution   96% EtOH:PBS     9:1 ratio 
(sequential extraction)       
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Appendix D(i) Primer sequences
Primer Sequence (5’ to 3’) 
D115.2 GTGCATAGGGCTTCTGTAGTAAGG 
5182LRPCR2 GTTGTGCCCAGTCATAGCCGAATAG 
D115.3 AAATGAATCCTTGAGGTTTATG 
D115.4 GCCCATGACTTTCATCTCC 
SD24 CTAATGTTGTGGGAAATTGGAGC 
SD25 CTCGAGGATAACTTGTTTATTGC 
P12 GGCTGGATAGACTTTACC 
P13 GGTATGACTTGGCTAGAC 
SY01.14 GAAGGCTCCTCTTGGGCTTAG 
LRPCRneo1 AATGGGCTGACCGCTTCCTCGTGCTTT 
SY01.15 ACAGGGAGCTAGAGGAAG 
SY01.16 GCTGTCACACCTTCATTTCC 
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Appendix D(ii) PCR thermocycler programme
Step Temperature (°C) Time (minutes) Number of cycles 
Initial denaturation 95 5 1 
Denaturation 95 1 
30 Primer annealing 
D115.3/D115.4 53 
1 
P12/P13 53 
SD24/SD25 58 
SY01.15/SY01.16 56 
Elongation 72 1 
Elongation 72 5 1 
Appendix E Embedding programme
70% ethanol 1 hour 
90% ethanol 45 minutes 
95% ethanol 45 minutes 
100% ethanol 45 minutes 
100% ethanol 45 minutes 
100% ethanol 45 minutes 
xylene 30 minutes 
xylene 30 minutes 
xylene 30 minutes 
paraffin wax 1 hour 
paraffin wax 1 hour 
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Appendix F(i) Linistat linear stainer programme: haematoxylin and eosin 
100% ethanol  single bucket 
90% ethanol  single bucket 
70% ethanol  single bucket 
50% ethanol  single bucket 
Running tap water single bucket 
Harris’ modified haematoxylin single bucket 
Running tap water single bucket 
1% acid alcohol single bucket 
Running tap water single bucket 
Eosin Y  single bucket 
Running tap water single bucket 
50% ethanol  single bucket 
70% ethanol  single bucket 
90% ethanol  single bucket 
100% ethanol  single bucket 
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Appendix F(ii) Linistat linear stainer programme: toluidine blue 
100% ethanol  single bucket 
90% ethanol  single bucket 
70% ethanol  single bucket 
50% ethanol  single bucket 
Running tap water single bucket 
Toluidine blue  double bucket 
Running tap water single bucket 
Nuclear fast red double bucket 
Running tap water single bucket 
50% ethanol  single bucket 
70% ethanol  single bucket 
90% ethanol  single bucket 
100% ethanol  single bucket 
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Appendix G (i) BCA assay protein standards 
Vial Diluent volume    source and volume final BSA concentration 
       (μl)        of BSA (μl)  (μg/ml) 
A 0 300 (stock) 2000 
B 125 375 (stock) 1500 
C 325 325 (stock) 1000 
D 175 175 (vial B) 750 
E 325 325 (vial C) 500 
F 325 325 (vial E) 250 
G 325 325 (vial F) 125 
H 400 100 (vial G) 25 
I 400 0 0 
(ii) REVERT total protein stain 
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Appendix H(i) Representative Agilent 2100 Bioanalyser results  
 
 
 
Appendix H(ii) Principal component analysis (PCA) 
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A  Female 
B 
Age (weeks) +/+ S/+ S/S 
Femur (mm) 
± SEM   
3 9.25±0.20 9.00±0.14 6.69±0.13 *** 
6 12.14±0.18 10.95±0.18 *** 8.47±0.14 *** 
9 14.21±0.11 12.19±0.23 *** 9.54±0.31 *** 
Tibia (mm) ± 
SEM    
3 12.81±0.25 12.63±0.14 9.67±0.09 *** 
6 15.66±0.16 14.64±0.15 *** 11.77±0.16 *** 
9 16.83±0.06 15.67±0.13 *** 12.59±0.15 *** 
3 10.41±0.33 10.78±0.18 8.51±0.26 ** 
Pelvis (mm) ± 
SEM   
6 14.89±0.21 14.49±0.22 12.20±0.36 *** 
9 16.98±0.18 15.92±0.13 *** 13.26±0.32 *** 
Appendix I (i) Morphometric analysis of female SEMD mice.
Tibia, femur and pelvic (illium and ischium) bone lengths were measured at 3, 6 and 9 
weeks of age in female mice of all 3 genotypes. (A) The average femur,   bia and pelvis 
lengths of mice homozygous for the muta  on was reduced, reaching  67.1%, 74.8% and 
78.1% of wild type bone lengths respectively by 9 weeks. The average femur,   bia and pel-
vis lengths of mice heterozygous for the muta  on was reduced to 85.8%, 93.1% and 93.8% 
of wild type bone lengths respectivel  by 9 weeks. (B) Numeric data used for the genera-
  on of graph A. 
Key: +/+ (wild type) S/+ (heterozygous for the muta  on) S/S (homozygous for the muta  on) 
**p>0.01, ***p>0.001, Two tailed T-test, SEM (standard error of the mean) n≥4. 
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A  Female 
B 
C 
Age (weeks) +/+ S/+ S/S 
Hip angle (°) 
± SEM  
3 9.09± 0.75 8.18± 0.99 16.09± 1.68 *** 
6 3.60± 0.60 3.01± 0.60 12.93± 2.36 *** 
9 4.43± 1.13 2.53± 0.61 12.68± 2.25 ** 
Appendix I (ii) Hip dysplasia in female SEMD mice.
The angle of the hip was measured at 3, 6 and 9 weeks of age in female mice of all 3 geno-
types . (A) Representative X-ray imaging of  9 week old female mice (dorsal view). (B) There 
was a 3-fold increase in the average hip angle of homozygous mice compared with that of 
wild type li  ermates. (C) Numeric data used for the genera  on of graph B. 
Key: +/+ (wild type) S/+ (heterozygous for the muta  on) S/S (homozygous for the muta  on) 
**p>0.01, ***p>0.001, Two tailed T-test, SEM (standard error of the mean) scale bar = 
2mm, n≥4. 
 +/+  S/+  S/S 
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Appendix I (iii) Morphometric analysis of the skull in female SEMD mice. 
ICD (inner canthal distance) and skull length were measured at 3, 6 and 9 weeks of age in 
female mice of all 3 genotypes. (A) Representa  ve X-ray imaging of  9 week old female mice 
(dorsal view). (B) There was no di  erence in ICD but the average skull length of mice homo-
zygous for the muta  on was reduced, reaching 83.1% of wild type bone length by 9 weeks. 
(C) Numeric data used for the genera  on of graph B. 
Key: +/+ (wild type) S/+ (heterozygous for the muta  on) S/S (homozygous for the muta  on) 
***p>0.001, Two tailed T-test, SEM (standard error of the mean) scale bar = 2mm, n≥4. 
A  Female 
B 
C 
Age (weeks) +/+ S/+ S/S 
ICD (mm) ± 
SEM 
3 6.52±0.10 6.83±0.05 6.58±0.13 
6 7.13±0.08 7.26±0.06 7.34±0.11 
9 7.33±0.11 7.46±0.06 7.58±0.17 
Skull (mm) 
± SEM  
3 16.85±0.22 17.11±0.15 14.89±0.12 *** 
6 18.88±0.18 18.48±0.29 15.91±0.39 *** 
9 19.50±0.45 19.79±0.10 16.20±0.21 *** 
  +/+  S/+  S/S 
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Appendix I (iv) Morphometric analysis of female OCD mice. 
Tibia, femur and pelvic (illium and ischium) bone length were measured at 3, 6 and 9 weeks 
of age in female mice of all 3 genotypes. (A) The average femur,   bia and pelvis lengths for 
mice homozygous for the muta  on were reduced, reaching  88.2%, 92.9% and 94.4% of 
wild type bone length respectively at 9 weeks. The average pelvic bone length of mice ho-
mozygous for the muta  on was reduced, reaching  94.4% of wild type bone length by 9 
weeks. The average   bia length of mice heterozygous for the muta  on was reduced to 
89.3% of wild type   bia length at 3 weeks but there was no sta  stical di  erence at 9 weeks. 
(B) Numeric data used for the genera  on of graph A. 
Key: +/+ (wild type) O/+ (heterozygous for the muta  on) O/O (homozygous for the muta-
  on) *p>0.05, **p>0.01, ***p>0.001, Two tailed T-test, SEM (standard error of the mean) 
n≥8. 
A  Female 
B 
Age (weeks) +/+ O/+ O/O 
Femur (mm) ± SEM 
3 9.25 ± 0.20 9.68 ± 0.48 8.61 ± 0.14 * 
6 12.14 ± 0.18 11.69 ± 0.10 11.48 ± 0.16 * 
9 14.21 ± 0.11 13.52 ± 0.20 12.54 ± 0.14 *** 
Tibia (mm) ± SEM 
3 12.81 ± 0.25 11.44 ± 0.39 ** 12.06 ± 0.09 * 
6 15.66 ± 0.16 15.21 ± 0.09 14.85 ± 0.13 *** 
9 16.83 ± 0.06 16.30 ± 0.11 15.64 ± 0.11 *** 
3 10.41 ± 0.33 9.68 ± 0.20 9.86 ± 0.11 
Pelvis (mm) ± SEM 6 14.89 ± 0.21 14.59 ± 0.13 14.55 ± 0.10 
9 16.98 ± 0.18 16.50 ± 0.16 16.03 ± 0.10 *** 
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A  Female 
B 
C 
Age (weeks) +/+ O/+ O/O 
Hip angle (°) 
± SEM  
3 9.09 ± 0.75 9.24 ± 0.66 8.57 ±  0.45 
6 3.60 ± 0.60 6.17 ±  0.86 2.95 ± 0.68 
9 4.43 ± 1.13 4.55 ±  0.52 3.73 ± 0.38 
Appendix I (v) Hip dysplasia in female OCD mice. 
The angle of the hip was measured at 3, 6 and 9 weeks of age in female mice of all 3 geno-
types . (A) Representa  ve X-ray imaging of  9 week old female mice (dorsal view). (B) There 
was no sta  s  cal di  erence in the average hip angle of heterozygous or homozygous mice 
compared with that of wild type li  ermates. (C) Numeric data used for the genera  on of 
graph B. 
Key: +/+ (wild type) O/+ (heterozygous for the muta  on) O/O (homozygous for the muta-
  on) NS (non-significa t) Two tailed T-test, SEM (standard error of the mean) scale bar = 
2mm, n≥8. 
        NS 
 +/+  O/+  O/O 
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Appendix I(vi) Morphometric analysis of the skull in female OCD mice.
ICD (inner canthal distance) and skull length were measured at 3, 6 and 9 weeks of age in 
female mice of all 3 genotypes. (A) Representa  ve X-ray imaging of  9 week old female mice 
(dorsal view). (B) There was no di  erence in ICD or skull length between  female li  ermates 
of all 3 genotypes. (C) Numeric data used for the genera  on of graph B. 
Key: +/+ (wild type) O/+ (heterozygous for the muta  on) O/O (homozygous for the muta-
  on) NS (not signific nt) Two tailed T-test, SEM (standard error of the mean) scale bar = 
2mm, n≥10. 
A  Female 
B 
C 
Age (weeks) +/+ O/+ O/O 
ICD (mm) ± 
SEM 
3 6.52±0.10 6.50±0.06 6.50±0.05 
6 7.13±0.08 7.13±0.07 7.32±0.03 
9 7.33±0.11 7.53±0.04 7.59±0.04 
Skull (mm) 
± SEM  
3 16.85±0.22 16.76±0.14 16.32±0.17 
6 18.88±0.18 18.85±0.12 18.53±0.16 
9 19.50±0.45 20.21±0.26 19.31±0.21 
        NS 
        NS 
  +/+  O/+  O/O 
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Protein 
Gene 
symbol 
OCD SEMD 
FC P value FC P value 
UPR stress sensors  
BIP Hspa5 1.07 7.63E-01 -1.21 4.20E-01 
ATF6 Atf6 -1.14 4.42E-01 -1.19 3.30E-01 
ATF6B/CREBL1 Atf6b 1.01 9.50E-01 -1.32 4.95E-02 
IRE1 Ern1 -1.03 8.06E-01 1.04 7.76E-01 
PERK Eif2ak3 -1.21 2.43E-01 -1.24 1.91E-01 
LUMAN Creb3 -1.03 7.52E-01 -1.19 3.71E-02 
BBF2H7 Creb3l2 -1.31 2.15E-01 -1.08 7.08E-01 
CREBH Creb3l3 1.22 3.85E-01 1.05 8.40E-01 
AIBZIP Creb3l4 -1.41 7.12E-02 1.10 5.65E-01 
OASIS Creb3l1 -1.07 7.31E-01 -1.61 3.71E-02 
UPR-associated genes  
ATF3 Atf3 1.14 8.22E-01 -1.13 8.44E-01 
ATF4 Atf4 -1.08 6.95E-01 -1.27 2.27E-01 
BCL2-related protein A1 Bcl2a1d -5.25 3.34E-02 -6.74 1.86E-02 
BCL2 like 15 Bcl2l15 7.16 2.85E-02 4.32 1.32E-01 
calre  culin Calr -1.08 5.39E-01 1.13 3.28E-01 
calre  culin 4 Calr4 -4.08 3.73E-02 1.55 4.54E-01 
calnexin Canx -1.17 2.81E-01 1.25 1.40E-01 
CD74 Cd74 -1.38 4.00E-01 -2.79 2.31E-02 
CHOP Ddit 1.40 4.26E-01 1.18 6.96E-01 
derlin 3 Derl3 1.09 7.28E-01 2.84 3.17E-03 
HSP40 member A2 Dnaja2 1.04 6.36E-01 -1.13 1.79E-01 
HSP40 member B12 Dnajb12 -1.20 1.47E-01 -1.31 4.35E-02 
HSP40 member C1 Dnajc1 -1.13 2.86E-01 -1.07 5.31E-01 
dolichol-phosphate mannosyltransferase Dpm1 1.11 5.59E-01 1.56 2.97E-02 
EDEM1 Edem1 -1.14 3.35E-01 1.07 6.22E-01 
eukaryotic transla  on initi tion fac or 2A Eif2a -1.05 4.26E-01 -1.06 5.46E-01 
ERp72 Pdia4 -1.32 1.95E-01 -1.34 1.70E-01 
predicted gene 5160 Gm5160 -6.04 3.27e-02 -1.68 4.75E-01 
HERPUD1 Herpud1 -1.22 3.39E-01 -1.30 2.18E-01 
HSP90 alpha member B1 Hsp90ab1 -1.09 4.70E-01 -1.28 4.84E-02 
GRP94 Hsp90b1 -1.16 3.69E-01 1.21 2.60E-01 
HSP9 Hspa9 -1.22 1.04E-01 -1.19 1.50E-01 
heat shock 70kDa protein 12A Hspa12a 1.20 2.87E-01 1.53 2.84E-02 
HSP25 Hspb1 1.63 1.60E-01 1.09 7.84E-01 
insulin-like growth factor 1 Igf1 1.35 1.64E-01 1.06 7.71E-01 
lecti , mannose-binding 1 Lman1 -1.28 1.70E-01 -1.35 2.60E-01 
ARMET Manf 1.02 8.08E-01 -1.20 8.24E-01 
mitogen-activa ed protein kinase 14 Mapk14 -1.04 6.34E-01 1.02 8.18E-01 
transmembrane protein 180 Mfsd13b -4.80 1.45E-02 -1.29 6.19E-01 
natriuretic pe ti e type A Nppa 2.11 3.22E-01 1.91 7.00E-01 
parkin Park2 1.15 4.49E-01 2.24 1.85E-03 
pep  dylprolyl isomerase F Ppif -1.89 3.34E-02 1.18 5.25E-01 
sec61 alpha subunit Sec61a1 -1.23 1.60E-01 -1.36 5.32E-02 
Appendix J Differential gene expression (i) The unfolded protein response and apoptosis 
265
Protein Gene symbol 
OCD SEMD 
FC P value FC P value 
SLC7A11 Slc7a11 1.66 5.39E-03 1.66 5.38E-03 
SLC22A29 Slc22a29 -1.31 4.42E-01 5.13 1.34E-03 
SLC23A1 Slc23a1 2.34 7.93E-02 4.21 9.87E-03 
SLC29A4 Slc29a4 1.57 2.70E-01 2.84 2.59E-02 
STEAP1 Steap1 -2.65 2.85E-02 -1.06 8.70E-01 
STT3 Stt3a -1.27 2.26E-01 -1.39 1.07E-01 
Tribbles homolog 3 Trib3 -1.23 3.20E-01 1.60 4.28E-02 
regulator of nonsense transcripts 3B Upf3b 1.16 2.38E-01 1.58 4.55E-03 
VCP Vcp -1.09 3.72E-01 -1.30 2.62E-02 
VLDLR Vldlr -2.07 1.87E-02 1.28 3.34E-01 
WFS1 Wfs1 -1.19 1.65E-01 -1.30 4.75E-02 
XBP1 Xbp1 1.03 7.76E-01 -1.09 4.55E-01 
ER overload response 
Caspase 12 Casp12 1.29 1.47E-01 1.06 9.25E-01 
Cyclin D1 Ccnd1 1.09 6.37E-01 -1.14 4.48E-01 
Myelocytomatosis oncogene Myc -1.45 3.64E-01 -1.85 1.51E-01 
Myeloid cell leukemia sequence 1 Mcl1 1.09 6.13E-01 -1.10 5.52E-01 
Matrix metallopep  dase 9 Mmp9 -3.16 8.40E-02 -2.25 2.00E-01 
NF-kB Nfkb1 1.00 9.68E-01 -1.05 6.27E-01 
IRE1-dependant decay (RIDD) 
BLOC1S1 Bloc1s1 1.09 7.33E-01 -1.05 8.37E-01 
HGSNAT Hgsnat -1.13 3.40E-01 -1.10 4.86E-01 
Platelet derived growth factor receptor Pdgfrb -1.07 7.52E-01 -1.06 7.90E-01 
Scavenger receptor A3 Scara3 -1.12 6.08E-01 -1.17 4.72E-01 
Appendix J Differential gene expression (ii) Autophagic flux 
Protein Gene symbol 
OCD SEMD 
FC P value FC P value 
EVA1A Eva1a -1.63 4.74E-03 1.09 5.16E-01 
Parkin Park2 1.15 4.49E-01 2.24 1.85E-03 
RAB9B Rab9b -7.62 2.50E-03 2.11 1.41E-01 
Unc-51 like kinase 3 Ulk3 1.04 8.74E-01 1.80 2.85E-02 
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Protein Gene symbol 
OCD SEMD 
FC P value FC P value 
FAM161A Fam161a 1.06 7.51E-01 1.60 3.34E-02 
Kinesin family member 5A Kif5a -1.02 9.29E-01 1.61 3.98E-02 
Kinesin family member C2 Kifc2 1.26 2.07E-01 1.90 1.09E-03 
Kinesin family member  17 Kif17 1.52 2.25E-01 2.48 2.26E-02 
MNS1 Mns1 1.51 1.14E-01 1.94 3.08E-02 
SNAB  Napb 1.05 7.06E-01 1.57 5.16E-03 
RAB3C Rab3c -3.64 1.52E-02 -1.08 8.61E-01 
RAB9B Rab9b -7.62 2.50E-03 2.11 1.41E-01 
RAB25 Rab25 -2.18 4.65E-02 1.89 8.91E-02 
Syntaphilin  Snph -1.68 5.00E-02 1.30 2.76E-01 
Spectrin beta Sptbn2 -1.17 5.38E-01 1.81 4.05E-02 
Syntaxin 1A Stx1a -1.05 7.64E-01 1.53 3.23E-02 
Syntaxin 1B Stx1b 1.10 6.24E-01 2.00 5.51E-03 
Syntaxin 16 Stx16 1.05 6.80E-01 1.56 3.15E-03 
Synapsin 3 Syn3 -1.71 1.03E-01 2.21 2.70E-02 
Synaptotagmin 8 Syt8 -2.44 2.68E-02 1.16 6.68E-01 
Synaptotagmin 14 Syt14 -3.28 1.34E-02 1.29 5.10E-01 
Synaptotagmin-like 2 Sytl2 -1.75 1.69E-02 1.42 9.32E-01 
Synaptobrevin Vamp1 1.24 2.29E-01 1.72 3.70E-02 
Appendix J Differential gene expression (iii) Vesicle trafficking and cilia formation
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Protein Gene symbol 
OCD SEMD 
FC P value FC P value 
TRAP Acp5 -2.50 3.32E-02 -2.43 3.76E-02 
Bone morphogenetic p otein 8a Bmp8a -6.06 9.74E-03 -1.34 5.89E-01 
Chordin-like 2 Chrdl2 -2.15 4.75E-02 1.49 2.53E-01 
C-type lectin omain family 3 Clec3b 1.83 3.05E-02 1.02 9.20E-01 
Dickkopf WNT signalling inhibitor 1 Dkk1 -3.91 7.92E-03 -1.38 4.18E-01 
Den  n matrix protein 1 Dmp1 -3.32 2.66E-02 1.13 7.90E-01 
Frizzled class receptor 1 Fzd1 -1.27 1.22E-01 -1.54 1.52E-02 
Growth diff ren  a  on factor 1 Gdf1 -8.42 4.42E-02 -10.81 2.96E-02 
Homeobox A5 Hoxa5 -1.12 4.35E-01 1.67 5.65E-03 
Homeobox A9 Hoxa9 -1.00E+00 9.97E-01 1.52 3.82E-02 
Homeobox A13 Hoxa13 1.08 7.47E-01 -1.86 2.50E-02 
Homeobox C4 Hoxc4 1.12 3.75E-01 1.71 2.40E-03 
Homeobox C5 Hoxc5 1.19 3.56E-01 1.67 2.06E-02 
Homeobox C6 Hoxc6 -1.22 1.02E-01 1.57 3.63E-03 
Homeobox C8 Hoxc8 -1.01 9.45E-01 2.23 1.44E-03 
Homeobox D3 Hoxd3 10.70 3.40E-03 12.25 2.50E-03 
Homeobox D4 Hoxd4 1.99 8.81E-01 2.46 3.59E-02 
IBSP Ibsp -2.87 2.46E-02 1.03 9.48E-01 
OC-STAMP Ocstamp -2.67 4.29E-02 -2.30 7.51E-02 
PHEX Phex -1.74 4.07E-02 -1.29 3.00E-01 
Patched Ptch1 -2.14 2.23E-02 1.29 3.62E-01 
Parathyroid hormone 1 receptor Pth1r -2.04 1.08E-02 1.34 2.02E-01 
SATB2 Satb2 -2.32 8.40E-03 1.53 1.12E-01 
Osteoponti  Spp1 -2.06 3.83E-02 1.00 9.88E-01 
RUNX2 Runx2 -1.73 1.18E-02 1.28 1.84E-01 
RUNX3 Runx3 -1.72 4.47E-02 1.36 2.13E-01 
VEGF-D Vegfd 1.95 2.86E-02 2.41 8.22E-03 
WNT4 Wnt4 -1.43 1.04E-01 -1.68 3.05E-02 
WNT5B Wnt5b -1.57 5.96E-02 -1.76 2.51E-02 
Wilms tumor 1 homolog Wt1 -3.85 1.16E-02 4.44 7.10E-03 
Appendix J Differential gene expression (iv) regulatory signalling and differentiation
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